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ABSTRACT 
A double-blind, placebo controlled research technique was used to 
determine the effects of two non-steroidal anti-inflammatory drugs, 
meclofenamate and diclofenac, in combination with physiotherapy 
treatment, on the rate and extent of healing of acute hamstring 
muscle tears. 
Sixty patients were recruited and treated at No's 1 and 2 Military 
Hospitals in Voortrekkerhoogte and Wynberg, Cape Town, 
respectively. Patients were randomly allocated to one of three 
treatment groups: meclofenamate, diclofenac and placebo. 
Patient assessments were performed on days 1, 3 and 7 of the 7 day 
study period. These assessments included pain assessment (visual 
analogue scale), swelling measurement (thigh circumference 
measurement at the site of the muscle tear) and muscle performance 
test (Cybex isokinetic dynamometer and data reduction computer). 
All patients received physiotherapy treatment on all 7 days of the 
study. This comprised early rest, ice, compression and elevation 
(RICE), and later, ultrasound and deep transverse friction massage. 
An intensive regime of strengthening and stretching exercises was 
used throughout the study, beginning with stretching and isometric 
exercises gradually moving onto isotonic exercises and aerobic 
exercise including swimming, running and cycling. No competitive 
sport was allowed during the study period. 
Statistical significance was determined using the analysis-of-
variance (ANOVA) test with an acceptance level of p<0.05. 
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No differences in pain, swelling or muscle performance were 
demonstrated between the three treatment groups. In terms of the 
pain and swelling assessments, the injuries did not appear to be 
very severe. Accordingly, the groups were divided into severe and 
non-severe sub-groups and statistical significance was determined 
using the ANOVA test with an acceptance level of p<0.05. A 
significant difference was found in the severe hamstring injury 
sub-group. In this group, pain reduction was greater in the placebo 
group than in the meclofenamate group on day 7. There were no 
other significant differences found in this sub-group analysis. 
Relatively few side effects were encountered, and those encountered 
were mild. No patients were withdrawn from the study as a result of 
these adverse events. Drowsiness and gastro-intestinal disturbance 
were the most common side effects reported. 
In conclusion, the study found that no benefit was gained from the 
use of meclofenamate or diclofenac in combination with 
physiotherapeutic modalities as compared to the use of 
physiotherapeutic modalities on their own. Thus the widespread use 
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1.1 OUTLINE OF THE PROBLEM 
Almost half of all sporting injuries seen in sportsmen and - women 
are those involving the musculo-tendinous unit (Bass, 1967). Acute 
muscle injuries are the most common of such injuries (Almekinders 
and Gilbert, 1986). 
Non-steroidal anti-inflammatory drugs (NSAID's) are the most widely 
used drugs used for sports-related trauma amongst South African 
athletes (Irving, 1989). There have been few studies performed to 
investigate the efficacy of such medication and most of these have 
supported the use of NSAID's: very few of these studies, however, 
have been performed with sufficient objectivity (Kellett, 1986). 
Only 7 of the 44 most recent studies performed in the past 16 years 
were done so scientifically; for example some studies included 
different types of injuries, whilst some investigated one NSAID 
against another without any placebo control. 
Only 7 studies utilized both a single injury type and a 
placebo group as a control, of these only 3 showed a 
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favourable result for the treatment group. It is interesting 
to note that only one out of these 7 studies used acute muscle 
trauma: the other studies all utilized acute trauma of the knee or 
ankle. 
Recently Almekinders and Gilbert (1986) showed histologically and 
biomechanically that injured muscle treated with NSAIDs tended to 
weaken in the immediate post-injury period whilst untreated muscle 
failed to do so. Reynolds (1987) and Huskisson et al. (1973) found 
in placebo controlled studies performed on injured sportsmen that 
there was no difference between NSAIDs treated and placebo treated 
groups. This view is shared by Andersson et al. (1983); Dupont et 
al. (1987); Goldie et al. (1974); Jenner (1987) and Van Marion 
(1973). 
Reynolds (1987) compared meclofenamate to placebo, in combination 
with physiotherapy, in a double-blind study of patients with acute 
quadriceps or hamstring muscle tears. Patients were tested for 
strength and endurance deficits, pain and swelling on days 1, 3 and 
7 after the injury. The findings indicated that there were no 
significant differences between the two groups, although small 
sample sizes were used (there were only 5 patients in each group). 
Various physiotherapy modalities have been tested in the past and 
proven to be successful in achieving desirable effects in the 
treatment of acute muscle injuries: the use of rest, ice 
application, compression bandaging and elevation of the injured 
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area is effective for reducing bleeding and swelling in the first 
24-48 hours after injury (Bierman, 1955; Laing et al. 1973). 
Ultrasound therapy has been shown to have a favourable effect on 
the healing of soft tissue injuries (Dyson et al. 1968; Mc Diarmid 
and Burns 1987) and its use is advocated in the treatment of such 
injuries (Fitch and Gray, 1974 and Burry, 1975; Oakes, 1981). Deep 
friction massage is a poorly documented treatment technique but is 
regarded as being very useful in the treatment of acute muscle 
trauma (Winter, 1968; Chamberlain, 1982; Cyriax, 1984). Intensive 
rehabilitation, for example stretching and strengthening exercises, 
plays a vital role in returning the injured sportsman to the sports 
field (Burkett, 1970; Fitch and Gray, 1974; Millar, 1975 and 1976; 
Oakes, 1981; Garrett, 1990). 
Whilst there seems to be consensus in the literature regarding the 
use of physical therapy or physiotherapy treatment for acute muscle 
injuries, the same cannot be said for the use of NSAIDs. The 
controversy seems to centre around the merits of the inflammatory 
response to injury: macrophage collagenase production is thought to 
be controlled by prostaglandin levels (Wahl et al. 1977) but not 
all prostaglandins are believed to be responsible for the 
inflammatory reaction. On the other hand the presence of 
macrophages, lymphocytes, bradykinins and other inflammatory 
cells is thought to be important in removing cellular debris 
and necrotic tissue following injury, thereby creating the 
correct environment for healing to take place. Well controlled 
laboratory experiments have shown that although NSAIDs reduce 
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swelling and inflammation, they also reduce maximum failure load in 
the muscle and slow down the clearance of cellular debris 
(Almekinders and Gilbert, 1986; Kellett, 1986). 
It becomes apparent, therefore, that the question to be asked is 
whether NSAIDs should be used in combination with the physical 
modalities or whether the injuries should be treated using the 
physical modalities alone. In view of this controversy, it was 
decided to determine objectively whether sodium meclofenamate and 
diclofenac sodium (both NSAIDs) used in combination with 
physiotherapy treatment, is more effective than the physiotherapy 
treatment on its own, in the management of acute muscle injuries. 
A double blind study design was used on patients with acute strains 
of the hamstring and quadriceps groups of muscles. Patients were 
divided into three groups; patients in group A received 
meclofenamate (NSAID), group B received diclofenac (NSAID) and 
group C received placebo. Patients were assessed on days 1, 3 and 7 
after injury for pain (visual analogue scale), swelling (thigh 
circumference measurement) and muscle power and endurance (Cybex 
isokinetic test). All patients received the same physiotherapy 
treatment after the injury. 
This is the first time that scientifically objective data, such as 
data obtained via an isokinetic dynamometer and data reduction 
computer, has been used in a study of this nature. It is therefore 
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believed that the results of this study will help to clarify the 
need for NSAIDs following acute muscle trauma. 
1.2 HYPOTHESIS AND NULL HYPOTHESIS 
1.2.1. Hypothesis 
Acute muscle injuries treated with meclofenamate or diclofenac, in 
combination with physiotherapeutic modalities (such as RICE, 
ultrasound, deep friction massage and stretching and strengthening 
exercises), heal faster than those treated with the 
physiotherapeutic modalities alone. 
1.2.2. Null Hypothesis 
Acute muscle injuries treated with meclofenamate or diclofenac, in 
combination with physiotherapeutic modalities (such as RICE, 
ultrasound, deep friction massage and stretching and strengthening 
exercises), heal as fast as those treated with the 
physiotherapeutic modalities alone. 
1.3 LIMITATIONS 
In order to ensure accuracy and objectivity, the study was 
limited to the assessment of muscle injuries to the quadriceps and 
hamstring muscle groups. Inclusion of other injuries for example 
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strains of other muscles, or joint sprains, would detract from the 
accuracy required to achieve a meaningful result. 
Injuries assessed should be of maximum severity in order for the 
largest possible improvement or deterioration to be seen in each 
test. 
An extended period might be necessary to obtain a larger sample 
size, for example, in excess of 60 patients. 
1.4 ETHICAL CONSIDERATIONS 
A project proposal was drafted and submitted to the University of 
Cape Town Higher Degrees Committee for approval, which was granted. 
Permission was also granted by the Surgeon General of the South 
African Defence Force (SADF) Medical Corps for the study 
experimentation to be conducted at the No's 1 and 2 Military 
Hospitals (Appendix 5). 
The details and implications of the study were explained to all 
patients and all signed a written consent form to this effect 
before they were admitted to the study. This consent form was 
issued in English and Afrikaans (Appendix 1). 
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The NSAIDs used were registered drugs and were considered safe in 
the dosages given. A doctor was always present at each initial 
visit to assess the patient and to prescribe the medication. Any 
adverse events reported during the study were reported to the 
doctors available and appropriate action was taken. 
Physiotherapy modalities used are commonly used modalities for the 
treatment of such injuries. 
Strict confidentiality was maintained at all times concerning the 




2.1 ACUTE MUSCLE INJURIES 
2.1.1 Introduction 
The focus of research into sporting injuries has been on serious 
ligamentous and skeletal injuries rather than on the less serious 
but far more common acute muscle strains (Almekinders, 1990). 
Little is known of the aetiology and treatment of these acute 
muscle injuries and very little objective and scientific research 
has been performed in this area of sports medicine (Kellett, 1986; 
Irving, 1989) . 
It is widely recognized that physical modalities play an important 
role in the management of acute muscle injuries, for example, the 
use of RICE (an acronym standing for Rest, Ice, Compression and 
Elevation which was popularized by Trickett in 1965), ultrasound 
(Dyson, 1987; Partridge, 1987), deep friction massage (Chamberlain, 
1982; Winter, 1968) and exercise therapy involving stretching and 
strengthening exercises (Oakes, 1981). 
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Non-steroidal anti-inflammatory drugs (NSAIDs) have become popular 
in the treatment of soft tissue injuries during the past 20 years. 
However, their use has become a controversial issue recently 
because very little sound scientific evidence exists to warrant 
their use (Kellett, 1986; Irving, 1989), particularly following 
recent research done by Almekinders (1990) which has shown that 
very few studies researching the efficacy of NSAIDs have been 
performed with suitable control, for example placebo controlled, 
and very few were performed with scientific objectivity. 
2.1.2. Causes 
Acute muscle strain injuries most often occur during eccentric 
contraction of the muscle and this is particularly so in muscles 
that cross two joints, for example the hamstrings, rectus femoris, 
triceps brachii, gastrocnemius and others. Possible reasons for 
this are that higher forces are exerted during eccentric 
contractions as compared to concentric contractions; muscle force 
production is higher when the muscle is activated while lengthening 
as opposed to being activated while being held at the same length 
or allowed to shorten. The function of the "two-joint" muscles 
during explosive sports such as rugby, sprinting or soccer, is to 
decelerate the joint by contracting eccentrically. In doing this 
they must absorb a great amount of energy, and frequently this 
muscle cannot absorb the required amount of energy, resulting in 
muscle strain injury (Garrett, 1990). 
This theory is contrary to the recently held belief that these 
injuries were due to muscle strength imbalances between the 
quadriceps and hamstring muscle groups during concentric muscle 
contractions (Burkett, 1970). 
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Other contributing factors which predispose muscles to acute injury 
are: 
* "two-joint" muscles, being predominantly fast twitch (type 
II) muscle type, require faster contraction time (Garrett, 
1990) 
* muscle fatigue (Froimson, 1969; Garrett, 1990) 
* previous inadequately treated injury (Burkett, 1970) 
* inadequate warm-up and muscle inextensibility (Sutton, 
1984; Safran et al. 1989). 
Tearing normally occurs at the musculo-tendinous junction in adults 
(Burry, 1975; Miller, 1977; Almekinders and Gilbert, 1986; Garrett 
et al. 1988). Although surgical exploration of such injuries has 
not been attempted there are a number of references regarding 
surgical findings which confirm this belief; this has been 
confirmed recently using magnetic resonance imaging in the 
hamstrings (Garrett et al. 1989). 
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2.1.3. Pathology and Healing 
In order to manage soft-tissue injuries effectively it is important 
to know the processes which take place following their occurrence: 
these will be described below. 
The healing of acute soft-tissue trauma has been shown to take 
place by scar formation and not by regeneration of damaged tissue 
(Frank et al. 1983). Models for such a process have been described 
in the past, usually for crush injuries such as that described by 
Burry (1975). This type of injury is uncommon, however, and a model 
put forward by Oakes (1981) in which he describes the process in an 
overstretch injury, which is more commonly seen (see 2.2.2.) is 
summarized below. 
Oakes(1981) describes three phases of repair: 
phase 1: Inflammation (0-72 hours) 
Vascular disruption, red blood cell extravasation 
and blood clotting predominate early on. 
Macrophages and monocytes are activated and these 
migrate to the damaged area. Burry (1975) points out that the 
basal lamina is normally left intact in the stretching injury 
and this forms the foundation for repair. Histamine, 
serotonin, prostaglandins and leukotrines are released by mast 
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and other cells and these contribute to vascular "leakiness" 
which leads to oedema and later fibrosis (Muckle, 1980). 
phase 2: Repair 
Macrophages clear away debris and blood clot and vascular 
budding is triggered by fiboblast migration. Collagen is 
synthesized in a disorientated form (awaiting phase 3) and 
continues to grow in diameter and also begins to contract. 
this is believed to lead to muscle stiffness (Evans, 1980). 
phase 3: Remodelling 
This is a natural and important sequel to phase 2 and is 
characterized by further collagen growth and re-alignment by 
tensile loading on the muscle which in turn helps to 
strengthen the muscle (Evans, 1980; Wilkerson, 1985). 
Almekinders and Gilbert (1986) researched the effects of NSAIDs in 
the healing of acute muscle trauma using a standardized strain of 
the rat tibialis anterior muscle. They found histologically that 
early macrophage inhibition and a macrophage filled basal lamina 
were major characteristics in the early period; myotubes filled 
with cytoplasm were a dominant feature at 4 days post-injury and 
almost complete regeneration with prolific endomyseal fibrosis 
predominated at 11 days. This slowed healing process was shown to 
have taken place much faster in the groups who did not receive 
NSAID. 
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Generally soft tissue injuries will keep the sports-person off the 
field for between 7 and 10 days (Millar, 1976; Bouchier-Hayes and 
Jones, 1979; Milenovi'c and Mili'c, 1980; Muckle, 1980; Simmons et 
al. 1982; Commandre, 1983; Edwards et al. 1984). Many of these 
injuries would resolve spontaneously (Bourne, 1980; Walker et al. 
1984) but pain being the biggest limiting factor in delaying full 
rehabilitation (Crean, 1981) may prolong the healing time. 
Re-occurrence of the injury is always a problem, and in this regard 
strength testing is vital to ensure that maximal loading of the 
muscle may recommence (Oakes, 1981). Failure load (determined 
mechanically on animal muscle) is representative of the degree of 
healing in muscle. Therefore testing muscle function mechanically 
for example using a Cybex dynamometer, which isotonically measures 
torque generated by muscle at a given joint, will give an 
indication of the possibility of recurrence of injury (Almekinders 
and Gilbert, 1986). Millar (1976) pioneered a rigorous regime in 
treating acute gastrocnemius tears and this involved early ice 
application, stretching and strengthening exercises, short-wave 
diathermy, ultrasound and interferential therapy. Of a sample of 
400 subjects, 68 % were symptom free (no pain and full 
extensibility) within a week. Of 94% of the cases that were 
followed up only 1% had recurrence of injury within 3 months. 
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rt is apparent from this study of Millar that the re-occurrence of 




Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of 
compounds which share similar properties being anti-inflammatory, 
anti-pyretic and analgesic (Abbott et al. 1980; Simmons et al. 
1982). With analgesics, these are possibly the drugs most in demand 
in South Africa today for the early treatment of injuries during 
the initial inflammatory phase described above (Irving, 1989). 
Relatively few studies have been performed on these compounds over 
the years and most of those performed lack suitable objective 
controls; they fail to comment on any other concurrent management 
or show genuine advantage of such medication. 
Almekinders and Gilbert (1986) showed histologically and 
biochemically that piroxicam (NSAID) delayed muscle regeneration 
but partially prevented early weakening and increased maximum 
failure load following a standardized strain of the rat tibialis 
anterior muscle. They suggest that this will be the trend with 
other NSAIDs, which are inhibitors of prostaglandin. Vogel reported 
in 1977 that NSAIDs could enhance the strength of collagenous 
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tissue in various organs, whilst Lord et al. (1980) found that 
prostaglandins of the F series, which are formed after the initial 
inflammatory phase, enhance the formation of ground substance which 
favours healing. This controversy helps to illustrate the lack of 
understanding of these injuries. 
As has been mentioned earlier, very few studies have been performed 
with the necessary objectivity to prove conclusively that NSAIDs 
are warranted in treating acute soft tissue injures. A majority of 
these studies lack either the control which the inclusion of a 
placebo group would give, or they include assessment of many 
different types of acute muscle injuries. It is felt that these 
injuries cannot be compared in a scientific study of this nature. 
Almekinders (1990) recently reviewed the literature on the use of 
NSAIDs in the management of soft tissue sports injuries. In this 
presentation, he categorized the studies performed into two tables, 
the first being those studies which were performed without the 
control of a placebo, and the second being those that were 
performed with the control of a placebo. On reviewing the 
literature for this study, a few more studies were found which 
tested the efficacy of NSAIDs in the treatment of soft tissue 
sports injuries. 
These studies will now be summarized in three tables, which will 
classify the published studies into poorly controlled (being 
studies which have been performed without a placebo control group, 
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have studied more than one injury type, have failed to use 
objective means to determine efficacy or all of the above), 
moderately controlled studies (which have used a placebo as a 
control but have failed to use objective means in testing efficacy 
or have used more than one injury type, or both of these) and well 
controlled and scientifically sound studies (which have used a 
placebo as a control, have used only one injury type and have used 
at least one objective test in determining efficacy). 
Table 2.1 POORLY CONTROLLED STUDIES OF NSAID EFFICACY 
IN THE TREATMENT OF SPORTS RELATED INJURIES 
REFERENCE 
Abbott et al. 1980 
Aghababian, 1986 
Aghababian et al. 1986 
Anderson & Gotzsche, 1984 
Beveridge, 1985 
Blackhouse et al. 1980 
Bodiwala, 1982 
Bouchier-Hayes, 1984a 
Bouchier-Hayes et al. 1984b 




Duncan & Farr, 1988 
Edwards et al. 1984 










Simmons et al. 1982 
Stull & Jokl. 1986 
Walker et al. 1984 































































The studies tabled above were all performed without a suitable 
control group, for example a placebo group, and most were performed 
on various types of different injuries. In addition, subjective 
measures were used to assess patient progress. These studies are 
therefore of little value as they cannot be assessed on scientific 
grounds. 
Table 2.2 MODERATELY CONTROLLED STUDIES OF NSAID 
EFFICACY IN THE TREATMENT OF SPORTS 
RELATED INJURIES 
REFERENCE INJURY RESULT 
Andersson et al. 1983 ankle no diff. 
Fitch & Gray, 1974 soft tissue drug better 
Huskisson et al. 1978 soft tissue no diff. 
Jenner, 1987 soft tissue no diff. 
Krishnan, 1977 bursitis/ drug better 
synovitis 
Lereim & Gabor, 1988 soft tissue drug better 










*Key: +INJ = too many injuries; PT= poor testing technique; 
GT = good testing technique. 
The above studies all used a placebo group as a control. However, 
most of these studies compared too many injuries and failed to use 
objective measures to determine the efficacy of treatment (Fitch 
and Gray, 1974; Krishnan, 1977; Huskisson, 1978). Santilli et al. 
(1980) compared many different types of injury but used objective 
measures such as swelling and passive functional capacity, in 
addition to subjective means, to determine the validity of the 
drugs. Andersson et al. (1983) also used an objective test (water 
displacement of the ankle to determine swelling) but they used too 
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many different types of ankle injury and they failed to use a 
placebo group as a control. 
Table 2.3 WELL CONTROLLED STUDIES OF NSAID EFFICACY IN 
THE TREATMENT OF SPORTS RELATED INJURIES. 
REFERENCE 
Dupont et al. 1987 
Goldie et al. 1974 
Hutson, 1986 
Mc Latchie et al. 1985 
Reynolds, 1987 
Van Heerden, 1977 

















The studies listed in Table 2.3 are all placebo controlled studies 
which were conducted on an injury limited to one anatomical area. 
However, the degree of objectivity in the testing techniques is 
still not sufficient in most of these studies for example, Hutson 
(1986) used subjective measures to determine drug efficacy, whereas 
van Marion (1973), despite commenting on the subjectivity of 
previous studies, failed to use truly objective measures to 
determine the effect of indomethacin on ankle injuries. The 
different types of ankle injures also varied and therefore this 
detracts from the validity of the study. 
It is interesting to note that only one study was performed on 
muscle injuries alone (Reynolds, 1987). 
As described earlier, certain substances are released into the area 
of trauma after an injury, the most important of these being 
histamine, serotonin and bradykinin (Oakes, 1981). These substances 
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have a vasodilatory effect and they stimulate the release of 
prostaglandins which sensitize the skin to chemical and mechanical 
stimuli (Moncada et al. 1975). Their release from the hypothalamus 
has a pyrogenic effect (Vane, 1971). 
NSAID's are known to interfere with prostaglandin production by 
inhibiting the cyclo-oxygenase enzyme. They are also known to 
inhibit neutrophil (hence anti-pyretic) and monocyte/macrophage 
activity (Almekinders and Gilbert, 1986). For these reasons 
NSAIDs are thought to be useful in the treatment of acute soft 
tissue injuries. 
All NSAIDs are easily absorbed from the gastro-intestinal tract 
where they bind to plasma proteins. They have a short half life and 
most are eliminated by hepatic metabolism (Huskisson, 1978). 
2.2.2. Sodium meclofenamate 
Sodium meclofenamate (meclofenamate) an anthranilic acid derivative 
is a NSAID exhibiting anti-inflammatory, analgesic and anti-pyretic 
activity (Ebner et al. 1983). It has been shown to be safe and 
effective in the treatment of rheumatoid arthritis, osteoarthritis, 
ankylosing spondylitis, traumatic oedema and extra-articular 
rheumatic diseases (Rennie, 1977; Multz et al.1978; Wilkens, 1978; 
Ebner et al. 1983; Boussina et al. 1983; Honorato-Perez et al. 
1983). 
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In these controlled trials on conditions such as post-traumatic 
edema, ankylosing spondylitis, rheumatoid arthritis, osteo-
arthritis and extra-articular rheumatic disease, using 
oxyphenbutazone, indomethacin, aspirin, and placebo as controls, it 
has compared favourably using subjective pain scales and swelling 
measurement as criteria for assessment. However, no studies have 
been performed using meclofenamate on acute muscle trauma. Fewer 
side effects were reported in the meclofenamate groups, which is 
contrary to the opinion of Katz (1977) who reported anthranilic 
acid derivatives to have a low potency compared to aspirin, and to 
predispose to gastro-intestinal problems. 
Reynolds (1987), however, in a double-blind placebo controlled 
"mini" study, found that meclofenamate was no more effective than 
placebo in patients treated with physiotherapy for acute quadriceps 
or hamstring muscle strains. As mentioned before though, the sample 
sizes (n=5 in each group) were too small to obtain a meaningful 
result. 
The recommended dosage for meclofenamate is one 50 mg capsule 3 
times per day. 
The following are contraindications to taking meclofenamate: 
* patients with gastro-intestinal disease 
* Patients with impaired hepatic, renal or 
haemopoietic function 
* children under 14 years 
* pregnant women or nursing mothers 
* patients with a sensitivity to aspirin or 
other NSAID 
* patients with asthma or other allergic 
condition. 
Structure and classification 
Figure 2.1 meclofenamate structure 
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The chemical structure of sodium meclofenamate monohydrate [N(2,6 








2.2.3. Diclofenac sodium 
Diclofenac sodium (diclofenac) is an acetic acid derivative 
(Moncada et al. 1975) and is a non-steroidal anti-inflammatory drug 
whose properties are analgesic (van Heerden, 1977), anti-pyretic 
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(Polman and Huybers, 1980) and anti-inflammatory (Duncan and Farr, 
1988) . 
Like other NSAIDs it owes its effect largely to its ability to 
counter the formation of prostaglandin from arachidonic acid. 
Numerous trials have been conducted in many spheres of medicine 
using diclofenac in dosages ranging from 25 mg to 150 mg, 1 to 3 
times daily (Voltaren, 1981). 
Duncan and Farr (1988) compared diclofenac and aspirin in a 
randomized, double blind, parallel group trial in the treatment of 
acute sports related strains and sprains. They found that 
diclofenac allowed for an earlier return to sporting activity than 
aspirin. Both drugs were tolerated well. 
Diclofenac is eliminated via the kidneys (66 %) and in the bile and 
faeces (33%) - 40 % of the dose is excreted in the first 12 hours 
of administration and 90 % from 72 hours onwards (Voltaren, 1981). 
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structure and Classification 
-The chemical structure of diclofenac--Sodium (sodium-[O [(2,6 
dichlorophenyl) -amino] -phenyl] cetate) is as follows: 
COO Na 
N 
Figure 2.2 diclofenac structure (Voltaren, 1981) 
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2.2.4. Figure 2.3 NSAID Classification (Moncada et al. 1975) 
NSAID 1-
. <:: 



































The value and use of physical or physiotherapeutic modalities are 
poorly documented in studies that have been performed to test the 
efficacy of NSAIDs. These measures are usually not mentioned, 
occasionally attention is paid to them (Huskisson et al. 1973; van 
Heerden, 1977; Chiapuzzo, 1979; Fitch and Gray, 1980; Milenovi'c 
and Mili'c, 1980; Santilli et al. 1980) and in others physiotherapy 
is specifically excluded (Muckle, 1980 and 1977; Anderson and 
Gotzsche, 1984). Burry (1975) suggests that it is likely that 
physiotherapy is more important in the treatment of soft tissue 
sports injuries than in any other disease of the locomotor system. 
The modalities most commonly mentioned in the research referred to 
above are R.I.C.E. (standing for rest, ice, compression and 
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elevation), exercise therapy and stretching exercises, ultrasound 
and occasionally shortwave diathermy and other heat modalities. 
Mention is also made of other modalities which are effective in the 
treatment of acute muscle injuries, such as deep friction massage 
(Winter, 1968; Chamberlain, 1982; Cyriax, 1984) and variations 
within the scope of exercise therapy such as isokinetic 
rehabilitation (Oakes, 1981). 
2.3.2. R.I.C.E. (rest, ice, compression and elevation) 
RICE is the treatment of choice in the first 24 - 48 hours 
following trauma to muscle (Fitch and Gray, 1974; Millar, 1976; van 
Heerden, 1977; Chiapuzzo, 1979; Santilli et al. 1980; Oakes, 1981; 
Irving, 1989). However, only two studies were controlled (Laing et 
al. 1973; Wilkerson, 1985). 
Rest is the most important treatment in acute soft tissue trauma 
according to Commandre (1983). Millar (1976) feels that rest is not 
indicated as this can lead to weakness in other muscle groups, can 
cause too tight a scar which takes long to stretch and severe cases 
may develop deformities such as "foot drop". Oakes (1981) stresses 
that rest should only apply to the injured part and suggests that 
the following principles be observed: 
* adequate time must be allowed for recovery of 
tissue, 
* a painfree muscle with full strength, power and 
extensibility must be obtained, 
* cardiovascular fitness must be maintained. 
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Ice, used for acute soft tissue injury, has a deep local effect 
which causes vasoconstriction, which helps to control initial 
bleeding which limits the consequences of injury. It also offers a 
certain amount of pain relief for the patient for up to 2 hours 
after ice application (Laing et al. 1973). 
Laing et al. (1973) outline what they believe to be the ideal 
treatment for a tear or haematoma of the quadriceps or hamstring 
groups of muscles, and strongly recommend ice application for no 
less than 20 minutes. This should then be followed by periods of 
compression bandaging (4-6 hours) and exercise in the form of 
walking initially and later more vigorous activity. 
Pressure bandaging is of equal importance for the same reasons 
outlined above and should not be overlooked (Laing et al. 1973). 
Fluid which is allowed to fill interstitial spaces delays recovery 
and may even predispose to re-injury (Wilkerson, 1985). Wilkerson 
adds that control of oedema will effect the following: 
(a) reduction of secondary hypoxic tissue damage 
(b) better healing by first intention of opposing 
ends of torn tissue 
(c) avoid the formation of necrotic tissue barrier 
around the injured tissue 
(d) reducing pain and muscle spasm 
(e) maintenance of joint function and mobility (in 
joint sprains). 
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Pressure bandaging and elevation of the part enhance venous return 
and increase "vascular suck" of the extracellular fluid thereby 
reducing oedema (Oakes, 1981). 
2.3.3. Ultrasound 
Dyson and Pond (1968) have shown ultrasound to be beneficial in 
various dosages in the healing of experimental wounds of rabbit 
ears. However, very few studies have been performed to test the 
efficacy of ultrasound. Only three studies could be found which 
used a controlled research technique (Dyson, 1976; Roche and West, 
1984; Mc Diarmid and Burns, 1987) as opposed to personal experience 
(Oakley, 1982) or case reports (Fergusson, 1981). 
The result is that little is known about the optimum treatment 
regimes for various conditions. It is left to the physiotherapist 
to study the available literature and adapt a carefully reviewed 
rationale for treatment for each case (Mc Diarmid and Burns, 1987). 
It is believed that ultrasound can stimulate the release of 
histamine from the mast cells in the inflammatory phase of soft 
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tissue trauma, and it would be seen as pro-inflammatory in this 
regard; however it would also stimulate healing by bringing on the 
proliferative stage of healing (Dyson, 1987). 
Dyson (1987) adds that ultrasound given in the proliferative phase 
of soft tissue healing is also beneficial as it accelerates repair 
by stimulating fibroblast activity which produce connective tissue, 
and the endothelial cells which allow for the formation of new 
blood vessels in the area. Whilst ultrasound facilitates scar 
contraction, no research has yet demonstrated the phenomenon known 
as "contracture" thought to be elicited by ultrasound. 
Partridge (1987), like Dyson (1987) found that therapeutic 
ultrasound begun in the inflammatory phase results in strong 
elastic scar tissue. 
Frequency and intensity settings in the treatment with ultrasound 
seem to be the most controversial issues debated in the literature: 
Scott (1975) suggests that 0.25 - 1 W.cm-2 be used for acute 
pathology (0.25 W.cm- 2 to begin with) but that the depth of the 
injured area below the surface should be taken into account. 
Intensities up to 2 - 2.5 W.cm- 2 should be considered for deep 
seated lesions such as deep muscle tears. 
Dyson (1987) reports research done by Hashish (1986) which has 
shown ultrasound intensities above 0.5 W.cm- 2 to be pro-
inflammatory, but that this may be beneficial in the short term for 
30 
acute soft tissue trauma in that it will accelerate the transition 
to the remodelling phase. 
2.3.4. Deep Transverse Friction Massage 
Deep transverse friction massage is a technique first described by 
Cyriax (1984). The technique involves the application of 
therapeutic movement to musculo-skeletal structures over a small 
area (Chamberlain, 1982). 
Very little research has been done on this modality but it has been 
shown to be effective in promoting the healing of soft tissue 
trauma (Chamberlain, 1982). 
Cyriax (1984) found that friction massage, applied to muscle, 
allowed it the necessary painless broadening ability during 
contraction which passive stretching and active exercise could not 
achieve. The treatment is said to effect the following in muscle: 
* traumatic hyperaemia which aids in pain relief, 
* freedom of movement by breaking down fibrous 
adhesions around the lesion (Cyriax, 1984). 
Cyriax and Chamberlain agreed on the following principles in 
technique which would ensure success in treatment: 
* the muscle should be in a relaxed position 
* application should be accurate, deep and across 
the fibres, 
* the therapist's finger and the patient's skin 
should move as one, 
* frequency and duration of treatment should vary 
with severity. 
There is, however, no experimental evidence to back up these 
claims. 
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Loading of the muscle during treatment should be avoided (Winter, 
1968; Cyriax, 1984) as this is painful and will put a stretch on 
the healing scar which is believed to be detrimental to the healing 
process. Millar (1976) suggests that avoiding loading the muscle 
from an early stage results in excessive scarring at the wound and 
may lead to reduced muscle tone and sometimes excessive weakness, 
ie. "dropped foot" from excessively weak tibialis anterior 
following gastrocnemius muscle tear. 
2.3.5. Rehabilitative Exercise 
This is a relatively well documented and accepted approach to the 
management of acute soft tissue injuries (Corrigan, 1967; Burry, 
1975; Millar, 1976; Oakes, 1981; Noakes, 1986; Irving, 1989). 
Increasing emphasis is being placed on active rehabilitation in 
such management (van Heerden, 1977). 
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Millar (1976) employed an intensive rehabilitation regime on 
sports-persons with gastrocnemius strains and was able to return 
68% of these people to the sports field within a week. The 
recurrence rate of injury was 1% of the total sample size of 400 
patients. This success, he believes, could be attributed to the 
early commencement of rehabilitation ("those patients who presented 
within 48 hours experienced the shortest absence from 
sport") involving regular ice application, compression bandaging 
muscle strengthening and stretching exercises and electrotherapy 
modalities such as ultrasound, interferential and shortwave 
diathermy. 
Pain free muscle with full power and extensibility are pre-
requisites for returning to competitive sport after an acute muscle 
injury (Millar, 1976; Oakes, 1981). Oakes describes a 
rehabilitation program in detail which he suggests could be used 
for 2nd degree hamstring strains in the "remodelling" and 
"repair" phases of healing. The emphasis initially is on frequent 
stretching. Later (weeks 1-3) jogging (with an adequate warm-up) is 
advocated to maintain cardiovascular fitness. He stresses that no 
maximal loading of the muscle as would occur with sprinting and 
kicking, should be done whilst moving onto the next phase (weeks 3-
4). These maximal loading activities should be phased in gradually, 
with pain being the most important guiding factor. This approach is 
also advocated by Irving (1989). Isokinetic testing of power and 
endurance is important in determining strength or endurance 
deficits in muscle (Oakes, 1981; Noakes, 1986). Burkett (1970) has 
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shown that weak hamstrings or an imbalance between the hamstring 
group and the quadriceps group of muscles of the same leg may 
increase the possibility of a hamstring lesion if such a weakness 
is not corrected. 
However, we now know that this is not the main reason why two-joint 
muscles tear: it is the inability of the muscle, which is 
contracting eccentrically in decelerating the limb, to absorb the 
excessive amount of energy imposed on it (Garrett, 1990). 
The emphasis therefore falls on the maintenance of muscle 
extensibility, endurance and power and adequate warm-up prior to 
exercising, a view which is supported by Pipes and Wilmore (1975) 
and Oakes (1981). 
They have found isokinetic training to be a preferable method of 
rehabilitation following soft tissue injury. Following research 
done by Garrett (1990), however, there is a definite indication 
that the emphasis should be on eccentric muscle work to prepare the 
muscle for eccentric loading during exercise. 
Anderson and Gotzsche (1984), in researching the effects of NSAIDs 
on soft tissue sports injuries, excluded the use of any form of 
rehabilitation from their treatment protocol. Muckle (1974, 1977 
and 1980) also in testing NSAID efficacy, excluded any injuries 
from analysis which required any ultrasound or manipulation. He 
does, however, mention that the analgesic effects of the drugs 
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allowed for earlier employment of static muscle contractions which 
would help avert muscle atrophy. Muckle (1974) stresses that muscle 
strength, power and extensibility should be regained prior to the 





It is obvious from the foregoing literature that there is a 
definite need for objective research into the use of NSAIDs in the 
treatment of acute soft tissue sports injuries. Some useful 
research has been done on animals (Almekinders and Gilbert, 1986) 
but this needs to be backed up by equally useful research on man. 
After consulting Professor T.D. Noakes of the Physiology 
Department at the University of Cape Town, and later Warner 
Lambert Parke Davis pharmaceutical company, it was decided that a 
study should be done to investigate the possibility of such a 
research project. 
In October 1986 a research protocol was established for a double 
blind study to investigate the effects of NSAIDs, in combination 
with physiotherapy treatment, on the healing of acute muscle 
injuries of the thigh. The study was to be conducted in two 
centres, namely: No's 1 and 2 Military Hospitals in 
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Voortrekkerhoogte and Wynberg respectively. Military patients were 
selected because of their availability and reliability of 
attendance. 
The use of Cybex isokinetic equipment to test muscle 
performance was deemed essential to ensure objective assessment of 
the effects of treatment. This is the first time such accurate 
measures have been used to assess muscle performance in testing 
this medication. Pain and swelling assessments were included in the 
assessment as NSAIDs are said to have analgesic and anti-
inflammatory properties. 
The sequence of events following injury and referral to the study 
would be as follows: 
1. Subjective assessment and screening for inclusion and 
exclusion criteria, 
2. Objective assessment including isokinetic muscle function 
tests, pain and swelling to be done on days 1, 3 and 7 
after the injury 
3. Physiotherapy treatment for seven consecutive days 
3.2 SUBJECT SELECTION 
Patients were referred for selection to this study by Defence 
Force medical officers and General Practitioners. They were 
assessed initially by a doctor for suitability using the 
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inclusion and exclusion criteria which were laid down in the 
research proposal (see 3.2.1. (a) & (b)). If they were found to be 
unsuitable, appropriate liaison with the referring doctor ensured 
that the patient received other appropriate treatment. Patients 
found to be suitable had the study objectives and implications 
explained to them, after which they were asked to sign a consent 
form, stating their intent to comply with the prescribed protocol. 
These patients were then admitted to the study. 





(a) Inclusion Criteria 
Males or females from the ages of 15 to 60. 
Patients under the age of 18 required parent's written 
consent before being admitted to the study. 
The patients were to have suffered acute muscle 
injuries of either the quadriceps femoris (including 
either rectus femoris, vastus medialis, vastus 
lateralis or vastus intermedius or a combination of 
these) or hamstring muscles (including biceps femoris, 
semi-tendinosis or semi-membranosis or a combination 
of these) 
The injury was to have been sustained no more 
than 48 hours prior to the first assessment 
The patient had to have signed the consent form 
(Appendix 1) 
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The use of any other drugs such as analgesics, 
anti-inflammatory agents (including oral 
medication, suppositories or gels), cortico-
steroids, topical-rubifacients or anti-coagulants, 
Hypersensitivity to aspirin or NSAIDs 
Significant diseases - including a history of peptic 
ulceration, haematologic or haemopoietic disease, 
asthma or bronchospasm. 
(iv) No competitive sport to be undertaken during the 
study. 
(v) Any other associated injury to the thigh or knee of 
either leg. 
Provision was made for patients to withdraw from the study for the 
following reasons: 
(i) voluntary withdrawal 
(ii) protocol violation 
(iii) drug intolerance 
(iv) serious illness. 
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3.3 EXPERIMENTAL PROCEDURES 
3.3.1 Pain Testing 
(a) Introduction 
A visual analogue scale was selected to assess the patient's pain, 
as this scale has been shown to be superior to other such tests 
(Scott and Huskisson, 1976; Liggins, 1989). In particular this 
technique of pain assessment, referred to as the numeric rating 
scale by Liggins (1989), is more accurate than the simple 
descriptive pain scales which have been used in the past (Liggins, 
1989) . 
The vertical visual analogue scale (or numeric rating scale) was 
selected for this study with the degree of severity descending in 
intensity from 10 to O. A score of 10 represented unbearable pain 
and a score of O represented no pain. 
Patients were asked to assess their pain in the five ways indicated 
below. In order to obtain an accurate indication of the patient's 
pain, five scales were used instead of one. 
(b) Implementation 
Pain was assessed under the following headings on 5 different 
visual analogue scales: 
1. Pain experienced in the previous 24 hour period. 
2. Pain on movement. The patient was positioned on 
his side to eliminate gravity and was asked to 
flex and extend the knee through the available 
range of movement. 
3. Pain on walking 10 metres (recorded as 10 if not 
able to do so). 
4. Pain on running 10 metres (recorded as 10 if 
not able to do so). 
5. Pain on palpation of the affected area. 
(c) Data collection 
40 
Each patient completed 5 visual analogue scales on days 1,3 and 7 
of the study. The patient's scores were added together for each day 
and recorded. The result was that three total values were recorded 
for each patient during the study, one for each assessment 
day. 
A total pain score was calculated for each assessment day in each 
group. Median values were then obtained. 
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3.3.2 Swelling measurement 
(a) Introduction 
swelling is commonly assessed in most studies researching the 
effects of NSAID medication. This is done by assigning values to 
the degree of swelling, for example where swelling is assessed as 
mild, moderate or severe, the numeric values 1, 2 and 3 will 
be assigned respectively (Corrigan, 1967; Huskisson et al. 1973; 
Fitch and Gray, 1974; Krishnan, 1977; Williams and Engler, 1977; 
Bouchier-Hayes and Jones, 1979; Chiapuzzo, 1979; Abbott et al. 
1980; Commandre, 1983; Mann, 1983; Edwards et al. 1984; Duncan and 
Farr, 1988). 
This method is open to subjectivity on the part of the observer. It 
was decided therefore that an objective measure should be used to 
determine the degree of swelling. 
(b) Design and measurement procedure 
swelling was measured using a plastic tape measure graded in 
centimetres and millimetres. Three measurements were taken of each 
leg with the patient positioned in prone lying for hamstring 
injuries and in supine lying for quadriceps injuries. The site of 
maximum pain was determined by palpation of the affected leg. The 
distance from this circumferential measurement to the superior pole 
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of the patella (in the case of quadriceps injuries), and the 
popliteal crease (in the case of hamstring injuries), was recorded. 
This was done so that: 
(i) measurements could be taken at the same sites during 
subsequent visits and 
(ii) a measurement at the similar anatomical site on the 
opposite leg could be taken for comparison. 
(c) Data Collection 
Three measurements were taken of the affected and unaffected legs 
at the site of injury and the corresponding site on the unaffected 
leg respectively. A mean was calculated from these three readings 
for each leg on each assessment day. A ratio was then calculated 
for each assessment day by dividing the mean value for the affected 
leg by the mean value for the unaffected leg. 
3.3.3 Cybex II Isokinetic Muscle Test 
(a) Introduction 
Isokinetic testing using a Cybex II dynamometer and data reduction 
computer provides an accurate measure of isokinetic muscle 
performance (Oakes 1981). 
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In researching the literature available on the efficacy of NSAIDs 
it is noted that objectivity is lacking in experimental procedure. 
One of the principal aims of this study was to determine 
objectively the effects of NSAIDs on the healing of muscle injuries 
by measuring the rate and extent of recovery of isokinetic muscle 
strength and endurance and assessing the rate of pain and swelling 
reduction. 
The Cybex II Data Reduction computer provides us with accurate 
measurements and readings of isokinetic muscle performance in terms 
of power and endurance. The machine accurately measures torque 
production at a given speed by the patient. By comparing these 
different torque values produced by each leg, accurate deficiencies 
in muscle power and endurance can be determined. 
(b) Positioning of Patients 
For the Cybex test, the patient was positioned in sitting with hips 
and knees flexed to 90°. The axis of rotation of the lever arm of 
the Cybex machine was positioned opposite the centre of the knee 
joint, which is opposite the medial femoral condyle. The distal end 
of the lever arm was secured to the patient via a shin-pad placed 
just proximal to the malleoli. Thigh and shin-pad-straps were 
tightened within comfortable limits to eliminate unwanted 
movement, for example hip extension, and to ensure that the lower 
leg and the lever arm of the Cybex machine moved as one. The 
unaffected leg was always tested first and practice runs of 5 
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repetitions were allowed to enable the patient to become accustomed 
to isokinetic exercise. The power test was always performed first 
on each leg. Quadriceps and hamstrings power was tested during 5 
reciprocal contractions using a speed of 60°.sec-1 . Data were 
measured as peak torque and expressed in Newton metres. 
Quadriceps and hamstring endurance was assessed during 25 
reciprocal contractions at a speed of 240°.sec-1 . Endurance was 
measured and expressed in 3 different ways, namely: 
(i) Total work, performed during 25 contractions and 
expressed in Joules. 
(ii) Torque acceleration energy which is a measure of 
the energy expended in the first 0.125 ms of torque 
production. This was expressed in Joules. 
(iii) Average power which is the total work produced in 
the 25 contractions, divided by the actual 
contraction time. Average power was expressed in 
Watts. 
Patients were instructed to do the following: 
1. Work maximally during all testing. 
2. The lower leg must move through the maximum 
available range of movement. 
3. Fold arms across chest throughout testing. 
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Testing was always done before treatment was given. However, pain 
and swelling measurements were done prior to Cybex testing. 
(d) Data Collection 
Both legs were tested on each of the three assessment days. The 
Cybex Data Reduction Computer gave a print-out of each test. 
Measurements of peak torque, torque acceleration energy, average 
power and total work were listed and recorded on the patient 
assessment form (Appendix 1). 
A ratio was obtained in each of these testing categories, for each 
patient on each assessment day. This was done by dividing the value 
obtained in each category for the affected leg by that obtained for 
the unaffected leg. Therefore in each testing category, a ratio 
was calculated for each patient for each assessment day. 
3.4. DRUG ADMINISTRATION 
3.4.1. Randomization 
Patients admitted to the study were randomly allocated to one of 
three groups, A, B or c. The random code was set up by Warner 
Lambert/Parke Davis in Wales, (UK), who also packed and supplied 
the drugs and placebos. 
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The random code was held by Warner Lambert (SA) Pty Ltd and could 
only be opened in an emergency by order of a doctor, for example, 
in case of a possible drug intolerance. This method ensured that 
the study was performed using a double-blind technique. 
3.4.2 Drug Dosage and Package 
Meclofenamate was packed in white capsules, each capsule containing 
50mg sodium meclofenamate. The diclofenac was packed in gray 
capsules each capsule containing 25mg diclofenac sodium. Half the 
placebo capsules were white and half were gray. 
Diclofenac sodium in the 25mg dosage is usually marketed in tablet 
form. As a result, experimentation had to be done for this study to 
determine whether crushed tablets placed into capsules would be 
safe and as effective as the capsule format. This experimentation 
was done by Warner Lambert in Milan, Italy, and they found that the 
capsule format was sufficiently effective. The tablets were 
therefore crushed and placed into capsules for this study (see 
Appendix 7). 
Each patient received a small box containing two bottles of 
capsules. The label on the box instructed the patient to take two 
capsules from each bottle 3 times a day, with meals. The bottles, 
therefore, each contained 42 capsules sufficient to last the 
patient for seven days. Patients in group A received meclofenamate 
capsules and grey diclofenac placebo capsules. Patients in group B 
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received diclofenac capsules and white meclofenamate placebo 
capsules. Patients in group C received white meclofenamate placebo 
capsules and grey diclofenac placebo capsules. This method of 
administration was necessitated by the fact that the capsules were 
of a different colour. 
Patients were assessed on days 3 and 7 to determine whether any 
side-effects had developed. No leading questions were posed. If a 
patient had experienced what he or she thought were side effects, 
he or she was examined by the doctor to decide on the course of 
action to be taken. The doctor also decided whether the side effect 
experienced could be related to either meclofenamate or diclofenac. 
3.5. PHYSIOTHERAPY TREATMENT 
3.5.1 Introduction 
All patients received the same physiotherapy treatment on all seven 
days of the study. This treatment commenced after assessment on day 
1 and stopped when the patient was fully recovered. The treatment 
used was described in the research proposal which was drawn up 
before the study commenced. As this was a multi-centre study, 
physiotherapists at the various centres were shown exactly what 
treatment to give. In this way, all patients received the same 
treatment. 
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3.5.2 Rest, Ice, Compression and Elevation (R.I.C.EJ 
This form of treatment is widely used and generally advocated in 
the management of acute soft tissue injuries (Corrigan, 1967; van 
Heerden, 1977; Chiapuzzo, 1979; Santilli et al. 1980; Oakes, 1981; 
Irving, 1989). 
Patients were instructed to rest from all sporting activity for 48 
hours after the injury. In addition, no competitive sport was 
allowed during the remainder of the seven day study period. 
Ice packs, which could include cryogel packs or ice cubes (whole or 
crushed ice) in a damp towel, were applied for 20 minutes over the 
injured area which was determined by palpation by the 
physiotherapist at the first visit. This was done as often as was 
possible in the first 48 hours. Elastic compression bandages were 
provided to each patient and were to be worn continually for the 
first 48 hours after the injury. The bandage was applied in double 
layers and extended from the groin to below the knee. 
The patient was instructed to keep the limb raised on a stool when 
sitting during the 48 hour period after injury, and encouraged to 
do this as often as possible. 
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3.5.3 Deep Transverse Friction Massage (Friction massage) 
Friction massage (Cyriax, 1984) was given on alternate days 
starting 48 hours after the injury. This was done for 10 minutes 
each session. The muscle tear was found by palpation and the 
friction massage applied as vigorously as the patient would allow. 
3.5.4 Ultrasound 
Continuous ultrasound therapy was given every day starting 48 hours 
after injury. Care was taken to omit areas where a haematoma might 
be present. 
A dosage of lW.cm-2 was given for 5 minutes over the affected area 
as determined by palpation. A 1.0 MHz sound head was used on all 
machines and, where possible, the same machine was used in each 
centre in an attempt to standardize the treatment. 
3.5.5 Rehabilitative exercise 
This started on day one with passive stretching techniques only, 
which were done every day of the trial. All stretching was 
controlled/overseen by the physiotherapist. 
(a) Quadriceps: The patient was positioned in prone lying on a 
flat examination couch. The knee of the affected leg was 
passively flexed until discomfort was felt. The physiotherapist 
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then instructed the patient to relax; after having felt the 
relaxation, the patient then flexed a little more and held the 
stretch for 10 seconds, and then relaxed the stretch. This was 
done 10 times at each treatment session for 7 days. 
(b) Hamstrings: The patient was positioned in a supine lying 
position on a flat examination couch. The affected leg was 
flexed at the hip, keeping the knee straight and the ankle in 
dorsiflexion, until the patient experienced discomfort. The 
patient was then instructed to relax and on feeling this, the 
therapist increased the stretch slightly and held it for 10 
seconds before relaxing. This was repeated 10 times at each 
treatment session for 7 days. 
Rehabilitative exercise was introduced 48 hours after the injury 
occurred and included the following: 
(1) Isometric exercises: 
This exercise involved tightening the hamstring muscles, holding 
for 10 seconds and then relaxing for 10 seconds; then tightening 
the quadriceps muscles for 10 seconds and then relaxing for 10 
seconds. This was repeated 10 times at each treatment session for 
the remaining days of the study. 
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(2) Aerobic exercise 
Patients were encouraged to start aerobic sport, for example 
swimming or running 3 days after injury. They were instructed to 
stop such activity if they experienced discomfort in the injured 
muscle. No competitive sport was allowed at any stage during the 
seven day study. 
3.6. STATISTICAL METHODS 
All analysis was done using the analysis-of-variance test. The 
acceptance level used was where p<0.05. 
In the event of there being a large variation in day 1 values, the 
transformation formula described by Cox (1958) was used to correct 
for this. Therefore, instead of using ratio values as described 




affected leg value - unaffected leg value 
unaffected leg value 
= y 
= X 
Mean values were then calculated for these y-values in each 
assessment and plotted on the y-axis on the graph. 
In the study by Reynolds (1987), it was found that injuries to the 
quadriceps and hamstring groups were not very severe. When it was 
discovered that this was also the trend in this study it was 
decided to separate the severe injuries from the non-severe 
injuries for purposes of a second analysis. 
(a) The groups were analyzed to assess whether the degree of 
severity was evenly distributed throughout the three 
groups in their respective sub-groups. This was done by 
applying the two-way analysis-of-variance test using 
injury severity as a co-factor. 
(b) The data were stratified in terms of severity levels 
and statistical analysis was done using the one-way 
analysis of variance test for each treatment group. 
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Between 1 January 1987 and 1 June 1989, 75 patients were admitted 
to this study. Of these, 15 were excluded for protocol violation or 
non-compliance. Of the 60 patients who completed the study, 21 
patients received meclofenamate, 19 diclofenac and 20 placebo, 
according to the random code which was held at the Warner Lambert 
(SA) head office in Tokai, Cape Town. 
Of the 60 patients who completed the study, 9 were seen in Pretoria 
at No 1 Military Hospital and 51 were seen in Cape Town at the No 2 
Military Hospital. 
There were 13 hamstring injuries and 8 quadriceps injuries in the 
meclofenamate group, 17 hamstring and 2 quadriceps injuries in the 
diclofenac group and 14 hamstring and 6 quadriceps injuries in the 
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placebo group (see Table 4.1). 
TABLE 4.1 TABLE OF PATIENT AND INJURY DISTRIBUTION 















TABLE 4.2. HEIGHT, WEIGHT, INJURY SEVERITY, AGE AND SEX 
DISTRIBUTION IN EACH GROUP 
MECLOFENAMATE DICLOFENAC PLACEBO 
WEIGHT (kg) 79.6 79.1 78.1 
±11. 9 ±11.2 ±8.0 
HEIGHT (cm) 179.2 176.0 179.8 
±7.7 ±9.2 ±6.5 
INJURY SEV. * 1. 9 1. 9 1.8 
±0.6 ±0.7 ±0.6 
AGE (years) 29.5 31. 3 28.2 
±10.0 ±9.6 ±7.8 
SEX MALE 21 18 20 
FEMALE 0 1 0 
* KEY: mild injuries= l; moderate injuries= 2; severe 
injuries= 3. Data presented as mean and standard 
deviation. 
There was only one female patient admitted to the study and she 
received diclofenac. The average weights and heights of the 
patients were very similar, as were their ages and the severity of 
their injuries (Table 4.2). 
The number of quadriceps injuries was not evenly distributed 
between the groups (see Table 4.1). It would be pointless to draw 
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conclusions from data where there were only 2 patients in one of 
the groups. Accordingly it was decided that only hamstring injuries 
would be assessed in this study and all data referred to 
hereinafter pertains only to these injuries. 
4.2 ADVERSE EVENTS 
A total of 13 out of 44 patients, or 28.6% of the total number of 
patients who sustained hamstring injuries encountered an adverse 
event during the study period. None of these adverse events 
warranted any reduction or alteration in medication, or any 
withdrawals from the study. The adverse events are described in 
Table 4.3. 
TABLE 4.3. ADVERSE EVENTS ENCOUNTERED BY PATIENTS WHO 
SUSTAINED HAMSTRING INJURIES 
ADVERSE EVENTS MECLOFENEMATE DICLOFENAC PLACEBO 
(n=13) (n=14) (n=17) 
stomach cramps 1 1 0 
drowsiness 2 3 1 
diarrhoea 1 1 0 
headache 0 1 0 
dry mouth 1 0 0 
incr. frequency of stools 0 0 1 
TOTAL 5 6 2 
It is important to note that the frequency of adverse symptoms was 
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4.3. PAIN TEST 
The line graphs drawn from the median values obtained for pain in 
each group are shown in Figure 4.1. There were no significant 
differences between any of the three groups. All groups showed a 
steady reduction in pain over the 7 days. 
4.4. SWELLING 
No significant differences could be found between the three groups 
in the swelling assessment (see Figure 4.2). 
It is immediately apparent from Figure 4.2 that the value for the 
placebo group on day 1 varies from the two drug group values on 
that day. The slopes of the curves on the graph are much the same 
throughout the remaining days. In order to correct for this 
difference at day 1, the transformation formula of Cox (1958) was 
employed as described previously. 
A graph of swelling was then drawn using this transformation. 




















QUADRICEPS PEAK TORQUE VS TIME 
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Figure 4.3. 
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• MEQ.OFENAMATE 
TIME (DAYS) 
+ PLACEBO <> DIC.OFENAC 
Figure 4.4. 
4.5. MUSCLE PERFORMANCE TEST 
4.5.1. Power test 
(a) Quadriceps (peak torque) 
Figure 4.3 shows the graph of quadriceps peak torque. No 
significant differences were shown between the three groups 
(p<0.05). 
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The starting positions of the three curves at day one differ widely 
and this was corrected for using the transformation formula 
described in 3.6 above. Again no significant differences between 
the three groups (p<0.05). 
(b) Hamstrings (peak torque) 
The graph of hamstring peak torque was analyzed (see Figure 4.4) 
and no significant differences could be shown between the three 
groups (p<0.05). 
The discrepancy in initial values was corrected for using the 
transformation described in 3.6 above, and statistical analysis of 
this data showed no significant differences (p<0.05). 
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4.5.2. Endurance test 
(a) Quadriceps endurance (Total work, average power and peak 
torque acceleration energy.) 
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The graphs drawn of quadriceps total work, average power and peak 
torque acceleration energy were analyzed (see Figures 4.5, 4.6 and 
4.7) and statistical analysis showed no significant differences 
between the three groups (p<0.05). 
The transformation formula described in 3.6 above was used again to 
correct for starting point discrepancies on day 1. Statistical 
analysis of the data again showed no significant differences 
between the three groups (p<0.05). 
(b) Hamstring endurance (total work, average power and 
peak torque acceleration energy). 
The graphs of hamstring total work, average power and peak torque 
acceleration energy were analyzed (see Figures 4.8, 4.9 and 4.10) 
and statistical analysis of these data showed there were no 
significant differences between the three groups (p<0.05). 
The transformation formula mentioned earlier was used to correct 
for the wide range of day 1 values and these data were analyzed 
statistically and no significant differences could be shown between 
the three groups (p<0.05). 
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4.5.3. Severe injury analysis 
In view of the fact that there were no differences found between 
any of the groups in the above analyses, it was decided to analyze 
the severe injuries apart from the non-severe injuries at the risk 
of dealing with smaller sample sizes. It was hoped that this may 
indicate the true effect of these drugs, in combination with 
physiotherapy treatment, on the healing of acute, severe hamstring 
injuries. Van Marion (1973) used a similar technique to eliminate 
mild to moderate injuries but could find no significant differences 
between indomethacin and placebo. 
Injury severity was determined in two ways in this study: 
(a) Patients were grouped according to their injury severity 
determined at the initial visit. The injury was subjectively 
assessed as being either mild, moderate or severe and 
assigned the values 1, 2 or 3 respectively. Analysis was done 
using the two-way analysis-of-variance test (p<0.05). 
(b) Patients were grouped according to objective injury severity 
criteria as follows: 
* hamstring peak torque at day 1 should be less than 60% of 
the normal leg. This test was selected for this criteria 
as the high resistance of the test makes it the most 
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difficult test to perform after an acute muscle injury 
* the total pain value at day 1 should be greater than 25, 
that is, giving an average greater than 5 out of 10. 
* the injury severity at day 1 should be equal to or 
greater than 2. 
After applying these limitations, two objectively determined sub-
groups for injury severity were obtained. In the severe-injury sub-
group there were 6 patients in the meclofenamate group, 5 in the 
diclofenac group and 6 in the placebo group. In the non-severe-
injury sub-group there were 7 patients in the meclofenamate group, 
9 patients in the placebo group and 11 in the diclofenac group. 
Graphs were drawn in the same way as before and statistical 
analysis was done as described in 3.6 above. 
(i) Subjective injury-severity analysis 
No significant differences could be found in this analysis and 
therefore there were no drug/severity interactions between any of 
the groups. From this we know that the random code used to split 
patients into the three treatment groups was an effective 
randomization. 
(ii) Objective severity comparative analysis 
A significant difference was found between the meclofenamate and 
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group was found to be superior to the meclofenamate group in 
relieving pain on day 7 (see Figure 4.11). Apart from this, there 
were no significant differences shown between the three groups in 
either injury severity sub-group. The placebo group also showed 
superiority over the diclofenac group although this difference was 
not significant (p<0.05). 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
Previous studies performed to test the efficacy of NSAIDs in the 
treatment of acute soft tissue sports injuries have failed to show 
that NSAID prescription positively influenced the treatment 
outcome. The only two studies which have shown greater efficacy 
than placebo, and which used objective measures to evaluate 
treatment outcome, failed to demonstrate a significant difference 
between the drug and placebo groups (Hutson, 1986; Van Heerden, 
1977) . 
This placebo controlled study has made use of isokinetic muscle 
performance testing, pain assessment and swelling measurement to 
test the efficacy of two NSAIDs on acute hamstring muscle tears. 
No significant differences could be found between any of the groups 
in the three tests performed. It is apparent that the placebo 
groups shows a tendency to improve from day 1 to day 3 in the 
muscle performance tests of the graph slopes are observed (see 
Figures 4,3., 4.4., 4.6., 4.7., 4.9.). Though this trend is not 
significant, it is in keeping with the research done by Almekinders 
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and Gilbert (1986) where injured muscle treated with NSAID was 
weaker in the initial post injury phase (1-4 days). It is however 
doubtful whether'a larger sample size would prove this trend to be 
a significant finding. Further analysis performed on severely 
injured patients also failed to reveal any differences apart from 
the superiority of placebo over the two drug groups in the pain 
test (see Figure 4.11); in terms of the analgesic properties of 
NSAIDs, this outcome would seem unlikely and is probably a spurious 
finding. 
No benefit could be found in the use of NSAIDs in combination with 
physiotherapeutic modalities. This study, therefore, can find no 
evidence for their use in the treatment of acute muscle trauma. 
This finding is compatible with the findings of Huskisson et al. 
(1973) and Almekinders and Gilbert (1986). 
Another important finding was that the swelling ratios in all three 
groups dropped below 1 by day 7. This may indicate that the 
muscles in the injured thigh had atrophied, despite an active 
rehabilitation programme having been used. This being the case, it 
is therefore very important to start such a programme as soon as 
possible. 
The adverse events encountered by the patients were mainly gastro-
intestinal in nature, which is not an uncommon feature of NSAIDs. 
Drowsiness, however, is not a common adverse event encountered with 
these drugs but it is more commonly seen with naproxen, piroxicam 
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and sometimes indomethacin (Williams and Engler, 1977; Bouchier-
Hayes and Jones, 1979; Simmons et al. 1982; Mann, 1983; Commandre, 
1983; Edwards et al. 1984). Anthranilic acid derivatives (for 
example meclofenamate) are said to be poorly tolerated in terms of 
gastro-intestinal irritation (Katz, 1977), and it is interesting to 
note that 2 out of 5 (40%) adverse events in the meclofenamate 
group are gastro-intestinal tract (GIT) related, as opposed to 2 
out of 6 (33%) in the diclofenac group and 1 out of 2 (50%) in the 
placebo group. 
Further research into the efficacy of NSAIDs in the treatment of 
acute muscle injuries is not deemed to be necessary as it is 
doubtful that a larger sample size would alter the result. The 
severe injury analysis failed to show any trend in favour of drug 
therapy and an attempt to try and obtain a sample with more severe 
injuries would likely be a fruitless exercise. It took two and a 
half years, in two major city centres, to recruit the patients for 
this study and this sample is therefore a good reflection of the 
acute hamstring injuries that are commonly seen. 
In conclusion, therefore, it was found that NSAIDs, in combination 
with physiotherapy treatment, have no effect on the rate of healing 
of acute hamstring muscle tears, and that physiotherapy treatment 
is effective in treating these injuries. These drugs should not be 
prescribed for acute muscle tears if consideration of their 
negative effects for example the side effects and delayed healing 
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(Almekinders and Gilbert, 1986). This finding therefore supports 
the null-hypothesis: 
"Acute muscle injuries treated with meclofenamate or diclofenac, in 
combination with physiotherapeutic modalities (such as RICE, 
ultrasound, deep friction massage and stretching and strengthening 
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PATIENT ASSESSMENT FORM 
A COMPARATIVE STUDY OF THE EFFECTS OF MECLOFENAMATE, DICLOFENAC 
AND PLACEBO, IN COMBINATION WITH PHYSIOTHERAPY, ON THE HEALING OF 
ACUTE QUADRICEPS AND HAMSTRING MUSCLE TEARS. 

















consent form signed /parent for patient under 18 











g:~~RVATIONI ~ ~~I ~1~=1~ 









Treatment with anti-inflammatory agents 
Treatment with analgesics 
Treatment with corticosteroids 
Treatment with topical rubifacients 
Treatment with anticoagulants 





History of peptic ulceration 
Haematologic or haemopoietic disease 




Date of injury 





D M Y 





DATE I I 
D 
Time of injury 
M 
24 hour clock 
Time of assessment 
24 hour clock 
Type of injury (site and extent of injury): 




MILD I I MODERATE 
/_j D SEVERE 
Details of post-injury first aid treatment: 
PATIENT I 
INITIALS 
F M L 
DATE OF BIRTH 
D M y 
PREVIOUS INJURY HISTORY 
D None 
Previous diagnosis 




PATIENT D OBSERVATION I l J NO DATE 
D M 
SEX HEIGHT 
11 M b F WEIGHT 
date started date stopped continuing 
continuing frequency other subj 
treatment assess-





F M L 
PATIENT 
NO 
MUSCLE PERFORMANCE TEST (CYBEX) 
POWER (60°.sec-1) 
PEAK TORQUE (Nm) 
ENDURANCE (2400.SEC-1) 
TOTAL WORK (J) 





DATE I . '----'--....__.. 
D M y 
AFFECTED LEG UNAFFECTED LEG 
PEAK TORQUE ACCELERATION ENERGY (J) 
PATIENT PATIENT 
INITIALS NO 
F M L 
PAIN (Vertical visual analogue 
Overall pain Palpation 















0 - No Pain 



























































D H y 
Measurement of thigh diameter at the site of maximum pain in both 
legs 
Affected Leg Unaffected Leg 
DODD DD!~D 
1 2 3 mean 1 2 3 mean 
PATIENT 
INITIALS....____,"--___,,_~_. 
F M L 
PATIENT 
NO 
MUSCLE PERFORMANCE TEST (CYBEX) 
POWER (60°.sec-1) 
PEAK TORQUE (Nm) 
ENDURANCE (2400.SEC-1) 
TOTAL WORK (J) 





D M Y 
AFFECTED LEG UNAFFECTED LEG 
PEAK TORQUE ACCELERATION ENERGY (J) 
PATIENT 
INITIALS 
F M L 
PATIENT 
NO 








I 0 0 0 
1 1 1 
2 2 2 
I 3 3 3 
4 4 4 
5 5 5 
6 6 6 
~ 
7 \7 7 
~ 8 8 
f---
9 l S 9 
I 
I 
~. 10 10 
L_ 
0 - No Pain 












































D M y 
Measurement of thigh diameter at the site of maximum pain in both 
legs 
Affected Leg Unaffected Leg 
:------1 !.--.. -. --1 r-i. 
I I i I i 
~ L__ ' __ : L___J 






















H probably ~ unknown I I 
i l 
f-----1 















~stop drug temp 
LJ stop drug perm 
PATIENT 
INITIALS 
F M L 
PATIENT 
NO 
MUSCLE PERFORMANCE TEST (CYBEX) 
POWER (600.sec-1) 
PEAK TORQUE (Nm) 
ENDURANCE (2400.SEC-1) 
TOTAL WORK (J) 





D M Y 
AFFECTED LEG UNAFFECTED LEG 
PEAK TORQUE ACCELERATION ENERGY (J) 
PATIENT PATIENT 
INITIALS NO 
F M L 
PAIN (Vertical visual analogue 
Overall pain Palpation 
in previous Pain 
24 hours 
ro 
I I o 














0 - No Pain 




























































1 2 3 mean 
Unaffected Leg 
----, --: ,--: r-----, 
' I I l; : i f 
__j i__j ._. __ : L__. 




































stop drug temp 
stop drug perm 
CONCURRENT THERAPY 









A SGudy of the effects of sodium meclofenamate and diclofenac 
sodium on the physiotherapy treament of acute quadriceps and 
hamstring muscle injuries. 
A trial is being conducted over seven days to establish the 
effects of anti-inflammatory drugs on physiotherapy treatment 
(i.e ultra-sound, cross friction massage and exercise.) 
Anti-inflammatory drugs are used to reduce inflammation and pain 
after injury. It is therefore thought that they hasten healing 
and rehabilitation of injuries, enabling the individual to return 
to sport sooner. 
The capsule or tablet that you receive may or may not be the 
active drug. Whether it is or not is also unknown to the 
therapists and will only be revealed when a code is broken at the 
end of the trial. 
The drugs are harmless to most people, but if you experience any 
problems you may withdraw from the trial immediately and 
continue with normal physiotherapy treatment. 
I .............................. hereby declare that I understand 
fully the details and implications of the abovementioned trial 




Date .............. " ................... " .. . 
(Afrikaans ook verkrygbaar) 
TOESTEKKIHGSVORM 
A study of the effects of sodium meclofenamate and diclofenac 
sodium on the physiotherapy treatment of acute quadriceps and 
hamstring muscle injuries. 
n Proef word gedoen oor 'n tydperk van sewe dae om die invloed 
van nie-steroied anti-inflammatoriese middels op fisioterapie 
behandeling te ondersoek (byvoorbeeld ultraklank, dwaarsfriksies 
en oefeninge.) 
Anti-inflammatoriese middels word gebruik om die inflammatoriese 
proses en pyn na besering te verlig. Dit word daarom aanvaar dat 
dit herstel en die rehabilitasie proses bevorder en dus die 
persoon in staat stel om sy sport vinniger te hervat na n 
besering. 
Die kapsuul of tablet wat u gaan kry mag aktief of onaktief wees. 
Die terapeut weet ook nie of u die aktiewe of onaktiewe middel 
gebruik nie. Dit word slegs aan die einde van die eksperiment 
onthu 1. 
Die middels is skadeloos vir die meeste mense. Indien u wel enige 
probleme ervaar staan dit u vry om u self onmiddelik te onttrek 
van die eksperiment en aan te gaan met normale fisioterapie. 
Ek .. .............................. verklaar hiermee dat ek al die 
besonderhede en implikasies van die bogenoemde eksperiment ten 
volle begryp. Ek gee hiermee my toestemming om deel te neem aan 





(English also available) 
80 
APPENDIX 2 
PATIENT DEMOGRAPHIC DATA AND DETAILS OF INJURY 
NAME SWB GROUP DATA 
NUMBER I MECLOFENAMATE GROUP 
AGE 24 AGE SEX HT WT SEVER. 
SEX N 24.0 M 195.0 100.0 1.0 
HEIGHT 195 25.0 M 178.0 75.0 1.0 
WEIGHT 100 18.0 N 183.0 77 .o 2.0 
INJURY TO HAMSTRING 20.0 M 185.0 96.0 2.0 
SIDE L 20.0 M 183.0 70.0 2.0 
DATE 30387 48.0 M 182.0 93.0 2.0 
SEVERITY 1 22.0 M 160.0 54.0 2.0 
!NJ: TRT. T !ME 1200 42.0 M 183.0 89.0 2.0 
ADVRSE REACT! ON NONE 53.0 N 180.0 70.0 2.0 
28.0 M 177.0 73.0 2.0 
27.0 N 167.0 94.0 2.0 
46.0 M 180.0 68.0 1.0 
29.0 M 187.0 78.0 2.0 
SI GtHF, DISEASES NONE 22.0 M 181. 0 81.0 3.0 
TREATMENT NECLOFENANATE 23.0 M 189.0 86.0 2.0 
29.0 M 167.0 66.0 2.0 
21.0 M 184.0 96.0 3.0 
NAME IEG 18.0 M 182. 0 66.0 1.0 
NUMBER ! II 40.0 M 172.0 86.0 2.0 
AGE 22 30.0 M 175.0 68.0 3.0 
SEX M 35.0 M 180.0 84.0 2.0 
HEIGHT 180 28.0 N 173.0 82.0 1.0 WEIGHT 73 
INJURY TO QUADRICEPS 29.5 179.2 79.6 1. 9 
SIDE L 10.0 7.9 12.1 0.6 
DATE 180387 
SEVERITY ') L 
INJ:TRT.TIME 2200 
ADVRSE F;EACT ION NONE PLACEBO GROUP 
AGE SEX HT WT SEVER. 
22.0 N 180.0 73.0 2.0 
19.0 M 182.0 86.0 1.0 
42.0 M 170. 0 70.0 2.0 
SIGN IF .DISEASES NONE 25.0 M 190.0 94.0 1.0 
TREATMENT PLACEBO 24.0 M 17~,.0 82.0 1.0 
25.0 M 185.0 82.0 3.0 
37.0 M 175.0 64.0 1.0 
NAME CDS 3't .o M 178.0 77 .0 1.0 
NUMBER IV 27.0 M 185.0 76.0 1. 0 
AGE 25 49.0 M 180.0 72.0 1.0 
SEX M 20.0 M 185.0 65.0 2.0 
HEIGHT 178 29.0 M 176.0 83.0 2.0 
~EIGHT 75 29.0 M 177.0 8~,. 0 3.0 
INJURY T8 HAMSTRING 1 ·1. 0 M 177 .0 70.0 ... ,, i..\.• 
SIDE R 30.0 M 166.0 69.0 2. 0 
DATE 250387 25.0 N 181. 0 81.0 2.0 
SEVEF;ITY l 22.0 M 17~,. 0 82.0 2.0 
lNJ:TRT.TIME 2000 27.0 M 18S .0 84. 0 2 (• ,V 
ADVRSE REACTIGN NONE 24.0 M 180.0 76.0 2.0 
30 .0 M 195.0 90.0 1.0 
28.2 179. 9 78 .1 1. 7 
SISNIF .DISEASES NONE 7.8 6.6 8.2 0.6 
TREATMENT MECLOFENAMATE 
NAME sec 
NUMBER VI DICLOFENAC GROUP 
AGE 19 AGE SEX HT WT SEVER. 
SEX M 23.0 M 182.0 94.0 2.0 
HEIGHT - 182 27.0 H 172.0 76.0 1.0 
WEIGHT 86 43.0 H 181. 0 80.0 2.0 
HlJURY TO OUADRICEPS 52.0 M 165.0 68.0 2.0 
SIDE L 48.0 M 173.0 77.0 2.0 
DATE 310387 26 .0 H 178.0 83.0 LO 
SEVERITY 1 27.0 F 160.0 93.0 1.0 
rnJ :TRT . TIME 1800 42.0 M 172.0 68.0 2.0 
ADVRSE REACTION NONE 28.0 M 182.0 64.0 2.0 
22.0 H 182.0 87.0 3.0 
28 .0 M 177 .0 95.0 2.0 
23.0 M 194.0 86.0 1.0 
40.0 N 178.0 87.0 1. 0 
SIGNIF.DISEASES NONE 30.0 N 157.0 52.0 3.0 
TREATMENT PLACEBO . 37 .0 M 172.0 70.0 2.0 
20.0 M 175.0 88.0 3.0 
27 .0 M 176.0 80.0 2.0 
NAME RHH 20.0 M 192.0 76.0 2.0 
NUl'IBER VII 
AGE 18 31.3 175.8 79.1 1. 9 
SEX M 9.9 9.4 11. 5 0.7 
HEIGHT 183 
\:!EIGHT 77 
INJURY TO HAMSTRING 
SIDE 0 I\ 
DATE 10487 
SEVERITY " L 
!NJ: TRT. TIME 2000 
AOVRSE REACT ION STOMACH CRAMPS NO FOOD 
5IGNIF.DISEA5ES CHONDRONALACIA PATELLAE 
TREATMENT MECLOFENAMATE 
NAME PAG 





INJURY TO QUADRICEPS 
SIDE R 
DATE 280487 
SEVERITY ~ L 
!NJ: TRT. TIME 2000 
AQVRSE REACT !ON NONE 








INJURY TO HAMSTRING 
SIDE L 
DATE 240987 
SEVERITY 'l L 
rnJ: TRT . TIME 2530 






SEX M II 
HEIGHT 183 
\:JEIGHT 70 
INJURY TO !lUADRICEPS 
SIDE R 
DATE 30587 
SEVERITY 'l L 
!NJ: TRT. Tl ME 2300 
ADVRSE REACTION ABD CRAMPS THROUGHOUT 


























!NJ: TRT. TIME 
ADVRSE REA CTI ON 













































HEADACHE FROM DAY 7 








































!NJ: TRT. TIME 

















































HlJ: TRT. TI NE 4700 
ADVRSE. REACT I ON NONE 








HIJURY TO HAMSTRING 
SIDE RISHT 
DATE 130987 
SEVERITY '"j ~ 
INJ:TRT.TIME 3145 
ADVRSE REACTION NONE 








HIJURY TO HAMSTRING 
SIDE LEFT 
DATE 170987 
SEVERITY r, i. 
!NJ: TRT. TI ME 2(H) 













!NJ: TRT. TINE 3700 
ADVRSE REACT! ON TIREDN. & LETHARGY D4 












!NJ: TRT. TIME 4530 









INJUR'( TO QUADRICEPS FENORIS 
SIDE LEFT 
DATE 171087 
SEVER ITY 2 
ItlJ: rnT. TIME 4700 









INJURY TO HANSTRINS 
SIDE LEFT 
DATE 261087 
SEVERITY . 1 
!NJ: TRT. TIME 2045 













!NJ: TRT. TIME 2015 
ADVRSE REACTION C/0 DRY MOUTH DAY 2 






HEIG HT 18(1 
~clGHT 72 


















rnJ: TRT. ilME 
ADVRSE REACTION 












ltlJ: TRT. TIME 
ADVRSE REACTION 




















































!NJ: TRT. TINE 
ADVRSE REACT ION 












!NJ: TRT. TIME 













!NJ: TRT. Tl ME 














































INJURY TO 280488 
SIDE QUADRICEPS FEHORIS 
DATE RIGHT 
SEVERITY 2 
HlJ: TRT. TIME 2100 













HiJ: TRT. TI ME 4130 
AOVRSE REACT! ON NONE 








INJURY TO HAt1STRING 
SIDE RI6HT 
DATE 220588 
SEVERITY ') L 
!NJ: TRT. T !ME 2500 









INJURY TO HAl1STRINS 
· SIDE LEFT 
DATE 280588 
SEVERITY 
!NJ: TRT. TI ME 4800 









INJURY TO HAMSTRING 
SIDE RIGHT 
DATE 280588 
SEVERITY ') L 
INJ: TRT. TIME 4330 
ADVRSE REACTION NONE 








HIJURY TO HAMSTRING 
SIDE LEFT 
DATE 50~188 
SEVERITY ') L 
!NJ: TRT. TIME 230 
ADVRSE REACT ION NONE 












!NJ: TRT. TI ME 1600 
ADVRSE REACT ION NOHE 













ADVRSE REACTiml NONE 












!NJ: TRT. TIME 
ADVRSE REACTION 












!NJ: TRT. TIME 
ADVRSE REACTION 












INJ: TRJ. Til1E 
ADVRSE REACTION 





















































I NJ: TRT. TI NE 
ADVRSE REACT ION 
















































































!NJ :TRT. TIME 2200 
ADVRSE REACT ION NONE 












!NJ : TRT. TI ME 3745 













!NJ: TRT. TINE 4630 
ADVRSE REACT ION NONE 












HJJ: TRT. TIME 4800 













INJ: TRT. TI ME 1930 
ADVRSE REACT! ON DROWZY DAY 3 












INJ: TR T.TlHE 3640 
AOVRSE REACT IOU NONE 












INJ: TRT. TIME 4700 
ADVRSE REACT ION NONE 












INJ: TRT. TIME 2320 
ADVRSE REACT ION NONE 


























!NJ : TRT. Tl ME 
ADVRSE REACT ION 












!NJ: TRT. TIME 
ADVRSE REACTION 


















































!NJ: TRT. TI ME 











































































































I NJ: TRT. TIME 1900 
ADVRSE REACT ION NONE 












!NJ: TRT. TIME 
ADVRSE REACT ION 




















PATIENT TEST DATA 
• 
~AMSTRING SERIES 
JLlADR![EPS ?EAK TORQUE : MECLOFENANATE GROUP RATIO 
Q .P. ~. ~;Jl UN AD1 AFD3 UNAD3 AFD7 UNAD7 R.D1 R.D3 R.D7 
230 3.i.5 279 : 14 310 302 0.889 O.BB9 1. 026 
l' " ~71 185 212 189 226 0.714 0.873 0.836 
.OJ ~,J .L 
:37 221 193 :87 21 4 187 l.072 1.032 1.144 
: 49 , .,, 174 lbl 18/i 167 0.866 1. 081 1.114 4. J L '(; 1 ""):':I :'.24 236 278 274 0.8% 0.949 1. 015 .. .... , -~· : :3 I'; •, 1·n 201 187 194 0.896 0.905 0.9114 i~L \,L l74 213 :67 197 182 207 0.817 0.848 0.879 • •j "';"' 241 207 251 250 262 0.801 0.825 0.954 - 1' ,.; -,.-.,.. ,, c 225 2~4 252 252 0.935 0.88/i 1. 000 ... 1 ..;.,.,.. 
: 
131 : ,:7 176 : 71 138 1 C.•1 ,) , 968 1. 029 0. 908 J.1-•• ~39 2::,9 176 197 175 197 0.665 0.893 0.888 ·.·: =. -:, ;: ~ 207 254 ·i -Y7 273 0.879 0.815 0.853 
... ..... .. •• 1 .. i.,j,J ._, 
~ ;>) i89 207 214 .,.,., 1.960 0.913 0.964 
. i : 
i..i.i. 
1EA!i • : c:; - • L l '19 2:9 21 6 224 0. 951 0.918 0.%5 L..W ·:: . _, j 41 21 40 45 44 0.308 0.079 0.091 
QUADR'. CEPS FEAK TCRQUE : PLACEBO GROUP RATIO G.P.P ~FD1 UNADl AFD3 UNAD3 AFD7 UNAD7 R.Dl R.D3 R.D7 131 ~28 128 128 134 pi ...... 1.023 1.000 1.098 
183 199 162 188 181 204 0.920 0.862 0.887 223 208 "I C1 i..JL 227 257 231 1.072 1.110 1.113 184 167 149 161 167 169 1.102 0.925 0.988 236 221 266 251 25/i 245 1.068 1.060 1.045 205 1 7~ 214 217 248 236 0.872 0.986 1.051 
L ·.JJ 
198 224 ,~. .. .:i..1 254 245 251 0.884 0.925 0.976 237 243 214 224 220 216 0.975 0.955 1.019 256 229 237 106 243 267 1.118 2.236 0.910 224 287 214 228 222 232 0.780 0.939 0.957 141 148 151 152 152 14/i (1,953 0.993 1.041 !54 295 324 292 282 288 0.522 1,110 0.979 292 251 185 250 299 265 1.lb3 0.740 1.128 215 273 26b 250 253 281 0.788 1.064 0.900 
MEAN 196 213 205 200 21b 217 0.94b 1.065 1.007 so. 39 41 49 49 42 40 0.165 0.339 0.075 
JUADRICEPS PEAt'. TORQUE : :i!CLOFENAC GROUP RATIO 
G.P. D AFD 1 UNAD1 AF D3 UNA D3 AFD7 UNAD7 R.01 R.D3 R.07 ... .,.~ 26'1 241 238 208 234 0.881 1.013 0.889 
,;_,_\j 
159 :91 1 C. ( 165 180 180 0.832 0.927 1.000 >v .J 
l 48 :79 l 'l"" ... .) 17~ .., .. 1 a-r . J.) 164 (l,827 0.715 0.933 
111 134 149 153 148 160 0.903 o.974 o.ns 
:44 I ~! 236 241 251 256 1.030 0.979 0.980 J...,JI 
207 180 198 172 186 156 1.150 1.151 1.192 
: 4~; 296 260 267 267 2~;9 0.857 0.974 1.031 
l!i8 2)1 197 207 167 168 0.836 0.952 0.994 
1~7 :69 195 193 183 199 ') . 905 1.066 0.920 
1J.) 
229 270 240 "! C. 1 263 283 0.848 0.956 0.929 .. ... ;~ .,. -- CC 267 274 :86 281 0.929 0.974 1. 019 :.. .;, .;. • ' J i :'! 2~,6 ,..._.,. c 254 ;:47 ~42 0.922 0. 925 1. 021 ~-·iJ £.,j.J • ,·u, ,vv 1:3 121 139 ~45 1~0 0.633 0.871 0.967 
21S :42 210 216 224 218 0.888 o. 972 1.028 
:67 1L'l 320 31 9 299 ~17 1.019 1. 003 0.943 ......... 
: '13 .__. ·.; ~88 228 196 21 8 0.839 0.825 0.899 i ~., ··:, c~ 261 ~71 :36 '"\ "T C 0.903 0.963 1. 004 
,vL ~.,, '-•.; 
:1EAt< '.o'i 1 "1-:' J.j/ 172 178 l74 175 0.894 0.9 55 0.981 SD. 44 :9 47 47 46 49 0. 105 0. 091 0.069 
HANSTRING PEAK TOR QUE : MECLOFENANATE GROUP RATIO 
H.P.M. AF D1 UNAD1 AFD3 UNAD3 AF D7 UNAD7 R.D1 R.D3 R.D7 
189 196 188 199 204 206 0.964 0.945 0.990 
71 119 94 120 100 120 0.597 0.783 0.833 
!19 80 135 82 141 123 1.488 1.646 1.146 
76 137 84 130 170 156 0.555 0.646 1.090 
93 109 104 95 132 129 0.853 1.095 1.023 
75 134 88 140 113 137 0.560 0.629 0.825 
98 118 114 121 110 113 0.831 0.942 0.973 
71 149 122 155 148 165 0.477 0.787 0.897 
89 122 103 134 138 138 0.730 0.769 1.000 
74 132 103 105 94 89 0.561 0.981 1.056 28 104 36 92 36 98 0.269 0.391 0.367 
45 161 58 149 73 166 0.280 0.389 0.440 
99 118 99 106 128 123 0.839 0.934 1.041 
NEAN 87 129 102 125 122 136 0.692 0.841 0.899 SD. 37 27 35 30 41 30 0.308 0.312 0.230 
• 
:iAl'iSTR:NG P~AX TORQUE : PL ACEBO GROUP ~ATIO 
H.P.P AFDl UNAD1 AFD3 UN AD3 AFD7 UNAD7 R.01 R.D3 R.D7 
50 8:1 4b 80 .:c ;.. ~. 0. ~,88 0.575 0.846 ._; .. 1 YW 
ill3 ·=~ : i)4 89 ~16 100 ' '11') 1. 169 1.160 -" - .... ~ n 1 1 1 80 119 110 t17 ,).333 0.672 0.940 . ,, ... 
: :)7 11 I :c10 111 113 'I I 0.%4 0.901 1.018 ...... u. • 
l ~.7 1 ~c 1:.6 : 55 160 , .;;:7 1.013 1. 006 1.019 ... .. ...  .. ..,, . .,.r, 
:4(1 136 !49 161 i ~'") ,) ,943 0.913 0.936 l i i. L, L 
7 1 129 30 134 100 i ~.5 G.550 0. ~.97 0.645 . ~- ~ij/ 96 , ,.,. 110 126 0.701 0.850 0.873 / .,i ~ ... J 
14 i30 l ·"'t ·., • ·,'1 148 1,., 0.723 1. 000 0.860 l LL ...... !. l L 
Jl . -~ J9 126 83 142 0.445 0.548 0.585 . "' 
.. 35 :j:, :01 !03 ·r:i 0.859 0.794 1.040 . ) 
oO 169 i73 149 132 : 42 0.473 1.161 0.930 
i5 , .:.~ . ~(l ~61 :a2 186 0.621 0.807 0.978 .;.,.•..; •~v 
79 ,.i -:r 104 l !i5 139 181 0.552 0.630 0.768 ... 1 ... , 
~EAN J 7 : ·"": ,• '.Ob ~:7 ' ·1'1 138 0.612 0.823 0.860 ,, - ~~ 4k. 4 ~D. , 1 -.~ 1~ ') ~ .,. ., 35 (1 ,144 0.208 0.150 _ .... , ~, ..... A,..; ._).:., 
HAl'ISTRIN6 PEM: TORQUE : DICLOFENAC GROUP RATIO 
H.P.D. AFDl UNADl AFD3 UllAD3 AF D7 UNA D7 R.01 R.03 R.07 
56 169 70 176 120 165 0.331 0.398 0.727 
46 108 71 108 81 113 0.426 0.657 0.717 
26 1 • 7 43 107 69 q4 0.230 0.402 0.734 i i,j 
71 81 1t 84 89 35 0.877 0.845 1.047 '. 161 ~59 159 157 160 160 1.013 1.013 1.000 
80 92 91 84 106 99 0.870 1.083 1.082 
118 156 134 168 130 163 0.756 0.798 0.798 
52 118 89 118 110 119 0.441 0.754 0.924 
91 113 114 113 119 117 0.805 1.009 1.017 
119 137 141 137 144 164 0.869 1.029 0.878 
159 171 149 169 159 174 0.930 0.882 0.914 
125 175 116 161 139 165 0.714 0.720 0.842 
20 76 15 67 19 75 0.263 0.224 0.253 
87 118 93 113 102 114 0.737 0.823 0.895 
74 138 123 175 131 162 0,536 0.703 0.809 
90 136 105 138 108 136 0.662 0.761 0.794 
121 117 137 141 169 144 1.034 0.972 1.174 
NEAN 88 128 101 130 115 132 0.676 0.769 0.859 SD. 40 30 38 33 36 32 0.251 0.235 0.198 
QUADRICEPS TOTAL NORK : MECLOFENAMATE 6ROUP RATIO 
~ ~ ;;. il ,t .. ; , AFD1 liNAD1 AFD3 UNAD3 AFD7 UNAD7 R.D1 R.D3 R.D7 
~ c ,·.~ 3610 3402 3606 3314 3779 0.970 0.943 0.877 ..... .;..; 
:956 2506 2994 3293 2814 29 47 1.180 0.909 0.955 
,:.673 16 52 2561 23 52 2638 1999 1.009 1. 089 1. 326 
: ;;4 "'.1'1 ":" '1 2191 2125 ")(11 t 2384 0.781 1.031 0.844 LLW L LVJ,.J. 
~336 2269 1676 2033 1913 2997 1.030 0.824 0.660 
~i42 2106 l't87 21 26 2048 "H1C. 1.017 0.935 0.968 L•J.w 
! ? ! 6 2381 1845 21 52 2062 2394 0.805 0.957 0.861 
i628 2058 1679 21 96 1907 24(}3 0.791 0.765 0.794 
'. 920 2408 ')"')"l 'l 20 65 2503 2633 0.797 1. 076 0.951 1,..;.4,."' 
: 4i0 2811 2511 2369 2:29 '11 ~,, LJ.I V 0.857 1.060 1. 073 
I ":' •°I C 2397 2360 ... ,*'.'~., 2435 ::64 0. 711 1. 003 1.076 - .. j ... 1 L,.'.toJ .J 
: 131 3279 3320 3493 3~,(10 .,...,.,,,, 0.909 0.950 1. 054 .J .,j i.i. 
• ... f C 2621 2461 2436 2838 2676 1.036 1.010 1. 061 .. ' .I. .... 
t~EAN 2::.6 2564 2401 2508 2486 26 13 0.915 0.958 0.961 :0. , =o ~32 :44 ~,41 :01 493 0.131 0.096 o.1e9 ... ... , 
GUADRICEPS TGTAL 'llDRY. : PL ACEBO GROUP RATIO 
Q .E. f . AFill UNADl AF D3 UNAD3 AF D7 UN AD7 R.Dl R.D3 R.D7 
2:m :494 1869 1899 2128 2009 0.839 0.984 1.059 
2373 29 51 26 54 2367 2894 31 92 0.974 0.926 0.907 
2117 3274 2964 3179 2971 3200 0.647 0.932 0.928 
1721 1830 t~159 1647 1912 1739 0.940 0.947 1.099 
3482 3037 ~ ct') J J..LL 3120 3535 3296 1.147 1.126 1.073 
2646 2799 2919 2869 2941 2974 0.945 1.017 0.989 
1477 2535 2162 2139 2562 2490 0.583 1.011 1.029 
2~90 ;:929 3230 3130 3095 3215 0.885 1.032 0.963 
:3~.o 2456 2998 2711 2786 2724 0.957 1.106 1.023 
2065 2756 21 98 2796 2320 2229 0.749 0.786 1.041 
1405 1399 !414 1489 1639 1459 1.004 0.950 1.123 
2831 3430 3816 2893 4376 3774 0.825 1.319 1.160 3597 3088 3521 3057 3793 3684 1.165 1.152 1.030 5244 3631 3756 3752 4021 3871 0.893 1.001 1.039 
11EAN 2464 2758 2755 2682 2927 2847 0.897 1.021 1.033 SD. 674 577 771 624 770 736 0.158 0.122 0.068 
~UADP.IC ~PS TOTAL WORK : DI CLOFENAC GROUP RATIO 
g .E.D. ~FD1 UNA Dl AFD3 UtlAD3 AF D7 UNAD7 R.Dl R.D3 R.D7 
::1~9 7t77 3589 3631 3671 3738 1.008 0.988 0.982 ..;:~..;i..:, ,, .,., i .., ; ~. 1665 1~53 1760 1866 0.951 1. 072 0.943 _Q.j i .. ' • ,j 
:316 2296 2285 2239 2204 2197 1.009 1.021 1.003 
· 7 ,i C 1671 1405 1561 1519 1675 (1 ,805 0.900 0.907 ~-:-~J 
:173 3681 4049 3850 3817 3797 1.079 1.052 1. 005 
~ 1·1 t "'J 1424 2432 2241 2802 2329 1.413 1.085 1.203 ... v~• 
- : . .:;'J 2907 3784 4336 3334 3221 0.909 0.873 1.035 - ., .,; 4 
2394 2270 2350 2456 2544 2620 1.055 0 .'~57 0.971 
~465 1743 1695 1796 1619 1931 0.841 0.944 0.884 
270~; 2648 2632 2467 2921 2911 1. 022 1. 067 1. 003 
~~54 .)405 3491 3501 3681 4098 1.014 0.997 0.898 
~''37 383 5 2·112 3783 3332 39 51 0.766 0.770 0.843 
~~ 03 i858 1548 1660 1597 172~, 0.755 0.933 0.926 
~232 - ~ "'.· - C 2848 2879 3057 2611 0.878 0.989 1.171 ·.J .i.L"' 
2345 .... ,'.j"j f 3351 3588 3634 7C'"",7 0.743 0.934 1. 032 .•v ... 1 .:,, ._tL.:J 
- e : O :694 3189 "7"'!! 7 3325 33 14 0.935 0.%3 1. 003 
__ · ... w ,_': .J J...) 
_:.29 :-1 62 3456 3647 3•j46 -:114 0.819 0.948 0.978 
MEAN =337 -- · "l"':' C. 7746 28 53 2815 2854 0.941 0.970 0.988 ... ; .. •,J 
SD . -:6 -, "':'r'! 809 889 776 797 0.159 0.078 0.090 : ~~ i.. 
HAMS TRING TOTAL NORK : NECLOFENANATE GROUP RATIO 
H.E .M. AFD! UNAD1 AF D3 UNA D3 AFD7 UNAD7 R.D1 R.03 R.D7 
1962 .. ,1'it 1915 2134 2363 2360 0.925 0.897 1.001 L.i.4• 
1604 1483 2066 2413 1932 2005 1.082 0.856 0.964 
1233 1380 1849 1402 1849 1952 0.893 1.319 0.947 
782 1509 1242 1653 1626 1416 0.518 0.751 1.148 
1138 941 1128 1119 1163 1474 1.209 1.008 0.789 
:814 2313 2020 2539 2032 2545 0.784 0.796 0.798 
1450 154b 1364 1518 1456 1240 0.938 0.899 1.174 
1144 2040 1790 2181 2158 2243 0.561 0.821 0.962 
1358 2004 1410 1911 1975 2193 0.678 0.738 0.901 
1183 1528 1379 1497 1241 1212 0.774 0.921 1.024 
349 1579 454 1349 625 1269 0.221 0.337 0.493 
924 1949 1096 2027 1387 1721 0.474 0.541 0.80b 
1602 1552 1236 1383 1840 2008 1.032 0.894 0.91b 
NEAN 1273 1688 1458 1779 1665 1818 0.77b 0.829 0.917 
SD. 419 359 440 432 458 441 0.2bB 0.221 0.168 
riAMSTRING TOTAL WORK : PL ACEBO GROUP 
H.E. P. AFD1 UNADl AFD3 UNAD3 AF D7 UNAD7 
~097 : 775 770 1446 1219 1445 
1209 916 1585 1365 lo06 1445 
114 2441 1345 2655 1444 2715 
1085 i548 1292 1343 1491 1301 
2S48 :707 2442 1798 2336 1928 
1394 1177 1613 1647 1407 1948 
~768 2355 2065 2745 2533 2959 
S19 2!34 i335 2252 1502 2041 
2165 2:91 2707 2214 2789 2382 
1041 1294 1246 1940 1343 1959 
463 ~89 672 989 Ql l 1031 
:301 2397 2283 2151 2547 2805 
~087 2789 2843 2712 2984 3009 
i365 2:87 1~52 2350 2263 2561 
MEAN i318 1~93 1675 1972 ~834 2109 
SD. 63 ~ :~9 661 539 639 624 
HAMSTRING TQTAL ~ORK : DI CLOFENAC SROUP 
H.E. D. AFD1 UNAOl AFD3 UNA03 AFD7 UNAD7 
493 1571 696 1924 1954 2503 
"""" LJi. 774 789 949 826 620 
278 9~;5 559 942 862 906 
382 495 256 496 313 518 
3092 2854 3119 2806 2896 3016 
1063 966 1362 1478 1480 1550 
1695 'l'l'l'l LL44 2053 2213 1860 1746 
928 1351 1082 1726 1724 1984 
974 974 1176 1206 1135 1083 
2123 2194 2163 2580 2500 2430 
2325 2759 2213 2763 2163 2771 
1904 2604 2112 3227 3062 3584 
190 845 181 167 452 1068 
1760 1873 1657 1697 1636 1475 
600 1651 1421 1810 1895 1768 
1352 1385 1847 2272 2075 2059 
1898 1862 2014 2454 2135 2099 
MEAN 1252 1608 1453 1806 1704 1834 
SD. 829 711 777 830 764 830 
RATIO 
R.D1 R.03 R.D7 
0.618 0.533 0.844 
1.482 1. 161 1.111 
0.047 0.507 0.532 
0.701 0.962 1.146 
1.493 1. 358 1. 212 
1.184 0.979 0.722 
0.751 0.752 0.856 
0.384 0.593 0.736 
0.945 1.223 1.171 
0.550 0.642 0.686 
0.468 0.679 0.884 
0.543 1.061 0.908 
0.748 1. 048 0.992 
0.624 0.533 0.884 
0.753 0.859 0.906 
0.391 0.277 0.194 
RATIO 
R.D1 R.D3 R.07 
0.314 0.362 0.781 
0.300 0.831 1.332 
0.291 0.593 0.951 
0.772 0.516 0.604 
1.083 1.112 0.960 
1.100 0.922 0.955 
0.763 0.928 1.065 
0.687 0.627 0.869 
1.000 0.975 1.048 
0.968 0.838 1.029 
0.843 0.801 0.781 
0.731 0.654 0.854 
0.225 1.084 0.423 
0.940 0.976 1.109 
0.363 0.785 1.072 
0.976 0.813 1.008 
1,019 0.821 1.017 
0.728 0.802 0.933 
0.301 0.194 0.20"1 
~LADRICcPS AVERAGE POWER : ~ECLOFENAl'IATE GROUP RATIO 
Q.A.F. AFil l UN AD1 AF03 UNAD3 AF D7 UN AD7 R.DL R. D3 R.D7. 
.:Y3EX :::9 .,. = ... , 302 .,.,,f 302 354 0. 93:, 0.941 0.853 ~ vi. ~• .U 
l"\Q '"f 243 272 '.;:89 2~,0 250 1.181 0.'141 1. 000 _..; ; ;~,., 291 239 217 247 75 (l .935 1.101 3.293 .. .. 4 
160 "'.l(! a:;, 205 197 204 228 0.780 1.041 0.895 L \' t,J 
2:4 210 158 :91 237 26 5 1.019 0.827 0.894 
:7! :. 10 159 179 l?l 180 ) . 972 0.888 0.950 
~34 -,~.., 184 208 199 239 ).829 0.885 0.933 LL ._ 
l69 145 1 O'l 15! >'H " 160 1.166 1. 205 t .,.,,t;, ,UL i..i L J.,,.)4-, 
, ;:,-, ': '1(\ 116 167 236 '"' .. ~ 0.69:, 1.174 0 .'196 ... .. , .,) L. .. V i..;;J ..,,.,.., 280 246 236 241 238 0.793 1. 042 1.013 L.:.. -
. :r, 234 !95 -: \ c. 2.i.6 118 0.726 0. 1107 1.091 ... , V ...... 
-,-, ~ -1,., 317 310 • • u ,...1_,j_ "".''l 295 0.914 1.023 1. 058 .•. .;..:.. 
· -:- o 239 -:,~ ., ""•1"l 278 "'": ""!'C 1.167 1.118 1. 183 - ·' ! ,.,, .. ~ .. J.,_i .. • 
·.! CA~: . ,: ,, 240 , ...  ,., .-,,,~ 239 "1') "T 0.932 1. 007 1.133 ,, i...:":11 ;. ~i. l .:..i. .:.: ..l .L1..I 
;:""'! 49 51 :.9 64 0.160 0.11:, 0.623 -- . ~··-· 
JUAD?. IC ~~-3 AVERAGE POWER : PLACEBO GROUP RATIO 
Q.A.P. AF D1 UNAD1 AFD3 UN AD3 ~FD7 UNAD7 R.Dl. R.D3 R.D7. C'(BEX i o~ .-."'' 173 133 ::6 ~99 0.863 0.973 1. 085 .. .. ,J L.:.O 
260 288 ::1 255 277 316 0.903 0.994 0.877 
256 -:: 1"7 312 ~.34 31 5 341 0.908 0.934 0.924 .,. , 
141 139 128 138 t ~O 131 1.014 0.928 1.206 .... u 
296 270 298 '1"11 ... , "' 301 285 1.096 1.100 1.056 
209 237 238 248 252 261 0.882 0.960 0.966 
126 'i1 'l 167 176 208 250 0.594 0.949 0.832 L_. ... 
226 259 273 274 258 262 0.873 0.996 0.985 
191 201 240 206 223 224 0.950 1.165 0.996 
lb7 ~33 165 222 188 192 0.717 0.743 0.979 11 " .... 121 117 127 137 130 0.926 0.921 1.054 
338 332 371 294 381 "'.'')') ..lL._ 1.018 1.262 1.183 
302 290 314 306 335 323 1.041 1.026 1.037 
281 344 336 341 371 363 0.817 0.985 1.022 
i'IEAN 221 248 242 241 259 257 0.893 0.995 1.014 SD. 68 64 77 66 73 72 0.129 0.117 0.100 
QUADRlC~PS AVERAGE POWER : DICLOFENAC GROUP 
G.A. P. AFDl UNADl AFD3 UNAD3 AFD7 UNAD7 
CYBEX 349 396 367 413 398 407 
MEAN 
SD. 
124 150 :46 130 150 
!~8 190 191 189 205 
113 :36 111 130 120 
~t5 340 =~9 347 364 





















































256 250 262 26 5 267 
ao ao 99 80 34 
HAl1STRiNG AVERAGE POWER : MECLOFENAl1ATE GROUP 
H.A. F. AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 
CYBEX , ,..., 10., :os 168 189 21 4 220 
iS4 142 186 210 170 169 
124 149 171 128 171 74 
74 139 116 150 163 134 
109 92 108 i.11 138 139 
t43 :89 157 191 158 199 
128 146 117 138 125 126 
147 8~, 154 125 161 174 
106 154 108 158 !62 178 
115 151 140 154 132 130 
35 157 38 128 56 116 
87 188 105 189 127 161 
166 151 118 132 184 198 
11EAN 121 150 130 154 151 155 
SD. 39 33 37 30 36 39 
RA TIO 
R.01. R.D3 R.07. 
0.881 0.889 0.978 
0.827 1.123 0.987 
1.042 1. 011 1.062 
0.831 0.354 0.889 
1.074 1. 063 1.049 
1.393 1.029 1. 170 
0.905 0.887 0.990 
0.995 0.987 1. 041 
0.832 0.989 0.943 
1. 022 1.149 0.935 
1.048 0.971 0.874 
0.783 0.806 0.923 
0.759 0.893 0.928 
0.860 0.937 1.214 
0.846 0.874 0.935 
0.893 1.000 1. 043 
0.796 0.974 0.983 
0.929 0.967 0.997 
0.151 0.091 0.090 
RATIO 
R.Dl. R.03 R.D7. 
0.893 0.889 0.973 
1.085 0.886 1. 006 
0.832 1. 336 2.311 
0.532 0.773 1.216 
1.185 0.973 0.993 
0.757 0.822 0.794 
0.877 0.848 0.992 
1.729 1.232 0.925 
0.688 0.684 0.910 
0.762 0.909 1.015 
0.223 0.297 0.483 
0.463 0.556 0.789 
1.099 0.894 0.929 
0.856 0.854 1.026 
0.361 0.253 0.405 
riAMSTRINS AVERAGE POWER : PLACEBO GROUP RATIO 
H.A.P. AFD1 UN AD1 AF D3 UNAD3 AFD7 UNAD7 R.D1. R.D3 R.D7. 
~YBEl !01 ioO 72 138 1"' .... 142 0.631 0.522 0.866 
103 78 148 120 152 142 1.385 1.233 1.070 
13 234 140 275 149 278 0.056 o.~09 o.536 
73 111 96 96 103 95 0.658 1.000 1. 084 
224 1 :,9 229 161 236 165 1.409 1.422 1.430 
116 11\'l ., ,. 138 : 42 126 1~9 1.137 0.972 0.746 
~40 187 160 201 201 232 0.749 0.796 0.866 ,, 189 I j , 195 l'l"f i64 0.378 0.579 0.750 I • .. ~ !4.J 
167 :67 194 162 210 18(1 1.000 1.198 1.167 
79 :.~O 95 140 101 148 0.527 0.679 0.682 
37 77 J(l 31 78 S9 0.481 0.741 0.876 
144 ::9 234 220 231 2:5 0.603 1. 064 0.906 
1 '1 4 182 :6i 276 282 " Q ' L,O 0.688 0.946 0.953 . ~'} :32 119 'l'l , 2l4 2::4 0.569 0.524 0.811 .... •1.. ,.,., 
:lEAil .. . ~69 ' l ' 174 166 , q, 0.733 0.870 0.910 :..:. -; • • I ..... , : r, :,6 61 60 59 60 64 0.365 0.284 0.216 .. .; . 
~Al1STR!N6 AVERAGE POWER : DI CLOFENAC GROUP RATIO 
H.A. P. AFD1 UN ADl AFD3 UNA D3 AFD7 UNAD7 R.01. R.D3 R.D7. 
CiBEX :-:, l 9~, 70 21 5 210 ;_70 0.272 0.326 0.778 ~.J ., , ,., 
70 30 , c 53 0.319 0.875 1.415 LJ I i. l!,-1 
71 31 79 81 85 82 0.877 0.975 1.037 ., .,. 
41 3~; 39 40 42 0.561 0.897 0.952 ,..:, 
281 261 272 241 257 261 1.077 1.129 0.985 
105 91 6 110 129 130 1.154 0.055 0.992 
142 185 180 194 158 156 0.768 0.928 1.013 
79 130 92 148 159 164 0.608 0.622 0.970 
106 107 120 110 119 105 0.991 1.091 1.133 
179 183 193 221 230 196 0.978 0.873 1.173 
236 206 21 5 223 183 231 1.146 0.964 0.792 
178 238 189 281 274 313 0.748 0.673 0.875 
18 77 16 77 39 96 0.234 0.208 0.406 
175 183 174 171 175 146 0.956 1.018 1.199 
58 147 129 175 178 180 0.395 0.737 0.989 
131 172 191 218 210 206 0.762 0.876 1.019 191 198 193 234 206 206 0.965 0.825 1.000 
IIEAN 121 151 131 166 160 167 0.753 0.769 0.984 SD. 76 62 75 69 69 75 0.297 0.298 0.206 
~UADRICEPS PEAK LILE . :l'!ECLOFENAMATE GROUP 
Q.P. T. AFD1 UNADl AFD3 UNAD3 AFD7 UNAD7 
CYBEX 51 .23 56 .52 51.61 54.62 55.56 56.10 
MEAN 
3D . 
42 .19 32 .27 35.49 32.52 36.20 34.52 
40 .01 38 .01 39.91 32.46 52.41 44.93 
22 .88 27 .84 28.62 25.86 20.31 26 .94 
33 .34 31 .25 20.52 29.15 30.27 33.18 
22 .78 19.55 20.48 23.73 23.26 23.21 
25 .06 20 .32 21.86 26.14 25.49 30.11 
22 .47 25 .42 28.44 38.27 41.80 34.13 
33 .81 33 .27 45.49 39.64 45.07 56.71 
Jl .65 42.28 41.93 37.98 35 .43 36 .82 
22 .89 35 .91 30 .18 36 .59 33 .42 37 .52 
55 .34 48.64 49.17 49.45 59.72 45.20 
43 .31 40.90 41.49 30 .12 44.06 35.71 
,c 
.~, ._i 
' . .  35 10 9 39 12 38 10 
QUADRICEPS PEAK T.A.E. : PLACEBO GROUP 
Q.P. T. AFD1 UNA D1 AF D3 UNAD3 AF D7 UN AD7 
CYBEX 24 .82 28 .58 22.93 26.94 27 .00 30.53 
34.57 34 .57 37 .84 37.92 37.25 39.46 
29 .27 44.98 49.56 47.08 50.16 48.91 
19 .77 24.65 24.14 22.49 23.68 23.48 
23 .48 29.54 24.37 29 .59 24.96 30.12 
27 .83 33 .68 32.17 29.57 33.74 35.17 
17 .89 21.60 17. 28 24.89 19.55 24.94 
29 .76 28.97 36.31 30.90 33.90 31.58 
24 .38 25. 33 28.77 24.67 31.47 29.28 
35.76 42.39 39.83 40.28 13.79 49.21 
11. 98 26. 41 18.89 26.90 28.29 23.16 
48. 51 50.60 67.25 55.77 78.66 51.67 
46.84 49.97 47.50 67.89 70.89 73.42 
44.93 48.50 55.41 47.51 56.97 58.36 
NEAN 30 35 36 37 38 39 
SD. 11 10 14 13 19 14 
RATIO 
R.Dl. R.03 R.D7. 
0.906 0.945 0.990 
1.307 1.091 1.049 
1.053 1.230 1.166 
0.822 1.107 0.754 
1.067 0.704 0.912 
1.165 0.363 1. 002 
1.233 0.836 0.847 
0.884 0.743 1.225 
1.016 1.148 0.795 
0.985 1.104 0.962 
0.637 0.825 0.891 
1.138 0.994 1. 321 
1.059 1.377 1.234 
1.021 0.997 1.011 
0.172 0.192 0.172 
RATIO 
R.Dl. R.D3 R.D7. 
0.868 0.851 0.884 
1.000 0.999 0.944 
0.651 1.053 1.026 
0.802 1.073 1.009 
0.795 0.824 0.829 
0.826 1.088 0.959 
0.828 0.694 0.784 
1.027 1.175 1.073 
0.962 1.166 1.075 
0.844 0.989 0.280 
0.454 0.702 1.222 
0.959 1.206 1.522 
0.937 0.700 0.966 
0.926 1.166 0.976 
0.849 0.977 0.968 
0.145 0.182 0.258 
QU ADRICEPS PE~K T.A.E. : DICLOFENAC GROUP 
Q. P. T. AF Dl UNADl AFD3 UNAD3 AFD7 UNAD7 
:r9EX 51. 07 56.62 64.68 58.01 55.16 55.17 
18.75 28.74 25.44 25.01 24.12 25.41 
22.67 22.61 25.00 22.51 25.98 23.58 
12.47 17 .19 !7. 00 18.41 18.02 19.01 
52 .34 29.57 36.00 33.88 38.03 32.91 
24 .98 20.59 14.85 11.93 21.08 20.65 
3! .12 40.00 34.41 37.34 31. 72 33.1~ 
23.67 30 .19 28.25 26.08 29.24 25.41 
10 .90 27.49 25.:8 ~7.52 19.65 26.21 
55 .85 49.58 56.31 37.S2 62.58 61.23 
75.85 55. 00 81.36 71.91 91.42 91.55 
45.77 56. ~8 43.54 53.62 55.77 54.87 
23 .52 31.49 21.28 26.63 23.82 23.88 
33.59 47. 33 41.90 46.72 41.18 36.58 
~3 .46 39.10 53.25 55.15 43.84 55.51 
36 .39 47.46 42.55 45.21 43.62 45.26 
~3 .68 48.71 67.58 73.02 65.12 66. 00 
~EAN 35 38 40 39 41 41 
SD . l b 13 19 18 19 20 
HA"STR INS PEAK T.A.E. : MECLOFENA"ATE SROUP 
G.P. T. ~FD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 
CYBEX 28.83 32.63 27.77 28.35 31.36 34.42 
15.05 14.23 15.64 19.23 19.09 19.81 
20.73 18.81 23.70 18.56 25.86 29.60 
13.52 18.38 18.52 21.45 29.31 26.86 
16.11 18.73 21.34 25.85 24.27 29.29 
18.0123.1215.91 21.86 18.86 22.24 
13.31 14.15 15.00 15.56 12.48 17.69 
19.68 16.98 35.86 12.27 33.46 40.62 
21.14 28.53 39.43 37.52 19.28 49.51 
19.36 21.59 21.55 20.74 19.71 20.10 
7.78 26.48 8.38 23.16 10.68 16.43 
15.47 27.68 16.83 30.51 22.66 29.72 
23.75 21.20 19.21 17.94 29.64 23.48 
NEAN 18 22 21 23 23 28 
SD. 5 5 8 6 7 9 
RATIO 
R.Dl. R.D3 R.D7. 
0.902 1.115 1.000 
0.652 1.017 0.949 
1.003 1.111 1.102 
0.725 0.923 0.948 
1.094 1.063 1.156 
1.213 1.245 1.021 
0.778 0.922 0.957 
0.784 1.083 1.151 
0.760 0.930 0.750 
1.126 1.501 1.022 
1.379 1.131 0.999 
0.803 0.812 1.016 
0.747 0.799 0.997 
0.815 0.897 1.126 
1.112 0.965 0.790 
0.767 0.941 0.964 
J.897 0.925 0.987 
0.915 1.022 0.996 
0.198 0.166 0.106 
RATIO 
R.D1. R.D3 R.D7. 
0.884 0.980 0.911 
1.058 0.813 0.964 
1.102 1.277 0.874 
0.736 0.863 1.091 
0.860 0.826 0.829 
0.779 0.728 0.848 
0.941 0.964 0.705 
1.159 2.923 0.824 
0.741 1.051 0.389 
0.897 1.039 0.981 
0.294 0.362 0.650 
0.559 0.552 0.762 
1.120 1.071 1,262 
0.856 1.034 0.853 
0.234 0.591 0.205 
HA~STRiNG PEAK T.A.E. : PLACEBO GROUP 
J .P. ! . AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 
CYBEX 10.51 15.17 11.47 17.59 15.55 15.25 
15 .09 11 .17 16.42 13.33 17.71 16 .89 
7.74 28.90 19.51 28.46 23.69 29.00 
4.26 18.52 18.39 20.22 6.82 16.72 
:6 .20 27 .73 36.81 28.75 37 .51 31 .67 
:• .97 17.09 27 .87 28.56 15.21 32 .14 
:S .44 24 .55 23.73 23.67 24.07 23.02 
1:.77 27.08 15.76 31 .40 16.51 26 .29 
20 .37 21.08 22.34 20.02 20.66 19.65 
23 .60 30 .78 23.53 34.79 15 .28 34 .59 
:) .09 12 .91 16 .44 21 .08 19 .86 22 .27 
22 .70 32 .42 32 .71 30 .59 32 .21 35 .24 
~J .38 34 .65 34. 93 41. 03 41.42 42.69 







HANS TRiNS PEAK T.A.E. : DICLOFENAC GROUP 
H.P .T. AF D1 UN AD1 AFD3 UNAD3 AFD7 UN AD7 
16 .20 31 .17 14.23 30 .15 28.13 35 .27 
: .65 11.08 9.73 14 .48 12.57 10.51 
14 .32 14.91 15.01 14.99 15.90 15.49 
0.01 9.87 8.89 12.16 8.96 12.36 
40 .75 38.51 35.05 37.12 38.57 36.25 
13 .24 16.92 11.18 10.50 12.81 1~.26 
22 .10 26.36 21.23 22.~2 21.24 20 .66 
9.07 :4.58 12.34 14.33 17.80 17.95 
19 .7; 16.72 25.34 17.51 22.33 16.64 
37. 29 36.60 38.90 45.25 48.69 40.95 
45 .65 26.54 47.87 43.27 52.53 60.52 
31 .16 37.84 27.82 31.03 38.79 40.05 
5.40 14.16 4.44 12.23 6.61 15.87 
2S .08 31.94 25.79 27.63 23.84 21.54 
12.59 26.10 27.98 26.25 26.06 32.56 
22.22 33.26 27.76 32.39 32.16 36.37 
26 .46 28.44 29.41 32.50 28.15 22.84 
NEAN 21 24 23 25 26 26 
SD. 12 9 12 11 13 13 
RATIO 
R.01. R.D3 R.D7. 
0.693 0.652 1.020 
1.351 1.232 1.049 
0.268 0.686 0.817 
0.230 0.909 0.408 
1.305 1.280 1.184 
0.876 0.976 0.473 
1.036 1. 003 0.859 
0.435 0.502 0.628 
0.990 1.116 1.051 
0.767 0.676 0.442 
0.782 0.780 0.892 
0.700 1.069 0.914 
0.877 0.851 0.970 
0.761 0. 786 0.894 
0.791 0.894 0.829 
0.319 0.222 0.238 
RATIO 
R.D1. R.D3 R.D7. 
0.520 0.472 0.798 
0.690 0.672 1.196 
0.960 1.001 1.0~b 
0.001 0.731 C.725 
1.058 0.944 1.064 
0.783 1.065 1.045 
0.838 0.955 1.028 
0.622 0.861 0.992 
1.182 1.447 1.342 
1.019 0.860 1.189 
1.720 1.106 0.868 
0.823 0.897 0.969 
0.381 0.363 0.417 
0.785 0.933 1.107 
0.482 1.066 0.800 
0,668 0.857 0.884 
0.930 0.905 1.232 
0.792 0.890 0.981 
0.360 0.239 0.215 
~JTAL PA IN ;;ALUES : MECLOFENA MATE GROUP 


















I • ..,._. MEAN 
SD . 







































25.36 12.57 3.86 MEAN 
12.23 8.31 3.38 SD. 
!OTAL F~l\ JALJES : Dl ~LOFENAC GROUP 
VAS ~3 27 
23 :5 




\ ') ..... 
:G 4 
4 
i '7 1, 
; 1 } \/ 
MEAN 
SD. 
SWELL INS ~EASUR EMENTS : ~ECLOFENANATE GROUP 
era ~FD1 LNA D1 AFD3 UNAD3 AFD7 UNAD7 
65 65 a4 64 64 64 
.! : 44 42 42 41 42 
<C 54 ~· :,4 53 54 'I 
:o :.9 59 59 59 59 ,•, 
50 50 54 54 53 53 
41 39 4'1 .... 41 41 41 
;c cc 55 55 55 55 .J ..... ..i .. ,
='l 53 c" 53 53 54 - ' 4 ._; ~ 
~< 51 52 53 52 52 .., .. 
54 C'f Jv 54 53 54 54 
58 ~"1 58 57 59 59 ..,, z:., 52 ~') 52 52 52 "" "" 62 62 62 62 62 62 
NEAN 53.77 53. 38 53.85 53.77 53.69 53.92 
SD. 6.46 6. 63 6.24 6.31 6.58 6.43 
RATIO 
R.D1 R.D3 R.D7 
1.000 1.000 1.000 
0.977 1.000 0.976 
1.019 1.000 0.981 
1.000 1.000 1. 000 
1.000 1.000 1.000 
1.051 1.024 1. 000 
1.000 1.000 1.000 
0.981 0.981 0.981 
1.039 0.981 1.000 
1.019 1.019 1.000 
1.018 1.018 1.000 
1.000 1.000 1.000 
1.000 1.000 1.000 
1.008 1.002 0.995 
0.020 0.012 0.009 
SWELLI!~G ~EASUREi'!EtHS : PLACEBO GROUP RATIO 
Cill .-, c: n1 HI ... ,~:lAD1 ~FD3 UN AD3 AF07 UNAD7 R.D1 R.D3 R.D7 
: -. =' :0 :.,., 51 ~,3 1.020 0.962 0.962 · - ,' L 
~8 :8 . ., c; 57 c., :.ooo 1.000 1. 000 .I .. :, ,J / 
:-4 53 :.7 c., :;7 57 1.019 1. 000 1.000 , •) 
= i5 !C 4~: 47 47 1.000 1.000 1. 000 ,. ~ J 
48 .! ~ d] 47 47 0.979 1. 000 1. 000 ~ j -t i 
C ' "" 53 C ·~ .:., C"I 1.038 1.019 1.000 . l ot .... .J i. , •L ,.i i. 
;; "'." :c =":!' :,4 =.~ a (1 ,964 0.981 1.000 .. ... ... .. ..  _· ..; -. C < • C 54 :,4 54 0.981 1. 019 1. 000 .. -~ ,; ,; 
. 52 =-~ 56 56 c; l.019 1. 000 0.982 ... '" _., . 
J (: 
, ,., 60 ::2 6•j 1.033 1.033 1. 033 ·=~ .'.;l 
; r. .... ;1. 3 4'l 44 0.976 0.977 0. 9~;5 .,. ~ ... . L 
; 'J =c 60 ~9 60 :). 967 0.%7 0.983 . - .u 
:.c q :.6 =, c., 1. 018 1.018 !. GOO ., "' ,,, C ,"j ~8 ~3 :.s ~.8 58 1.017 1. 000 1.000 
~EAN 5:.: ; .: 7 .• ; "'." c.., :2. . 64 5~.86 54 .14 l .002 0.999 0.994 ... . ~ "'! .: .. . .; , 
SD . " - . =. I C =·. 46 
;: I C 5.29 4.84 (! ,024 0.020 0.018 ,. .. ..... .. - ... , ._ ... .; 
SWELLI NG l'IEASUREl'IENTS : DICLOFE!iAC GROUP RATIO 
CII AFDl ~tlA D1 AFD3 UNAD3 AF D7 U/JAD7 R.D1 R.D3 R.D7 
:,9 57 59 :;] 57 57 1.035 1.035 1.000 
53 :.2 C7 :3 53 53 1.019 1.000 1.000 ... ._, 
48 46 47 47 47 47 1.043 1.000 1. 000 
47 46 46 46 46 46 1.022 1.000 1.000 
54 ~4 ::.5 :;4 :,4 54 1.000 1.019 1.000 
i ,, i (J 69 S9 69 69 l .000 1.000 1. 000 ' " 
JO 61 ~o 61 bO 60 0.984 0.994 1.000 
46 45 51 51 49 49 1.022 1.000 1.000 
51 51 51 51 51 51 1.000 1.000 1.000 
61 59 bO 58 60 60 1.034 1.034 1.000 
57 58 56 55 58 Sb 0.983 1.018 1.036 
42 42 42 43 42 43 1.000 0.977 0.977 
38 38 39 39 38 39 1.000 1.000 0.974 
46 46 4b 46 46 46 1.000 1.000 1.000 
59 60 59 59 59 60 0.983 1.000 0.983 
55 ~~ 55 55 55 55 1.000 1.000 1.000 
_.,, 
55 55 55 55 55 55 1.000 1.000 1.000 
NEAN 53.00 52.65 53.12 52.88 52.88 52.94 1.007 1.004 0.998 
SD. 7.70 7.95 7.30 7.06 7.44 7.22 0.018 0.015 0.013 
"'AMSTP.l NS INJURY DATA 
QUADRI CEPS ?~a :c;QUE : MEC!..OFENAMATE SROUP ~ CHANGE @LOG((x+0.5)/(100.5-~)+2 ,, G.P. M. AFD1 ~:JAD1 ~FD3 UNA D3 AFD7 UNAD7 DAYl DAY3 DAY7 DAYl DAY3 DAY7 
28 (1 :l 5 2~9 314 310 302 -il -11 ~\ 0.28 0.28 0.31 '' ~ ,~, :~5 ·11 '1 189 226 -29 - 13 -16 0.25 0.28 0.27 su v ... . .;. ... ...... 
237 '1'') ~ :93 :Bi 214 187 ( .,. 14 0.32 0.31 0.34 
_.,.:, 
I _, 
·.t !61 1 -:-=, :74 t "l 136 167 -13 8 11 0.28 0.32 0.33 
... -t ~ J.. i i. ·"' · ··::·1 ; -.~, 224 236 278 274 -10 -5 0.28 0.29 0.31 
,._ ,.. , 
"- ·.J.L 
, L. ~ 182 • 0") 201 187 194 -10 -9 -! 0.28 0.28 0.29 
., ,.; ... , - _,. 
:74 213 lei 19i 182 207 -18 _ p; . "' -12 0.27 0.27 0.28 
:'13 241 :'}7 '; C. f ~50 262 -20 - ~8 -5 0.26 0.27 0.29 ,.,., .. 
:11 245 -:.-. c ': CA '\ C"I r, c,, -7 -11 0 0.29 0.28 0.30 t.i..; .i.,., "t .;.Ji. i..J.i.. 
181 187 : 76 , -; 4 138 152 -~. .,. -9 0.30 0.31 0.28 .. , J. ,j ::9 - d n _ i 0 197 175 ! 0 7 - ,)_) -1' -11 0.24 0.28 0.28 &. V7 .. II ... ·"1 "\C 2:-~ -,·,' 2:.4 , .... ,., ,.,. -12 -1·~ -15 0.28 0.27 0.27 ..:. .... : __, L,,J.j L.l'-' 
!l~ : 1)~! :39 2(}] 214 ,.., .... ri 96 -9 -4 1. 37 0.28 0.29 ... i. i. 
MEAN . ,J c, -.. " : '?9 .-,:"') 216 2:4 0.361 0.286 0.296 ~~7 SD . . ·~ .!9 :1 ~(l H 44 0.292 0.016 0.020 'i._i 
QU ADRI C~~S ~ ~A~ TORQUE : PLACEBO GROUP 7. CHANGE @L06((x+0.5 )i( 100.5-x )+2 (LP.P AFD 1 UNA Dl HFD3 UNAD3 AFD7 UNAD7 DAY! DAY3 DAY7 DAY! DAY3 DAY7 
131 128 128 128 134 122 'i (I 10 0.31 0.30 0.33 .. 
183 i99 162 188 181 204 -8 -1 4 -11 0.29 0.27 0.28 ... ,,,.,. 208 ~ C') ..,,,i 257 231 7 11 11 0.32 0.33 0.33 i.L.J LV L ~LI 
184 167 :49 161 167 169 10 -7 -1 0.33 0.29 0.30 236 '; "'Ii 266 251 256 245 7 6 4 0.32 0.32 0.31 
LL• 
205 235 -: i . 217 248 236 -13 -1 5 0.28 0.30 0.31 
_ .. ., 
198 224 .~.s 254 245 251 -12 -7 -2 0.28 0.29 0.30 237 243 214 224 220 216 -2 -4 " 0.30 0.29 0.31 ,; 256 229 237 186 243 267 12 27 -9 0.33 0.38 0.28 224 287 :~4 228 222 ,~.., 4..JL -22 -6 -4 0.26 0.29 0.29 141 : 48 151 1 C. ') .,,. 152 146 -5 -1 4 0.29 0.30 0.31 154 295 324 292 282 288 -48 11 -2 0,23 0.33 0.30 292 2~1 135 250 299 265 16 -26 13 0.34 0.25 0.33 215 273 ib6 250 253 281 -21 6 -10 0.26 0.32 0.28 
NEAN 196 213 205 206 216 217 0.294 0.304 0.304 SD. 39 41 49 39 42 40 0.031 o:02a 0.017 
GUADRIC:}S ?EA~ TORQUE : SICLOFENAC GROUP ',' CHANGE @L06((x+0.5)/(100.S-x)+2 
I , ~.P. D ,·v:n1 lJNAOl AFD3 UNAD3 AFD7 UNAD7 DAY1 DAY3 DAY7 DAY1 DAY3 DAY7 
r'! . J .. 
'~"':' 1 2b9 241 238 208 234 -12 -11 0.28 0.30 0.28 
~,.,, 
:59 191 f c.~ '"" '' ~ ,o,., 180 180 -i7 -7 0 0.27 0.29 0.30 148 170 ! '1~ 172 1 c. 't 164 -17 -28 -7 0.27 0.25 0.29 
J.i} l.L.~ .&.JV 
! ·1 t 134 149 153 148 160 -10 - ,) -8 0.28 0.30 0.29 
J. .:.. .. 
2.\4 237 236 ;:41 251 256 3 - ·l -2 0.31 0.30 0.30 L '"' t\ "7 180 198 172 186 i56 15 1 ~ 19 0.34 0.34 0.35 
~"'' 
'" 2~ ~. 236 260 267 267 259 -14 ., ;; 0.27 0.30 0.31 -J lo8 201 197 207 167 168 -16 -5 -1 0.27 0.29 0.30 . ~-:: 169 195 183 183 !99 -9 7 -8 0.28 0.32 0.29 
.,._, .; 
2:'.9 270 240 ~' ~ 1 263 283 -15 -4 -7 0.27 0.29 0.29 
~,.,. 
- ,7 ·~-  2c7 274 286 281 -7 ., ~ 0.29 0.30 0.31 - .,. ~ .. •1.• -,) ,: =:6 : 56 235 254 247 242 -8 -7 2 0.29 0.29 0.31 ;jfj 153 1 ·1 1 139 145 1 C.(1 -37 -13 7 0.24 0.28 0.30 .i.L~ ~v -,, ::5 'i.t "': 2:0 21 6 224 218 -11 -3 ""( 0.28 0.30 0.31 ~~~ " -,1 ... ~,, •'"l 320 H9 299 3i7 ' (I -6 0.31 (1 .30 0.29 .... ,:i : iO .: ,:. 23(1 ~88 :20 196 il8 -16 -18 -10 0.27 0.27 0.28 ~ -:: '":o "' C:7 ... , , 1 27 1 236 235 -10 -4 0 0.28 0.29 0.30 ...... L o.' J L.0.1. 
MEAN : bli 177 P " J L 178 , .,,1 .J . 17:, 0.282 0.294 0.299 SD . .\4 39 47 47 46 49 0.020 0.018 0.016 
rlANSTRING PEAK TORQUE : MECLOFENANATE GROUP 7. CHANGE @L0S((x+0.5)/{100.5-x)+2 H.P.N. AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 DAY1 DAY3 DAY7 DAY1 DAY3 DAY7 189 196 188 199 204 206 -4 -6 -1 0.29 0.29 0.30 71 119 94 120 100 120 -40 _.,., -17 0.23 0.26 0.27 LL 119 80 1-· ,)J 82 141 123 49 65 15 0.47 0.58 0.34 76 137 84 130 170 156 -45 -35 9 0.23 0.24 0.32 93 109 104 95 132 129 -15 9 2 0.27 0.32 0.31 75 134 88 140 113 137 -44 -37 -18 0.23 0.24 0.27 98 118 114 121 110 113 -17 -6 -3 0.27 0.29 0.30 71 149 122 155 148 165 -52 -21 -10 0.22 0.26 0.28 89 122 103 134 138 138 -27 -23 0 0.25 0.26 0.30 74 132 103 105 94 89 -44 -2 6 0.23 0.30 0.31 28 104 36 92 36 98 -73 -61 -63 0.20 0.21 0.21 45 161 58 149 73 166 -72 -61 -56 0.20 0.21 0.22 99 118 99 106 128 123 -16 -7 4 0.27 0.29 0.31 
NEAN 87 129 102 125 122 136 0.260 0.289 0.287 SD. 37 27 35 30 41 30 0.108 0.115 0.082 
~AMSTR ING P~fll. TCR QUE : PLACEBO GROUP ... CHANGE @L OG ((x+O.S)/(100 .5-x)+2 i , H.P.P ;FDl UNAD1 AF D3 UNAD3 AFD7 UNA D7 DA'fl DAY3 DAY7 DAY1 DAY3 DAY7 ~,1 35 46 80 ~c. 65 -41 -43 -15 0.23 0.23 0.27 
·-·· J•' 
:, -:: ::c. :04 89 116 100 21 17 16 0.36 0.34 0.34 
_._,., ..... 
"' 
~ 1 t 80 119 110 117 -67 -33 -6 0.21 0.24 0.29 
.L ... 
.. •.ii 111 100 t tt 113 111 -4 -10 'i 0.29 0.28 0.31 
•. u 
L 
~ :-7 1 1:.: 156 155 160 l "·"' 1 1 '1 0.30 0.30 0.31 
J.. J.j 
"' . L · "'-" ~40 136 149 161 172 -6 -9 -6 0.29 0.28 0.29 
... . _\ ,i. 
1L9 90 i34 100 155 -45 -40 -35 0.23 .-·, ·j ;!' l.• 1L,J 0.24 "~ 107 '16 113 110 126 -30 - 15 -13 0.25 0.27 0.28 :;,1 130 1'1'1 LL l"'l i.L 148 p') ,L -28 'J -14 0.25 0.30 0.27 ._ .... 137 69 126 83 142 -55 -45 -42 0.22 0.23 0 'J ~ ··" 85 85 107 103 99 -14 -21 4 0.27 0.26 0.31 : (, :69 173 149 f ~.., 142 -:!3 16 -7 0.22 0.34 ~.29 J '.' ~ -.JL =~ I C.,. 130 !.61 182 !.86 -38 -19 _, 0.24 0.27 0.30 · ~·j L - ,~ :43 104 :65 139 181 -45 -37 -23 0.23 0.24 0.26 
~EAN - - ::4 ~Go 1n 1 ·1.., :38 :), 257 0.274 0.285 
- .;..L~ 
SD . "!'"1 ~-. H 
0.093 0.077 0.076 
... , ._\ ,.l 
L • ' ~,.:., ,J ~i 
HAMST RING ?EAK TORQUE : DI CLOFENAC GROUP l CHANGE @L06( (~ +0.S)/(100.5-x)+2 H.P.D. AFD 1 UNA D1 AFD3 UNAD3 AFD7 UNAD7 DAYl DAY3 DAY7 DAYl DAY3 DAY7 56 169 70 176 120 165 -67 -60 -27 0.21 0.21 0.25 46 108 11 108 81 113 -57 -34 -28 0.21 0.24 0 ·1 C. 
I • ... ., 26 113 43 :07 69 94 -77 -bO -27 0.20 0.21 0.25 ~, ! - 81 71 84 89 85 -12 -15 5 0.28 0.27 0.31 16! 159 159 157 160 160 1 0 0.30 0.30 0.30 80 92 91 84 106 98 -13 8 8 0.28 0.32 0.32 118 156 134 168 130 163 -24 -20 -20 0.26 0.26 0.26 52 118 89 118 110 119 -56 -25 -a 0.22 0.26 0.29 91 113 114 113 119 117 -19 1 2 0.27 0.30 0.31 119 137 141 137 144 164 -13 3 -12 0.28 0.31 0.28 159 171 149 169 159 174 -7 -12 -9 0.29 0.28 0.28 125 175 116 161 139 165 -29 -28 -16 0.25 0.25 0.27 20 76 15 67 19 75 -74 -78 -75 0.20 0.20 0.20 87 118 93 113 102 114 -26 -18 -11 0.25 0.27 0.28 74 138 123 175 131 162 -46 -30 -19 0.23 0.25 0.27 90 136 105 138 108 136 -34 -24 -21 0.24 0.26 0.26 121 117 137 141 169 144 3 -3 17 0.31 0.30 0.35 
MEAN BB 128 101 130 115 132 0.251 0.264 0.279 SD. 40 30 38 33 36 32 0.035 0.035 0.033 
guADRIC£?S TOTAL ~ORK : ~E CLOFENANATE GROUP ~ CHANGE @LOG((x+O.S) /( 100.5-x)+2 
,, 
Q.E. M. AF!}l UNA D1 AFD3 UN AD3 AFD7 UNAD7 DAY1 DAY3 DAY7 DAY1 DAY3 OAY7 :: c.,\ ~ 3610 3402 3606 3314 3779 -3 -6 -i2 0.30 0.29 0.28 
... vv,.; 
2?56 2~06 2994 3293 2814 2947 18 -9 -5 1) ,35 0.28 0.29 ·1 L , --:r L.V IJ 2652 2~b1 '1'7 C') i..J..JL 2638 1989 9 33 0.30 0.32 0.40 1:44 'j ,.,~.., 21 91 21 25 2011 2384 -22 3 -16 0. 26 0.31 0.27 
i..~v• 
.·• 1' --:r L 2:69 1676 2033 1913 2897 ' -18 -34 0.31 0.27 0.24 
~ ...... u 
"' :142 1!06 1987 2126 2048 2115 ') -7 - ) 0.31 0.29 0.30 L l911l 238! 1845 2152 2062 2394 -20 -14 -14 0.27 0 'l"l ,LI 0.27 '.628 2!)~;9 1679 21 96 1907 2403 _')1 -24 -21 0.26 0.26 0.26 L• 1S20 2408 .,.,,,., 2065 2503 2633 -20 g -5 0.26 0.32 0.29 
I.LL._ 
1410 .-,n• i ·1 ~ I t 2369 2329 2170 -14 6 7 0.27 0 ., ., 0.32 
.=:C.t .. ...... 
..u. l 7(! :1 2~~7 2360 23 53 :;:435 ?264 -29 0 8 0.25 0.30 0.32 -001 --:c 1~'1(\ 3493 3500 ~~..,., -9 -5 C 0.28 0.29 0.31 
._ I .._ 4 ,., ._, ; I ·- .> L -.J ,; ._,IL• 
J 271 5 ~621 24 61 2436 2838 2676 4 6 {\ ., 1 'J . ,.),l 0.30 0.32 
~EAN - - C ·- ;:5~4 ;: 401 2508 L. . - -... 2486 ·'1£.17 LVJ..J 0.287 0.2·15 0.298 SD . - - · -:--r; :,~4 ~Al 501 493 0.101 0.078 0.084 
.. . .J, -:i.. 
1UADR lmS : :TAL wORK : ?~ACEBO GROUP '/. CHANGE @L0S((x+0.5)/(100.5-x)+2 Q. E.P . AFD1 LN ~D1 AF03 UN AD3 AFD7 UN AD7 DAVl DA'/3 DAY7 DAY! DAY3 DA Y7 2092 2494 1369 1399 2128 2009 -16 _., 6 0.27 0.30 0.32 L 2873 'i C~t ;:~54 2867 2894 3192 -3 -7 -9 0.30 0.29 0.28 
.. ,..,. 
211 7 3274 2964 3179 2971 3200 -35 -7 -7 0.24 0.29 0.29 1721 :830 1~159 1647 1912 1739 -6 -5 10 0.29 0.29 0.33 3482 3037 3512 3120 3535 3296 15 13 .., 0.34 0.33 0.32 I 2646 2799 :919 2869 2941 2974 -5 '1 -1 0.29 0.31 0.30 L 1477 "' ~~ c 2162 2139 2562 2490 -42 7 0.23 0.30 0.31 
i..J..).J 
,.) 2590 2ns ::30 3130 3095 3215 -12 7 -4 0.28 0.31 0.29 ,, 2350 2456 2998 2711 2786 2724 -4 11 2 0.29 0.33 0.31 2065 275b 2198 2796 2320 2229 -25 -21 4 0.26 0.26 0.31 1405 1399 1414 1489 1639 1459 0 -5 12 0.30 0.29 0.33 2831 3430 3816 2893 4376 3774 -17 32 16 0.27 0.39 0.34 3597 3088 3521 3057 3793 3684 16 15 3 0.34 0.34 0.31 3244 3631 3756 3752 4021 3871 -11 0 4 0.28 0.30 0.31 
MEAN 2464 2758 2755 2682 2927 2847 0.285 0.309 0.310 SD. 674 577 771 624 770 736 0.098 0.083 0.079 
QUADRICE PS TO TAL WORK : DI CLOFENAC GROUP ., CHANSE @L0S((x+0.5)/(100.S-x)+2 ,. Q.E.D. AFD1 ~NAD1 AF03 UN AD3 AFD7 UNAD7 DAYl DAY3 DAY7 DAYl DAY3 DAY7 31~;8 3133 3:89 3b31 3671 3738 I _, -2 0.30 0.30 0.30 .. .. lb31 1715 ~665 1 c.~~ 1760 [866 _ .. 7 -6 0.29 0.32 0.29 -" '-'.J V •' .. 3l6 2296 2285 2239 2204 2197 2 0 0.30 0.31 0.30 ~ 34~; ~671 :405 1561 1519 1675 -20 - H} -9 0.27 0.28 0.28 317~ 3681 4049 3850 3817 3797 a 5 I 0.32 0.31 0.30 .. 2012 1424 2432 2241 2802 2329 41 9 20 0.43 0.32 0.35 3552 3907 3784 4336 3334 ":"' ., ")1 "'-•• -9 -1 3 4 0.28 0.28 0.31 2394 2270 2350 2456 2544 26 20 ~ -4 ~ 0.31 0.29 0.30 •' - ,; 1465 1743 1695 1796 1619 1831 -16 -b -12 0.27 0.29 0.28 270~1 26 48 2632 2467 2'121 2911 " 7 0 0.31 0.32 0.30 i. 3454 3405 3491 3~,01 3681 4098 1 0 -10 0 ~1 ,..,,. 0.30 0.28 2937 3835 291 2 3783 ~-::' ~"') 3951 ., ~ -23 -16 0.26 0.26 0.27 ·J W.)4,. - 1.J 1403 1858 1 ~,48 1660 1597 1725 -24 -7 -7 0.26 0.29 0.29 ·:332 3225 2248 2879 30 57 2611 -12 -1 17 0.28 0.30 0.34 2845 3327 3351 3:88 3634 3~123 -26 _,, ~\ 0.26 0.29 0.31 '; C. I 0 2b94 3l89 ~.., . .,. .,~., .. 3314 - 7 -4 r', 0.29 0.29 0.30 LJ.l\J . .),.j. J..,) ,.,\,.,1 4 .J ",J 2:39 ~162 :.4~,6 :647 3046 311 4 -18 _., 0.27 tL:9 0.30 4 
MEAN "'I C ~-r ·1"'7 1'~ 27 46 2853 2815 2854 0.294 0.297 0.301 
iw ..;J ~· ... ..,, 
SD. 756 o~., u~ i.. 809 889 776 797 0.040 0.016 0.021 
HANSTRING TOT AL WO RK : MECLOFENAMATE GROUP 7. CHANSE @L06(( x+0.5)/(100.5-x )+2 H.E.M. AFD1 UNAD1 . AFD3 UNAD3 AFD7 UNAD7 DAYl DAY3 DAY7 DAYl DAY3 DAY7 1962 2121 1915 2134 2363 2360 -7 -10 0 0.29 0.28 0.30 1604 1483 2066 2413 1932 2005 8 -14 -4 0.32 0.27 0.29 1 '1 7 "1 4 J.., 1380 1849 1402 1849 1952 -11 32 -5 0.28 0.39 0.29 782 1509 ~242 1653 1626 1416 -48 -25 15 0.23 0.26 0.34 1138 941 1128 1119 1163 1474 21 1 -21 0.36 0.30 0.26 1814 2313 2020 2539 2032 2545 -22 -20 -20 0.26 0.26 0.26 1450 1546 1364 1518 1456 1240 -6 -10 17 0.29 0.28 0.35 1144 2040 1790 2181 2158 2243 -44 -18 -4 o.n 0.27 0.29 1358 2004 1410 1911 1975 2193 -32 -26 -10 0.25 0.25 0.28 1183 1528 1379 1497 1241 1212 -23 -8 ., 0.26 0.29 0.31 4 349 1579 454 1349 625 1269 -78 -66 -51 0.19 0.21 0.22 924 1949 1096 2027 1387 1721 -53 -46 -19 0.22 0.23 0.27 1602 1552 1236 1383 1840 2008 3 -11 -8 0.31 0.28 0.29 
NEAN 1273 1688 1458 1779 1665 1818 0.268 0.275 0.289 SD. 419 359 440 432 458 441 0.100 0.082 0.080 
HAKSTR IN6 TOTAL WOR K : PLACEBO 6ROUP ! CHANGE @LOG(( x+0.5)/(100.5-x)+2 H.E.P. AFD1 UtMDl AFD3 UNA D3 AFD7 UNAD7 DAYl DAY3 DAY7 DAYl DAY3 DAY7 l097 t ·1 ; c .1 iJ ,J if (\. 1/V 1446 1219 1445 -38 -47 -16 0.24 0.23 0.27 1.209 816 1585 1365 1606 1445 48 16 11 0.47 0.34 0.33 :14 2441 1345 ., ..... 1444 '17 1c; -95 -49 -47 0.18 0.22 0.23 .1.0 .... £. J J.,J :085 l ~;48 ::92 1343 1491 1301 -30 -4 15 0.25 0.29 0.34 2~,48 1707 24 42 1798 2336 1928 49 36 21 0.47 0.41 0.36 1394 1177 1613 1647 1407 1948 18 -2 -28 0.35 0.30 0.25 i768 "'~"c L~ .. •J 2065 27 45 2533 2959 -25 -25 -14 0.26 0.26 0.27 :3i9 :134 1335 2252 l502 2041 -62 -41 -26 0.21 0.23 0.25 :165 2291 2707 .,.., t. L"-.Llf 2789 2382 -5 ')") ,.,. 17 0.29 0.36 0. 34 1041 ;394 1246 1940 1343 1959 -45 -36 -31 0.23 0.24 0.25 463 189 072 989 911 1031 -53 -32 -12 0.22 0 ') C ,,.., 0,28 1301 2397 2283 21 51 2547 2805 -46 6 -9 0.23 0.32 0.28 2087 :789 2843 2712 2994 3009 -25 .. -1 0.26 (1 .31 0.30 ., :365 2187 I,.., ~"') 2350 2263 2561 .;..L.;6. -39 -47 -12 0.24 0 ·n ,,.., 0.28 
MEAN ;::8 :893 : ~ 7~; :972 1884 '.:l09 0.277 0.285 0.288 SD . ·= c .• i .. 1 :,69 ~cl 539 639 624 0.123 0.089 0.081 
HAIISTR!NG TOTAL WORK : DI CLOFENAC GROUP l CHANGE @LOG(( x+0.5 )/( 100.5-x) +2 H.E.D. AFDl UN AD1 AFD3 UNAD3 AFD7 UNAD7 DAYl DAY3 DAY7 DAYl DAY3 DAY7 493 1~,71 b96 1924 1954 2503 -69 -64 -22 0.20 0.21 0.26 "'I "':'") L.)L 774 789 949 826 620 -70 -17 .,.~ .);, 0.20 0.27 0.40 278 5·55 559 942 862 906 -71 -41 -5 0.20 0.23 0.29 382 495 '.2 56 496 313 518 -23 -48 -40 0.26 0.22 0.24 3092 2854 3119 2806 2896 3016 8 11 -4 0.32 0.33 0.29 1063 966 1362 1478 1480 1550 10 -8 -s 0.33 0.29 0.29 1695 ., . ,,,,, LJ,.~J. 2053 2213 1860 1746 -24 -7 7 0.26 0.29 0.32 928 1351 1082 1726 1724 1984 -31 -37 -13 0,25 0.24 0.28 974 974 1176 1206 1135 1083 0 -2 5 0.30 0.30 0.31 21 23 21 94 2163 2580 2500 2430 -3 -16 3 0.30 0.27 0.31 2325 2759 2213 2763 2163 2771 -16 -20 -22 0.27 0.26 0.26 1904 2604 2112 3227 3062 3584 -27 -35 -15 0.25 0.24 0.27 190 845 181 167 452 1068 -78 8 -58 0.20 0.32 0.21 1760 1873 1657 1697 1636 1475 -6 -2 11 0.29 0.30 0.33 600 1651 1421 1810 1895 1768 -64 -21 7 0.21 0.26 0.32 1352 1385 1847 2272 2075 2059 -2 -19 1 0.30 0.27 0.30 1898 1862 2014 2454 2135 2099 2 -18 2 0.31 0.27 0.31 
IIEAN 1252 1608 1453 1806 1704 1834 0.261 0.269 0.294 SD. 829 711 717 830 764 830 0.044 0.032 0.040 
QUADRI CEPS AVERASE POWER : MECLOFENANATE SROUP % CHANGE @L06((x+0.5 )/ (100.5-x )+2 Q.A .P . AFD1 UNADl AFD3 UtlAD3 AFD7 UNAD7 DAY1 DAY3 DAY7 DAY1 DAY3 DAY7 CYBEX 329 352 1 r, -, 321 302 354 -7 -6 -1 5 0.29 0.29 0.27 
vv , 
287 :43 ~1'! 289 250 250 18 -6 !) (! .35 0.29 0.30 
,. , ,. 
·"": 7'1 :91 'HO 217 247 175 -7 10 41 0.29 0.33 0.43 
~ · ~ ,...,, 
'.60 205 205 197 204 228 r • --i. 4 -11 0.26 0.31 0.28 :::4 210 158 191 237 265 2 -17 -11 0.31 0.27 0.28 :71 176 i59 179 171 180 -3 - 11 -5 0.30 0.28 0.29 i:34 "': ,,I"\ 184 208 199 239 -17 -1 2 -17 0.27 0. 28 0.27 
i.i.L 
lb9 :,15 rn2 151 212 160 17 'i1 ,. .. 0.34 0 "! ~ 0.40 L.I. . ,; .:, ,..,.,~53 220 196 167 236 237 -30 17 () 0.25 0.35 0.30 """' 280 24,S 236 241 238 -21 4 l 0.26 0.31 0.30 
i.i.i. 
! 70 :34 195 21 5 21 6 198 _,,., -9 9 0.25 0.29 0.32 L I ~' 6 ~(12 -r, 7 310 ~ 1 '! 29~, -9 "I 6 0.28 0.31 0.32 
-.:.1., ,J J.L 
L ~' "?C ~39 ")".!"7 212 278 .,~~ 17 1 'i 18 0.34 0.33 0.35 
:.. : i ,...,, 
L. .. • oJ a 
MEAN - -.-, 240 ... ,,,,, 223 239 235 0.292 0.306 0.317 
1..i.i. 
so . :7 =-:r 4Q = 1 39 50 0.033 0.026 0.047 
..... 
QUADR IC~~~ ~V ERASE PO WER : PLACEBO SROUP I CHANSE @L06(( x+0.5 )/( 100 .5-x)+2 Q.A.P. AFDl liNADl AFD3 UNA D3 AFD7 UNAD7 DAYl DAY3 DAY7 DAY! DAY3 DAY7 CYBE X :95 226 178 183 216 199 -14 -3 9 0.28 0.30 0.32 260 288 :;:51 255 277 316 -10 - ,:, -12 0.28 0.30 0.28 256 317 312 334 315 341 -19 -7 -8 0.27 0.29 0.29 141 139 128 138 158 131 1 -7 21 0.31 0.29 0.35 796 270 298 271 301 285 10 10 6 0.32 0.33 0. 31 209 237 238 248 252 261 -12 -4 -3 0.28 0.29 0.29 126 "'H "i 167 176 208 250 -41 -5 -17 0.23 0.29 0.27 
L.iL 
226 259 273 274 258 262 -13 0 -2 0.28 0.30 0.30 l '11 201 240 206 223 224 -5 17 0 0.29 0.34 0.30 167 233 165 222 188 192 -28 -26 -2 0.25 0.26 0.30 112 121 117 127 137 130 -7 -8 ~ 0.29 0.29 0.31 ., 338 ,.,., JJ,_ 371 294 381 322 2 2b 18 0.31 0.37 0.35 302 290 314 306 335 323 4 "1 4 0.31 0.31 0.31 J 281 344 336 341 371 363 -18 -1 2 0.27 0.30 0.31 
NEAN 221 248 242 241 259 257 0.283 0.303 0.307 SD. 68 64 77 6b 73 72 0.023 0.027 0.023 
GUADRJ CE?S ~vERAGE POWER : DI CLGFENAC GROUP G.A.P. AFD! ~NAJl AFD3 tNAD3 4FD7 UNA D7 C'/BEX -:,~q ·. -- :67 413 ~98 407 
i1EAN 
SD. 
::4 :~o i46 1:~ 1so 152 
., -= 





' ~ 1 
- • J - '1 '":' __ ;, .;...;., i 
























335 :,45 366 419 
-: •::. 















•CL -,o t 





HA NS TRJNS H'IE~ASE rJWER : i'.ECLOF ~NAi'IATE GF:OlJP H.A.P. AFD~ UN AD1 ~F il3 UNAD3 AFD7 UNAD7 C'I BEX . :i1 2')5 168 :S9 214 220 - .J .. • 
l S4 :42 :96 210 170 169 
i2 4 l.\9 171 128 171 !74 ~, ; 7r• il6 150 163 134 
! "t c - 7 
1(19 C': 109 :11 138 139 
:43 :89 ~57 I Ct .&. I .L 158 199 ~:3 140 .,, -, i38 '.,. 126 U I 1 L J 147 35 154 125 lbl 174 
1% 154 108 1 ~-8 162 178 
' I C LJ 151 140 154 t 7") LlJ.. 130 
35 1 C"'I ..... , 38 i28 ~,6 116 
87 188 105 189 127 161 166 151 118 132 184 198 


























:, - 3 - 13 
-22 
-24 
' C - .!. .. : 


















- l 'i -8 






DA Y3 DAY7 
-11 - 3 
-11 
34 '"I J.. 
-23 ., ... Li. 
-3 -1 
-18 -21 
-15 . -1 







OAY l DAY3 DAY7 
0.28 0.28 0.30 




.-. ·1 1 ·., ,1. , 
0. 32 0.32 
It ~') 
I._, 1..JL 
(I . 28 
( 1 ~ f 
..J ,,JJ. 
0.42 0.31 0.34 
0.28 0.28 0.30 
0. 30 (!.30 0. 31 
0.27 !).30 0.29 
0.31 0.34 0.29 








(1 iO \ : ... , 
(;,28 
') . 30 




/1 ~' ....... .. 
(! I 26 i) I 30 <) I 30 
0.291 0.296 0.303 
0.038 0.019 0.021 
!LOG( (x+0 .5 )/(100.5-x) +2 
DAYl DAY3 DAY7 
0.28 0.29 0.30 
r, ~'! 0.29 0.30 \.• .v• 
0.27 (! ,4(1 •J .30 
0.23 0.26 0.36 
0.35 0.30 0.30 
0.26 0.27 0.26 
0.28 0.27 0.30 
0.67 0.36 0.29 
0.25 0.25 0.28 
0.26 0.28 0.31 
0.20 0.20 0.22 
0.22 0.23 0.26 
0.33 0.28 0.29 
0.300 0.282 0.290 
0.115 0.049 0.030 
1AMSTR! ~6 AvE~ASE PC~ER : ?LACEBO BRDUP 
H.A.P. hf~ ! 2N AD1 ~FD3 UNAD3 AF D7 UNAD7 
f \ ~ __ , .;. 
'I L, •-'-' 
,,., c 









:38 _.: :95 ~23 i64 
., --
•: l 
~AMSTRitlS HV f~AGE 
H.A. P. ~FD! UiliiD1 
•: ·/BEX =~ l 9~i 
23 "".''"! i i. 
71 ·J I u. 
:..1 .ii 
~Q I :6: 













l'IEAN t'1 1 .;.L.., 151 
SD. 76 62 
--. --~ 


































227 214 2S4 
60 ·= 4 
: DlCLOFENAC SF:QUP 
UN AD3 AFD7 UNAD7 
..-d C 210 :70 .• U.J 
'~::1 -c. C"l' _, .j 
81 e r. ,:,7 
39 40 4~ 
~'41 2:7 261 
110 129 130 
'.94 ::0 :56 
i48 159 164 
110 119 ' .·. C ... '.J,j ,,.., ~ 230 196 "-"-• ,,., .,. 
183 231 i.~.J 
281 274 ~ · '7 ._iiJ 
77 3<i' 96 
171 175 146 
175 178 180 
218 210 206 
234 206 206 
166 160 167 
69 69 75 
/. CHANGE 



















































c' ! -22 
·- 4'1 . L 
-2 4 













~LDGf (x+0 .5 )/( 100.5-xl +2 
DAYl )AY3 uAY7 
0.24 0.23 0.28 
(l , 42 0.36 r, ,'1 ··' · ..;~ 
0.18 0.21 : , 'i "'!' V ,L.:.• 
r) I 24 (! , 3(1 f\ 7") ·•1 1 W L 
') , 43 0.44 0.44 
0.34 0.30 0.26 
0.26 (:.26 0.2B 
0. 21 (! ,23 0.26 
0. 3C> 0.3~ ) .34 
i) .23 o.:5 0.25 
:) .22 (1 . 26 0. 29 
·) . 24 (). 32 (l .28 
.·\ '1~ 0.29 0.29 \.' 1,J..W 
') . 23 ,., '1~ 0. 27 'J . """" 
,_) . 270 0.288 0.291 
0.073 0.061 0. 051 
@l03 ~{ x+0 . 5)/(100.5-x }+2 
DAYl DAY3 DAY? 
() .2(1 0.20 0.26 
0.20 0.28 0.43 
0.28 0.30 0.31 
0.23 0.28 0.29 
0.32 0.33 !) .30 
0.34 0.18 0.30 
0.26 0.29 0.30 
0.24 0.24 o.~o 
0.30 0.32 0.33 
0.30 0.28 0.35 
0.34 0.29 0.26 
0.26 0.25 0.28 
0.20 0.19 0.21 
0.29 0.31 0.35 
0.21 0.25 0.30 
0.26 0.28 0.31 
0.29 0.27 0.30 
0.265 0.267 0.305 
0.046 0.042 0.045 
9U ADR!CE PS PEAK T.A.E . :MECLCF ENAMATE GROUP 
G.P.T. ;F~: ~~AD1 AFD3 UNAD3 AFD7 ~NAD7 
CYBEX ~~.23 ~6.~2 51.61 54 .b2 55 .56 56.1 0 
~0.0! :a .01 39 .91 32 .46 52 .41 44 .93 
2:.3~ 27.E4 28 .62 25 .86 20.31 26.94 
_:.:~ :1.~s 20 . s2 29 .1: 30 . 27 33 . 19 
:2.73 19 . 5~ 20 .48 23 .73 23.26 23.21 
:~.J6 20.:2 21.86 26.14 25 . 49 3C .:! 
~: .;~ 2S . 4~ 28 .44 38.27 41.60 34 . 13 
:~.81 :J.l7 45 .49 39 .64 4~. 07 ~6.71 
ii,S~ 42 .:B 'l.93 37.98 35 . 43 36 .82 
::.3? :.: . ?1 :.,) .18 36 . 5'1 33 .42 :7 . 52 
~~ . 1~ 48 . t4 4~ .17 49 . 45 ~9.72 4~.:c 
. (i '.j , l ;", ... 
3LlADRIC~~5 ~~AK T.A.E. : PLAC EBO GROLP 
~.P. T. ~~~1 .~A91 ~FD3 UNAD3 AFD7 UNAD7 
[Y BEX :J,;2 ~3.58 22 .93 2~ .94 27. 00 30 .53 
!4.57 34 .57 37 .84 37 .~2 37 .2~ 39 .46 
29 .27 44.98 49.56 47. 08 SO.lb 48.91 
i9.7i 24 .65 24 .14 22 .49 23 .68 23 .42 
:3 .43 29.54 24.37 29 .59 24 .96 30 .12 
27.a3 33.bB 32.17 29 .57 33 .74 35 .17 
:7.89 21 . aO 17.28 24 .89 19.55 24 .94 
2~ .76 28 .97 36 .31 30 .90 33.90 31 .58 
24. 38 2S .33 28.77 24.67 31 .47 29.28 
35 .76 42 .39 39 .83 40.28 13.79 49.21 
ll .93 26.41 18 .89 26.90 28.29 23.16 
d8,51 ~0 .60 67.25 55.77 78.66 51.67 
46 .84 49.97 47.50 67.89 70.89 73.42 
44.93 iS.50 55.41 47.51 56.97 58.36 
MEAN 30 35 36 37 38 39 
SD. 11 10 14 13 19 14 
Yo :HANGE 
DA Yl DAY3 DAY7 
-9 -6 -1 
11 ..• 
C 

























l c . .:. .. , 
10 




























21 C'l , ,,. 
-30 -3 
17 _, .. 
@LDS1(x+0 .5 l/ (100.5-x )+2 
DAY l rA Y3 DAY 7 
0.28 0.29 0.30 








(i . 30 
') . 24 
0.33 












r, 1 L .. • ,uu 
f 1 'i O \.• ,.:.., 
,-. ,o 
'· ' • Ll.l 
0.34 0.30 0.39 
0. 32 0 . 42 ( ,_ 1' l. ... . .. w 
0.039 0.046 0.041 
@LOG(( x+0 .5)/(100.5-x)+2 
DAYl DAY3 DAY7 
0.28 0.27 0.28 
0.30 0.30 0.29 
0.24 0.31 0.31 
0.26 0.32 0.30 
0.26 0.27 0.27 
0.27 0.32 0.29 
0.27 (\ 'l ~ "' ...... 0.26 
(1 .31 0.35 0.32 
0.29 0.34 0.32 
0.27 0.·30 0.20 
0.22 0.25 0.3b 
0.29 0.35 0.49 
0.29 0.25 0.29 
0.29 0.34 0.30 
0.275 0.302 0.306 
0.023 0.037 0.062 
guADRI C~?~ ~~At T.A .E. : DICLOFENAC SROUP 
Q.P. T. ;F~! ~NA D1 AFD3 UNAD3 AFD7 UNAD7 
CY BE X 5!.~7 ~6 .62 64.6E 58. 01 55.16 55. 17 
12.7~ :? . 74 25 .44 2S. O! 2~.12 25.41 
1: .: 7 22.61 25 .00 22.51 25.98 23.58 
~EAN 
SD. 
:=.~~ ~7 . :9 l! .00 18.41 18. 02 19. 01 ~=. :~ 2~.s1 36.00 33 .as 38. 03 32. 91 
~; .~3 20.59 l~ .85 1: .93 21. 08 20.65 
: : .: : ~0.00 34.41 37 .34 31.72 33 . !5 
: :. t7 ~: . !9 2S.:~ 26. 08 29.24 25.41 
SS .3~ ~9.53 5t .3l 37.~2 62.58 61.23 
1 ~ . ~~ ~~.c0 91. 36 71. 91 9! .42 91.55 
~~.-- ~! , qg 43.54 53 .62 55.77 ~4.87 
: : . ~~ ~: .~9 ::.:s 26 .63 23.82 23.&8 
.\1 
j ,j ., 
rlANST~i NG PEAK T.A.E. : ~ECLOFENAMATE GROUP 
Q,P. T. AFD1 ~NAD1 AFD3 UNAD3 AFD7 UNAD7 
CYBEI 23 .33 32 .63 27.77 28.35 31. 36 34.42 
MEAN 
SD. 
!~ .05 : • .: 3 :5 .o4 19.23 19. 09 !9.81 
:o.7: i3.e1 2: .70 10.56 25.86 29.60 
i3.52 :S.39 18.52 21 .45 29.31 26.86 
16.1 1 :S .73 21.34 25.85 24.27 29.29 :a .o~ :3 . 12 ~5 .91 2:.86 10.86 22.24 
::. : : :~. :~ l ~. 00 15.~6 12.48 17.69 
1) .68 :~.98 35.86 12.27 33.46 40.62 
: l.! 4 ~3 .53 39.43 37.52 19.28 49.tl 
19. 36 21.59 2!.55 20.74 19.71 20.10 
7.78 26 .49 8.38 23.16 10.68 16.43 
lS.47 27 .68 16.83 30.51 22.66 29.72 
23.75 21.:0 19.21 17.94 29.64 23.48 







































- -, ', -~ 
-21 
7. CHANGE 























-44 -45 -24 
12 7 26 














(! , 33 
(\ 1 1 
·.! 1 WJ. 
(1 .33 
(! . 29 
0.32 
(! .37 
( 1 ·"'.:Q 
V ,._ I 
.-~ '1 0 ..... , 
,) • 48 
.·, ~ ... ..... ,..., 
t) . 26 ·) . 27 
·:;. 26 0.26 
1) .27 0.28 
,·, .,..,, ;°\ i Q ·.i , .j~I •.• I .. } 
i:1 .26 il .29 
•:u s o .21 
DA Y7 
0.30 




0 . . :.4 
{\ 'i {. 
.• ,LU 
·, "'"' : , .;;v 
C . 31 
!) .30 
.·, -:' ""!' 
\.; ,._, ,.; 
,: . 29 
.\ -::-;, .: , ...... , 
0.291 0.313 0.303 
0.045 0.049 0.022 
@L06((x+0.5 )/ (100 .5-x)+2 
DAVl DAY3 DAY7 
0.28 0.30 0.28 
0.32 0.27 0.29 
0.33 0.38 0.28 
0.25 0.28 (1 .32 
0.27 0.27 1..t.27 
0.26 0.25 0.27 
0.29 0.29 0.25 
0.34 0.13 0.27 
0.26 0.31 0.21 
0.28 0.31 0.30 
0.20 0.21 0.24 
0.23 0.23 0.26 
0.33 0.32 0.37 
0.280 0.272 0.279 
0.039 0.059 0.038 
~AMSTRl ~3 PEHK ~.~.E. : P~AC EBO GROUP G.P.T. ";~- ~NAD! ~FD3 JNAD3 AFD7 UNAD7 CYBEX : ~ . ~~ ~~ -~ 7 l ! .4i l~ .59 15 .55 15 .25 
-~.:;, ::.: : : t.4:2 :=..33 : 7.71 :6.89 
- ,;; 2? .C0 !i .~1 28 . 46 23 .69 29,00 1.:~ :s.~: :e.:9 20.:: ~.e2 16 .72 
~~.J7 ~7.~S 27.87 29 .Sb 15 . 21 32.14 
~ ~. ~~ 24.~~ 2: . ;3 :3.67 24. 07 28.02 
::. ~' 27.08 :5.76 3: .~o 16 .51 26 .29 
2~.21 ~: .Je 22 .34 20.v2 20 .6b 19.65 : ~.~0 30 . 7S 23 .e3 34.79 15.29 34.59 
:~.~i :2.=: i6 .44 :: .cs !9.8b 2: .27 
~AMST R!~3 =~;~ : .; .~. : ~!CLQFENAC SRGUP ~.P.I. °F~l - ~~D~ AFD3 U~AD3 AFD7 UNAD7 
MEAN 
SD. 
lo .: J ~: .:7 14.23 30.15 28 . 13 35.27 
7.~~ 11 .GS 9. 73 !~.48 12.~7 :0.51 
14 .32 !4 ,ql 15. Jl 14 .99 15. 90 15.49 
).01 9.B7 ~.89 !2 . l6 8.96 12 .36 
40 , 7~ 36. ~l 35 .05 37 .! 2 38.57 36 .25 
1~ .24 :6 .92 11.18 !0.50 12.81 i2.26 
22 .l ~ ~6 .36 2! .:3 22 .22 21.24 20.66 
~.07 i4 ,5S !2 .34 14 .33 17. 80 17.95 
:9 ,77 16 .72 2!.34 17,51 22.33 16.64 
37.29 36 .60 38.90 45.25 48.69 40.95 
45.6~ 26 . ~4 47.87 43.27 52.53 60.52 
~:.!c :; ,34 ~~ .32 31 .03 38.79 40.05 
5.40 14 .16 &,44 12.23 6.61 15.87 
25. 0S 31 .94 25.79 27.63 23.34 21.54 
12 .59 26 . iO 27.98 26.25 26.06 32.56 
22.22 33 .26 27.76 32.39 32.16 36.37 
26.46 28 .44 29.41 32.50 28.15 22.84 
21 .~ ... '.::4 9 12 25 11 26 13 26 13 
'/. CHANGE 







_ \ .. 








































- .;.) 2,) 
,., 




-4 ' _, 
-14 -1 
,• c. 34 ~ ... I 
-14 19 
11 _q ... 
-10 ' ·-· 
-64 -~,8 
-7 11 
; -20 I 
-14 -12 
-10 23 
2AY1 DA'/3 JA Y7 
. ·j C 
,·, '".If; 
\I 1LV 
•.) I 39 
:) , 28 
'J . 31 
(• r:, 11 
•,1 1LL 





(l , 38 
0. 30 
1\ .,,., ...  , ._,v 
0.22 
(l ~~ -..•,v ... • 
.·, ,., c ·..,; ,L,.; 
,) . 31 







'I ,1 v ..... .. 
0.22 
~.26 0.2~ 0.28 
· ·i C 
. , L.; 
(1 ;,., 
·..,, , .JL J.28 
\ ·:: c, ,·, 'J i :-, ·u1 ~ ,LU V ,L I ~ • vY 
0.26 0.26 0.28 
-~ .:75 0. 289 0.27~ 
l .0~9 0.045 0.0:9 
@L0Gf (x +0.5 )i t100 .5- i ~~2 
~A Yl JAY3 DAY7 
(! .23 0.22 (l .26 
;).25 0.24 0.35 
0.29 (1 .30 0.31 
0. 18 0.2 5 0.25 
( 1 1'1 
'.' • VL (1 .29 0.32 
0.26 0.32 0.31 
(! .27 r).19 o.~1 
0.24 0 ''"7 '"' 0.30 
0.35 0.45 0.40 
0.31 .r, .,,. V ,41 0.35 
0.66 (1 .33 0.28 
0.27 0.28 0.30 
0.21 0.21 0.21 
0.26 0.29 0.33 
0.22 0.32 0.26 
0.24 0.27 0.28 
0.29 0.28 0.36 
0.284 0.288 0.305 
0.102 0.051 0.045 
:4 
--, - ~ 
,-
, ,: 
i--"T . ,., _ . 
1 .: -:, , 
~EAN 
- _, .... 
._ . ... '.I 









·i ~ ,..., 










25.36 l2 .57 3.86 MEAN 
12.23 8.31 3.38 SD. 
fO TAL F~iN VALUES : DIC~CF~NAC GROUP -,, 
JC 
-, 7: 
.J . • 
"'.·[1 .l 
;.. ,J 't 
',j . , ;: ... · .. , 
. 0 
; : . 
• .i f .. 
: 1 
19 
SWELLING MEASUREMENTS : 
· .... ~FDl ~;~ADl AFD3 .. .:. 65 :4 -·· ,.,. 
44 .1 2 ... -' 
cc 54 :4 u,.; 
:.9 :,9 .:.o , , 
50 :.o 54 .. . 59 '12 , , 
c;: :5 cc ...... _ ...  
:::. 1 C':' C") 
·.J ~ ,,,; ,,. 
er CI ~') J ,, , .. ,,.
54 53 54 
58 57 58 
,'l 52 C'l •. ,. JL 
62 62 62 
i'IEAN 53.77 ~13.38 53.85 
SD. 6.46 6.63 6.24 
MEAN 
:n ww. 
~E:L~FENAl'1 ATE SROUP 
L!N A03 AF D7 UNAD7 
~4 64 64 
42 41 42 
~4 c_,- 54 ...;..,1 
59 59 59 
54 ~' C7 vv J,j .. 41 41 'H 
55 55 =c ., J 
C7 .. ,.;.  53 :,4 
53 ~., 52 ,,,. 
C:.1' 54 54 , . ., 
C'7 59 59 '" 
52 52 C'l •. ,. 
62 62 62 
53.77 53.69 53.92 
6.31 6.58 6.43 
•; CHANGE ~ 
DAY1 DAY3 DAY7 
0 0 0 
" (I -2 -i. 
'} 0 -2 4 
0 0 (I 
0 0 0 
5 ") 0 4 
0 0 (I 
-2 -2 _., 4 
4 -2 0 ., 
" 0 ,. i. 
2 2 0 
0 0 0 
0 0 0 
~WELLI ~G ~~ASURE~EN!S : PLACEBO GROUP 
.• ~~91 u~ AD1 AFD3 UNAD3 AF D7 UNAD7 
::,: 
' ' 
;: ... .::; i:.t ,_ ,., . .1 .. .J • 










t.l1 ,J2 j(! t.; :,O 
~: 42 43 42 q 
~7 .. , 
.: , ;:a .-c .u 
.::., i. 
.u 
~E AN ::. :: '. : . :~ 35 . ~7 53 .64 53 .86 ~4.14 ·:J . :.::. :.~·7 ~;.-iJ :.::. : .:·t 4.84 
3WELL::1S ~~;suREMENTS DICLOFENAC GROUP ... A~D! :!;,AD1 AF03 'JtJAD3 siFD7 UNAD7 
:;e, :,7 ~9 57 57 <.7 . ,;1 
C'> ~7 :,3 <;~ ,:"t ... •i. _ ..J .. ., .. ., 
.l8 4!i 47 47 47 47 
~7 46 46 46 46 46 
C ,t 54 cc; S4 54 54 -.• "':' •. ., 
70 o9 69 b9 69 
- 1\ bl ·:JV d 60 60 - ' 'J 
~6 45 51 51 49 49 
c. ' 51 51 51 51 51 ,i. .. , 
ua 59 60 58 60 60 
57 58 56 55 58 56 
42 42 42 43 42 43 
38 38 39 39 38 39 
46 46 46 46 46 46 
59 60 59 59 59 60 
55 c~ J,J 55 ~.5 55 55 
c c 55 55 55 55 55 JJ 
MEAN 53.00 52 .65 53.12 52.88 52.88 52.94 SD. 7.70 7.85 7.30 7.06 7.44 7.22 
% CHANGE 
DAY l DAY3 DAY7 




















































_'l 0 L 
(l 0 
0 0 








--·· -. - ·-·-- .. ,._ 
£NJURANCE .::~~E~ 
C/H RATIJ t?F ~!}E 
,C•."•.! C·i~ ,. ·r1~; , ; :-a .. ;., · own 
, ,,r,u: M:';JT ... ..,, ... ,, ... . ,1 
~W ELLINE :AFF. ~!:E 
:'.:~AFF .2::E 
';AlT 
MU SCLE 7 E~! :~NT 'C 
AVERAGE POWER !W) 
PEAK T. AL \ J J 
~USCLE TEST 
PONER ( mm, l 
ENDURANCE (jQULES) 
Q/H RATIO AFF S!DE 






: UNAFF. S !DE 
GAIT 
MUSCLE TEST CONT 'D 
AVERAGE POWER (W) 
PEAK T.A.E. (J) 
~ 
H 
~FJl ~NAO! ~FD3 ~~AD3 AFD7 ~~AD7 
2SO 
'.29 
3503 :t!O !402 :~ 00 3314 3779 
I ' ~ {- j .- ',"'I~ 
- r - l. L ...... .i 
• otc 
a I ... ~ 
67 
(; 
--::-!.. (1 .............. 
:~ .83 :: .t: 27.77 :~ .:~ ::.36 3~. ~2 
· •~ 279 242 ~co 2~~ :~6 ,;'.~ ~=; { C , \!~ 164 :S4 
2t30 ~:97 S23b 3320 
l ~b 1908 1°47 ~· ·· .- ·<r,,., L•V .L 





















288 314 271 '") Q! L , . 
172 203 197 190 
47.25 47.~0 40. 03 45.68 
15.00 23.83 25.33 32.86 28.24 33.22 
AFDl mlADl AFD3 UNAD3 AFD7 UNAD7 
165 231 185 '11'1 189 226 LJ..._ 
71 119 94 120 100 120 
2956 2506 2994 3293 2814 2947 
1604 1483 2066 2413 1932 2005 
43 51 53 
0 0 0 
4 3 1 
6 1 
1 0 0 
11 4 2 
43 42 41 
44 42 42 
l 1 t .. .. 
287 243 272 289 250 250 
154 142 186 210 170 169 
42.19 32.27 35.49 32.52 36.20 34.52 
15.05 14.23 15.64 19.23 19.09 19.81 
IV 
POWER 1 \\i T": : 
, ,:,,'I_ C-,~ 'T T,-• . ,-,_ , ;; : . -·· 
.-OWEF. . .;Tr. : 
~/H RA T:2 A;F Sl:E 
?AI N t 1NrJ · :2~H 
:~A LP Hir[N 
!~OVEM~NT 
: ~AL ;~!~~G 
; ~CS GING 
SW ELL ING :AFF . S!:E 
SA IT 
,uscL~ 7E~T ~~~T ' J 
AVEfiAGE P~WER (~J 
PEAK T. A. E. • J ) 
MUSCLE !EST 
POWER ! NIHN ) 
ENDURANCE (J OULES) 
Q/H RATIO AFF SIDE 








~USCLE TEST CONT'D 
AVERAGE POWER (W) 
PEAK T .A.E. (J) 
~ ~FD1 UNAD1 AFD3 UN AD3 
;.. : :g 223 168 2,f7 
AFD7 UNAD7 
:11 245 
i3 33 l!l 










: "".'.:. ... ..; ... • ·,1 . ; . 
~) .39 41 .S: 3:. ~4 34 .1: ~ , .~~ 45 .C0 
:..8 .84 2~).:: -0 "; i 3(:.33 : 0. 46 2: .. : ·) 
,-.,:: 
2561 -;: ~, .......... . 
, ' I _;. 
2:38 






























40,01 33.01 39 .91 32.46 52.41 44.93 
20 .73 18.81 23 .70 13.56 25.86 29.60 
! i t ., ! 
,, ff 
l .i.1 
M AFOl UNAOl AF03 UNA03 AFD7 UNAD7 VIII a ~so 336 303 315 202 359 
104 192 lbS 215 157 214 
2964 4552 4097 4200 3829 4492 




























328 422 385 :96 358 401 
99 284 257 267 321 270 
42.46 56.34 52.31 50.70 47.19 54.21 
17.98 27.11 31.20 29.45 43.40 32.87 
:~USCLE -: : T 
1; ~.n: 1 i - , : , . . .: ;: : • r: r: ... .11..~ - .. . , .... ;; 1 . • - ·-'"' 
~USCLE -- ::ur·~ 
:1H RAT:: gfF ;~DE 





SWELL: NG :AF~. SIDE 
: -.:~·JAFF . SI DE 
::AlT 
"USCLE TEST CONT' D 
AVERAGE PQWER !W) 
PEAK T. A.E. ( J) 
MUSCLE TEST 
POWER ( NIHH) 
ENDURANCE (JOULES) 






SWELLING:AFF. SI DE 
:UNAFF .SIDE 
GA IT 
MUSCLE TEST CONT' D 
AVERASE POWER (W) 
PEAK T.A.E. (J) 
~ AFD1 UNAD! AFD3 UN AD3 
~ ~:: ::a 12s ::a 
AFD7 UNAD7 
134 ; ., ,., • .;.L 










• C OJ 
2009 
4 
~ AFD1 UN AD1 AFD: U~AD3 AFD7 LiNAD7 
G 



























37.33 44.53 39.87 42.45 44.41 44.77 
24.13 26.84 24.91 27.87 27.59 27.87 
P AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 
Q 249 269 271 246 275 269 
115 145 138 131 146 141 
2561 2954 2946 3038 3018 3051 


















139 154 301 312 299 328 
89 89 136 120 185 153 
28.91 28.98 45.56 41.98 46.78 43.21 





., ,! ,:, .. , : - := ""." .-. ."':.11 , r ' ri . :..,.; ___ -- . -- ·' ' .., 
- : :it, • - • .: • ~: 
... . ,: :- ' .: - : : -; 
-'- ........ _ .. ' 




S~E~L ING :AFF . ~:DE 
:~N AFF .SIDE 
GAii 
:"'JSCLE : ~ST CO NT 'D 
AVERAGE f0WER (WI 
PEAY. T.A .E. (J) 
i'IUSCLE TE S: 
POWER ( NW HI) 
ENDURANCE (J OULES ) 






SWELLI NG:AFF. SIDE 
: UNAFF. SIDE 
GAIT 
MUSCLE TEST CONT"D 
AVERAGE POWER (W) 
PEAK T.A.E. ( J) 
AFDl UNAD1 ~F}3 L\AD3 ~FD7 UNA D7 Xll l 
H 1a3 199 :62 :as ~a1 : 04 
D 
g 




0 " ,, 
; \ 
·' 




































51.07 56.62 64.68 58.01 55.!b 55.17 
16.20 31.17 14.23 30.15 28.13 35 .27 
AFD1 UNAD1 AFD3 UNAD3 AF D7 UNAD7 
193 229 215 246 227 245 
123 1 t., .... 115 119 122 117 
1875 2707 2386 2496 3166 3013 
1835 1648 1751 1318 2341 1824 
64 53 54 
4 ') (I L 
6 7 2 
6 3 0 
5 1 0 
7 28 " 16 1 3 ,) 
55 55 55 
55 55 55 
2 t 1 ... 
226 328 264 262 326 336 
219 198 192 137 239 202 
37.41 45.96 40.46 51.67 42.63 45.51 
28.23 25.35 27.42 23.15 30.44 27.91 
2 
, ,1 •_;ti. C C- : : -: , - l l"'! I ! , ._ • "' .... 
:- : -: :- - .-.. .... -
- - . - - - - --~ ;~~~ :: -~~=ri : " : 
SWEL. .. '.;,3 :AF J:. ~: :E 
::,NAFF .~ ;~E 
~VERAGE ?GWER r~ ; 
PEAK T,il .E. :J) 
NUSCLE TEST 
POWER I NiHN) 
ENDURANCE /JOULES ) 






SWELLI NG:AFF. SI DE 
:UNAFF .SIDE 
GAIT 
AVERAGE ?~WER (W) 
PEAK T. A.E. ( J ) 
AFD1 UN ADl 6FD3 L~AD: AFD7 UNA D7 
37 ~ 11 
·1 ·/ '7 ..... , 
. . ,:· 
.i, .;. , 





. a: I 







~il2 -: ~ ;. - 1 -~ 7 
I ':'.°(d 




141 139 128 138 158 131 
73 111 96 16 103 95 
19.77 24.65 24.14 22.49 23.68 23.48 
4.26 18.52 18.39 20.22 6.82 16.72 
D AFD1 UNAD1 

























4 2 0 
7 29 4 16 5 
53 53 53 
52 53 53 
2 
124 150 146 130 150 152 
23 72 70 80 75 53 18.75 28.74 25.44 25.01 24.12 25.41 
7.65 11.08 9.73 14.48 12.57 10.51 
5 
.: · ·~ : - -=- . - ;;. ;:-: 2. :c 
· .. ~·:..:~: t ~ENT 
. --... - - . ... -:: . ._ _;i. -· 
: ilALCNG 
SWELL~!~G:AFF . SIJE 
: ~:lAFF . SIDE 
GAIT 
PEAK ~,~.E. {J} 
MUSCLE : ~ST 
POWER i NWTl'I ) 
ENDURANCE (JOULES ) 
Q/H RATIO AFF S:DE 








~USCLE TEST CONT 'D 
AVERAGE POWER (~) 
PEAK T.A.E. (J) 








- ; I 
31 

































i -; ~ 
... ~ ... · 
! 
2. 7 


































. • ... .:.· 













































160 205 205 197 204 228 
74 139 116 150 163 134 
22.88 27.84 28.62 25.86 20.31 26.94 
13.52 18.38 18.52 21.45 29.31 26.86 
9 
. . :- : -:~T __ __ ._ --- · 
' -
I "'! f1 IJCM!: •.1 T , 11..J , ...,, 1_,1 I 




E~ELL:NG :AFF. ~l:E 
!:JNAFF.S!DE 
~'1IT 
~USCLE T~ST CONT 'D 
~VERAGE POWER (WI 
PEAK T.;Lt . ( J) 
MUSCLE !EST 
POWER (NWTl'I ) 
ENDUR ANCE (JOULES ) 
Q/H RATIO AFF SIDE 






: UNAFF . SIDE 
GAIT 
l'I USCLE TEST CONT'D 
AVERAGE POWER (W) 
c AFDl Ll~~ 81 ~FD3 UNAD3 A?D7 UN AD7 
:482 30:7 ~~,, ~!20 















~6.:0 27 .~: 36 .81 23 .75 37 . 51 31 .67 
~F Jl J~AD1 ~~J3 U~AD3 
~ _3Q : cc 140 ~51 
~l JL 94 99 
:240 li97 ~375 !940 
1;42 :250 1797 1369 
4 
4 












:ab • C '-• ,.1,J 
106 18 
1370 194S 














17.00 22.04 18.46 23.12 21.31 24.68 
p 
H 
10.86 12.12 11.73 12.32 12.89 11.77 
AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 
205 r~ .i .. 214 217 248 236 
132 140 136 149 161 172 
2646 2799 2919 2869 2941 2974 
1394 1177 1613 1647 1407 1948 
64 64 65 
6 5 1 
8 7 3 
3 2 0 .. 
4 0 .) 
4 24 .., 'l t t 5 .j LJ. J. 
54 53 52 
52 52 52 
1 1 1 
209 237 238 248 252 261 
116 102 138 142 126 169 --~ .... .. -- ·,- ...... , - -- -- -- -· --
.,I. ~· 
14 
,.. , .. :~ : : -: .:-:-1·.;,.....,_,_ ' -oJ . 
; .~ALKIN3 
;JQGG!NS 
_ _ ··· :,:,:c ,:1n~ -il_,__ .. . 1 .., ,r,1 I , .., •wl. 
;:...NAFF.2lJE 
.. ,. ......... - ---- ,- ri\ , - : !\ ·: _: i...,_:. :: . :_..;:\, -.J 
: .. ,: 
:;;ALUNG 
: JO GGING 
: ~:;AFF. S iDE 
~USCL~ TEST C~NT'D 
?EAK , . ~. E. l J ) 
r!USCLE iE3T 
POWER i N~Tl'I) 
ENDURANCE (J OULES) 







:UNAFF .SIDE . 
GAIT 
~USCLE TES! CCNT'D 
AVERAGE POW ER (W) 
PEAK T.A.E. (J) 
/\ AFD 1 tNAD 1 
207 
~FJ3 L~AD3 ~FD7 J~AD7 








.:. ... i.. 
"'. ,Y':'. -Z 
L. .. , •• 1y 
:138 
45 





- · V =.1 
. . . 




""'"':' ""' .1 .,. , ·-= .- •. :.- .-~ ! C -·. --:- ":"~ ·C .,;; .... ,, .j ~ .· i ....... ... .... . .. ...... - ··· ·· · ·- - .... ... ' . ... : .... 
71 




-· c. -:-:-c - -· _, ,_, 






- -:":"".' ... -..: ~: 
0 
55 
• ;;: C .:. , . .' 
126 :12 :t7 :76 : )8 250 
140 187 160 201 201 232 
17.89 21.60 17.28 24.B~ 19.~5 24.94 
25.44 24.55 23.73 23.67 24.07 28.02 
AFDl UNADl AFD3 UNAD3 AFD7 UNAD7 
237 243 214 224 220 21li 
75 107 96 113 110 126 
2590 2928 3230 3130 3095 3215 
819 2134 1335 ~ru:I'\ 1502 2041 i.i.Ji. 
31 45 50 
7 ,, 0 .. 
9 C 2 J 
6 3 1 
6 2 0 
8 3li 5 17 1 4 
53 55 54 
54 54 54 
2 t t • • 
22li 259 'i(i 274 2~,8 262 ,.,.., 
71 188 113 195 123 1li4 
29.76 28.97 36.31 30.90 33.90 31.58 
11.77 27.08 15.7li 31.40 lli.51 2li.29 
. . 
17 
"i .e.- : : -::i 
·· --:..L..- -- · 
. - - . -- - - ... -
.J. :- - 1-: • - - .- - ; : - :.i ~ 
: ,~,.JING 
. ,J,:: : ; .. iC' , _ _ ·,n; 1 , J.,.., ,._ 
- : -..: :, .. -. ;: . . -
•",!!·~- : - -
cnr . .. .: .. J. ,- : - - ·;, ,:,: : .. . 1.., ;,.;,'o:-: · 1w._ .· ,.;.J -L.. .. I 
,=~1·1 ' .'/l': l :2 -h 
:~ALdNS 
;2S55ING 
SWELL: hG:AFF. 3:~E 
:UNAff.SIDE 
~uscLE !CC! s:~r ·J 
AVERAGE POWER (W) 
PEAt; T.il .E. ;J ) 
MUSCLE TEST 
POWER (N WTM) 
ENDURANCE (JOULES) 
Q/H RA TIO AFF SIDE 





SWELL INS:AFF . SiDE 
:UNAFF.SIDE 
GA IT 
ftUS~LE TEST CQNT 'D 
AVERAGE PQWER (W) 
PEAK T. A. E. ( J ) 
F' AFD1 UNAD1 
4 '.:S6 229 
;:,:03 LNAD3 
237 ' ::i~ 






' . . ... .' L 
2?Z4 
.- .... ,,,, 
--·:..:. 
3 





























'i \ <. ...... ~ 
\ ·i 
.J. 
:11 176 i:9 179 ~71 190 
143 189 157 : 91 159 199 
22.78 19.55 20.48 23.73 23.26 23.21 
19.01 23.12 15.91 21.96 18.86 22.24 
D AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 
H 244 237 236 241 251 256 
161 159 159 157 160 160 
3973 3681 4049 3850 3817 3797 
3092 2954 3119 2806 2896 3016 

























365 340 :69 347 364 347 
281 261 272 241 257 261 
32.34 29.57 36.00 33.88 38.03 32.91 
40.75 38.51 35.05 37.12 38.57 36.25 
: 9 
20 
: .o: ... •. ,:· / ·. H""·: ! l "l [p CC ! _ 1 .. 1..: ., r;;,..., _ , - ,..,.; -1.. ..; , 
: .-:ALfINS 
. -.... ::'" -~-- -.,. -~..:i ~:'rJ 





S~ELLl~G :AFF. 31JE 
::.;NAFF.Sm 
2AIT 
AUERAEE POW ER (Ml 




0/H RATIO AFF SIDE 





SNELLI N5:AFF. SIDE 
:UNAFF.SIDE 
!:AIT 
MUSCLE TE ST CDNT 'D 
AVERAGE POWER (W) 
PEAK T.A.E. ( J) 
: AFD1 UNAD1 ;FD3 lNAD3 AFD7 UNAD7 
198 
30 
! 7 '1 ... , .. 186 
S4 1% 
10!2 :424 24 32 2241 2802 2~29 





2830 7' , c~ .• - .::. .. , .,j 3104 3372 
''"I C 1 ....... 
3397 














249 297 266 280 312 317 
75 175 l ll 181 201 238 
31.90 36.28 31.13 27.46 33.42 35.37 
9.31 18.16 5.53 20.21 20.22 26.62 
D AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 
H 245 286 260 267 267 259 
118 156 134 168 130 163 
3552 3907 3784 4336 3334 3221 
1695 2222 2053 2213 1860 1746 
~ 52 H 
2 1 1 

















313 346 338 381 286 289 
142 185 180 194 158 156 
31.12 40.00 34.41 37.34 31.72 33.15 
22.10 26.36 21.23 22.22 21.24 20.66 
27 
:~S~LE i -w l 
: ~~0VEMENT 





SWELLING :AFF . SiJE 
: L;NAFF. s; DE 
SAii 
jLJSCLE TEST C3NT 'D 
AV ER AGE POMER (WI 
PEAK i.A. t. (J ) 
l'IUSCLE TEST 
POWER (NWTl'I) 
ENDURANCE (JOULES ) 
Q/H RATIO AFF SIDE 








MUSCLE TEST CONT'D 
AVERAGE POWER (W) 
PEAK T. A.E. (J) 
D AFD1 U~AD1 AFD3 UNAD3 ~FD7 UNAD7 
H 




1 1 (1 .. ~· ..., :~9 
2620 
!C82 :~26 1724 1994 
46 66 
4 
<. t .. 






23 .67 =~.!9 :s.:~ :~.os 2~.:4 2~ . 4! 
~ AF~l ~~AD! A?D! L~AD3 ~?D7 JNA07 
u :74 :67 !97 :82 207 
98 
i9~6 





·1 ~ c. ") 
L. ... i.J4 2062 2394 
~4~0 !~~6 13~4 1~18 1456 1240 









8 4 13 
55 
1 
184 :22 184 208 199 239 
128 146 117 138 125 126 
25.06 20.32 21 .86 26.14 2S.49 30.11 
13.31 14 .1 5 15.00 15.56 12.48 17.69 
D AFDl UNADl AFD3 UNAD3 AFD7 UNAD7 
H 153 i69 195 183 183 199 
91 113 114 113 119 117 
1465 1743 1695 1796 1619 1831 
974 974 1176 1206 1135 1083 
59 58 59 
3 1 0 
6 2 3 
3 1 0 
l O 1 








164 197 187 189 183 194 
106 107 120 110 119 105 
20.90 27.49 25.58 27.52 19.65 26.21 
19.77 16.72 25.34 17.51 22.33 16.64 
28 
30 
.. ,: ;'"' i = -:.:: ,, ____ __ __ .., , 
~ AFD1 UNAD1 ~F D3 UN AD3 AFD7 ~N AD7 u 
" :93 :41 207 
71 1~9 





· ,er, , , a, 
... ! ! V .;. _..; J. 21 ~.8 2243 t;, 




• ,: .- : - : .: : .- .-· •!! ' '"t ----- ·--~ ' ... _,,, -· 
-.-: ."i,! I-: .: I I .. < 
'11 :· : -::; 
:~ALPA TICN 
:~ALWlG 
: ~OGG ING 
SWELL'.~G :AFF. SIDE 
: 'JNAFF. SIDE 
iuSCL~ ~~ST ~ONT 'D 
AVERAGE POij ER (WI 
rEAK T.A .E. (JJ 
~USCLE ' EST 
POWER i NWTl1) 
END URANCE (J OULES) 
G/H RATIO AFF SIDE 





SWELLINS :AFF. SIDE 
:UNAFF .SIDE 
GAIT 
~USCLE T~ST CONT'D 
AVERAGE POWER (ii) 
PEAK T.A.E. (J) 
.I. 
e.-::-_, ,., :4 
I °7 .~ .. , 
: :. 47 :~ .42 :~.44 !~.27 4!.30 ~4 .13 
69 
4 










'/ ! , 
.- - ,-. ..., 
~~:, 1 













1 ::. 1 .. ..  ..,. 
1 ~'r'7 ,,:..,.., ,......, 
0 
235 
159 189 :63 d l 165 210 
47.98 39.01 50.44 40.88 53.10 55.46 
19.79 29.67 29.58 37.38 39.38 48.85 
P AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 













214 228 222 232 
69 126 83 142 
2198 2796 2320 2229 


















167 233 165 222 188 192 
101 148 79 150 95 140 
35.76 42.39 39.83 40.28 13.79 49.21 
23.60 30.78 23.53 34.79 15.28 34.59 
4(1 
41 
:~J~: :..~ -::1 !\ AFD1 UNAD1 Arn, UNAD3 AFD7 LINAD7 4" 
. _ ... ; 
V , 1;.., 
. L : ·'"' .· C'C• r -i~T ~: h :29 '1 7 f t 240 2:1 263 2S3 
! _,n .. 1·, 
L J 'J 
119 137 ~41 137 144 :64 C!-i J~'.r ~NL ~ :: :Ji..E3 } 2705 2649 2632 2467 2121 ., ,  t t .. 1 .. 
2123 2194 L!.t;;; 2590 2:~10 2430 - .: .. \ 7; .- > r- ~ C: 1 T1 C c. ') 63 65 
:.: .; !i -, ; ..... !'ii r ,.. ... u .. >J L 
: '. ' , .. iV j2 1!24H c. ' i. 
·""'· .. 
-· ' ~ALF'A:rn; 5 6 c. -· ! ~QtiEMENT 5 4 J 
:;.ilU'. HG ,; .) ') , .. : ~JG6IN6 9 29 :. 1 1 ~ I C ... •' . '~WE!..!..!\~ :~Fr:. 2:~E 61 I;(! 60 
~ ... :·,~FF. S ! DE 59 58 60 - ,, ,T' 
r , 
1 
.:- r :. . 
i. 
"1 !JS1: ~~ - --,, T !- :-: \ n , r, • :.: j ... ..... i l ! "' 
AVEfiAS C: : ,- · iCC• ''" ' 229 224 .:.-t i '":· 1 ~ .L~.l :79 
, .. n~. , , ..,, ; 
l...L r.' 
: 79 ·. •J, ~93 ., ... ,. • "!A 196 .;.1.,v L.L.1,, ;._~ " =~~! ' - :.5 .s:, 49. :;8 S6.31 ~7 C. ·j 62 . :,8 ;... i '":·~ ; '--: ' :. ' -. ._. ; . .. ... \.:,.,~..,; 
37 .29 36 .bO !8.90 45.25 48.69 4'j. 95 
~-_·SC ... ~ - J . p AFD1 UNAD1 /• ~r17 !i , ..,,., iJNAD3 AFD7 UNAD7 43 ccwE F: ,. ,; "T irri!\ ., 187 245 1·~0 213 176 21)6 
... , ,1 1. 
" 
113 1 'i ! 1% ' . ., '18 102 .LI J..~ i : ;~Dt:F::Hi·cLE . ~ :t;LES} 1903 2042 :9:7 20 73 1994 2~07 
610 1169 598 610 :,04 354 ~/ H P. PT~ D AFF .; ~ DE 60 ,;, 56 ,, c·Arn :,);.; ,: ; :24l1 4 ", t L .I, :~ALPArn:m ,; 0 , :~OV:14ENT '1 0 0 L ::.ALY. ING 4 ,:_ 0 : J066ING 7 j"J 4 9 ", .., LL L ,j SWELL it;G : AFF. S!DE 52 52 51 : UNAFF . S !DE 52 ,;t 51 •' • ~AiT 3 ·j 1 L :~USCL; T~~T ........ ca~n · D 
Ai/ER ASE POW ER (W) 172 195 175 199 i80 202 
52 105 59 100 37 28 PEAK T.A.E . (J) 37.35 45.91 39.01 46.72 31.47 45.00 
19.26 26.88 20.21 27.03 16.21 18.39 
NUSCLE TEST " AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 44 POWER (NW TN) H 229 245 225 254 252 252 
89 122 103 134 138 138 ENDURANCE (J OULES) 1920 2408 2222 2065 2503 2633 
1358 2004 1410 1911 1975 2193 !UH RATIO AFF SIDE 39 46 55 PAIN (VAS):24H 6 2 1 :PALPATION 7 4 1 :KOVEl'IENT 5 2 0 :IIALKIN6 5 2 0 :J066IN6 9 32 3 13 1 .., ,) SIIELL ms: AFF. SIDE 53 52 52 : UNAFF. SIDE 51 53 52 6AIT 3 t t .I, 
J, MUSCLE TEST CONT'D 
AVERAGE POWER (II) 153 220 196 167 236 237 
106 154 108 158 162 178 PEAK T.A.E. (J) .. 33.81 33.27 45.49 39.64 45.07 56.71 
21.14 20.53 39.43 37.52 19.28 49.51 
MUSC~£ 7cCT p AFDl UNAD1 AFD3 UNAD3 AFD7 UNAD7 4S 
.... .... 
F'GWER '. :'i!ITM) H ~41 148 1:1 1 ~'l ,. 1 ~.., :46 ..... . 
77 
,,) 35 85 107 :03 07 , .) E~~D1J~Ar,CE ~:CULES ) :405 1399 >14 1489 1-!: 39 i4 59 
. A63 989 ",'l 989 911 1031 , J L 11 /U E~T !O AFF S:DE ~'i ~7 68 
:.J , I, ., ,. 
"' ;•4 ! ~. :/AS} :2~11 6 5 2 ) :PALFATION g 6 ., .,; 
: ~OVEMENT 8 4 -:;'I ALK ING 5 4 •, ,;. :JOG6EiS 10 :r -:- 26 ::, 1 "• ,;,,: ; .... SWEL. : !iG: AFF . £IDE 41 42 ,. ., ~.L. ~JNAFF.S!!JE ,P · L 43 44 :~lT .-,, - .. lf!i 1•""r' l C , ,UJw .. - rec ; ; _.., J CJNT') 
~·,H~•:ic ?CW ER 11.1 1 I ~ '"! ·, '1 i : .-,~ 1 "'7i' l ~fl ~ n ! ..... ...L. ... ... i ... . , - ,., , .... ,v 
7"7 ~.., ~o -:: t "'M 29 .J I ii ~ . : 0 =EAi. ' . !"1 .t. • t co 26.41 13 .89 26.90 2S .~9 'i1 1 L . ... ; •••JU .. .. , ..... 
10 .09 12.91 16 .44 1 ! !~O 19 .86 'l'l ~-, 0.J. ,vw ... ..:. ; 
:-;%S~~ --r.T Ci AFD1 ~NADl AFD3 J:J AD3 AFD7 UNAD7 ~6 
. :.:; ; 
P8WE~ {;~WTM ! i1 11 . ..... 214 164 202 156 198 . 
!11 l!)b 94 1' ~ 87 l t)O .... ,; ENDUP. A:G {~~JLES i 1382 2088 !995 2057 1950 1941 
380 836 './76 804 585 798 )/H RAilu AFF ,: ~ ~I C <.G 57 S6 
....,.._J L ~,; 
~AIN t11AS) :24H 4 2 "' ,;.
:PALPATION 8 5 4 :l'IOVEMENT 5 'l .) ,. 
:WALK ms 7 2 ., ,. 
: jQ66W6 10 34 5 16 8 19 SWELLI N6 :AFF. SIDE 44 42 43 :tJNAFF .SIDE 43 42 43 GA IT 4 2 ,, ,. MUSCLE : EST co:n·o 
AVERAGE POWER (ii) 120 170 161 166 164 149 
29 71 80 62 45 63 PEAK T.A .E. (J) 22.18 21.77 23.59 28.39 21.28 18.69 
14.06 11 .ao 18.43 6.70 4.04 14.64 
l'IUSCLE TEST " AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 47 I POWER (NIHN) Q 125 216 141 179 159 212 
98 132 95 117 113 117 ENDURANCE (JOULES) 1630 2195 2026 2434 2189 2117 
572 870 997 1116 487 1593 Q/H RATIO AFF SIDE 78 67 75 PAIN (VAS) :24H 4 4 2 :PALPATION 2 3 0 :l'IOVE11ENT 8 8 3 :WALKING 8 4 3 :JOGGING 10 32 6 25 4 12 SWELLIN6:AFF. SIDE 99 51 51 :UNAFF.SIDE 52 52 52 GAIT 4 3 2 l'IUSCLE TEST CONT'D 
AVERAGE POliER (W) 208 162 191 223 226 224 
69 48 as 90 40 127 PEAK T.A.E. (J) 33.44 33.54 40.98 36.98 24.23 31.S3 
27.22 22.76 29.29 30.49 16.36 29.50 
.~USCLE TEST M AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 48 FOWER ~!·HtT~} n j C_f :~4 165 184 159 !64 il . ~ ... 
83 n 94 98 91 94 
ENDURANCE ~J C~LE2 i 20 75 1821 '; i 'JC 21 74 2068 1978 .... ~."" 
901 793 128 \ 1 \'t .J.,.•,J 7~,8 818 
g/p RATIQ AFF S!:E 55 57 C_"f ~, 
?AU~ \ •);4S; :24H 3 2 I • :PALPATiON 3 "• I i. J. 
:~0\/E!'!ENT ! ,\ 
'.' 
:liALUNG -1 7 ;, .. .j ,• 
:JOGGING 5 14 4 I') ! ... --SWELLINS:AFF. SIDE ~,2 ~') ~'l ~L . •L 
:UNAFF.S:DE ~-" t:'j ~-; -'"' , •L .. . S11 iT .., r , 
1 i. i. 
~l:SCLE 'j"!""i""T !~:':UT ' T1 I C.J I ;.., .. ,,,, .I 
AVl:fiAGE ?2WER i if l !64 t !. i l80 19 4 1 ::. o j 1") - ... ,, ... w ·' LIL 
69 65 99 76 60 64 
~~Ai: ~ ,;; .~. ' 1 ·. 32.93 :4 .91 21 .20 36.98 37 .15 31.cB 
17.7b 19.56 22.li ,, 1 ~L J..1. ,..,1,.,; ~6. 06 19. 9~ 
MUSCLE TEST !'1 AFD1 ~N AD1 AFD3 UNAD3 AFD7 UN AD7 49 F'G \iER f N~;r,) Q a3 '; j(i 183 247 134 -~· ! ") ~ 1 v LJ.4 
141 156 136 157 1~3 1~6 
ENDUR MiCE (~JULES ) 2751 2687 2913 3343 '2669 3385 
2004 1948 2303 2527 1851 1793 
Q/H RATIO AFF SIDE 204 74 79 
PAIN !VAS):24H 9 6 ~ v 
:PALPATiml 10 9 7 
:~OVEMENT b 8 8 
:lilALWIG 7 6 6 
:JOGGIN6 10 42 10 39 9 35 SWELLING:AFF. SIDE 70 70 68 
:UNAFF.SIDE b9 70 68 
SAIT 4 3 ') ,. 
MUSCLE TEST CONT'D 
AVERAGE PGWER (W) 256 244 383 267 303 222 
157 157 231 188 146 142 PEAY. T .A.£. (J) 61.05 38.12 68.83 43.15 43.28 29.49 
26.58 49.50 29.22 38.05 31.47 32.11 
MUSCLE TEST " AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 50 POIIER (fllHN) Q 178 188 155 178 179 168 
9b 106 34 126 111 118 ENDURANCE (JOULES) 2152 2200 2013 2270 1932 2383 
1834 1800 1971 2073 2003 2229 Q/H RATIO AFF SIDE 54 61 62 PAIN (VAS) :24H 3 2 0 
:PALPATION 5 2 0 
:"OVENENT 1 2 0 
:IIALKING 2 0 0 
:JOGGING 3 14 3 9 1 1 SIIELLING:AFF. SIDE 50 51 51 
:UNAFF .SIDE 50 51 50 GAIT 2 1 1 NUSCLE TEST CONT'D 
AVERAGE POIIER (II) 218 218 223 201 233 201 
138 142 158 155 174 161 PEAK T.A.E. (J) 45.14 42.83 50.19 35.64 45.70 32.93 
44.10 40.48 39.70 51.86 37.80 40.40 
MUSCL£ TCST ~ AFDl UNADl AFD3 UNAD3 AFD7 UN AD7 53 
PCwEH . ~~~T t'i ) H 181 187 176 171 138 1 c;') . ., ... 
74 I~., ..,;;i. 103 105 94 39 
EJ,DuF:ANCE ; JC:ULES) 2410 2811 2511 2369 2329 2170 
1183 1528 t,70 1497 1241 1'H"> . .... J ..... ..... 
G/H ~AT ID AFF SIDE 41 58 68 
?AIN \VqS):24H b .) 4 
:PALPATiml 8 7 8 
:110VEMENT 5 ~ 5 " : ~ALKINS 4 ,, ! ~ 
: JOGGING 5 28 -., ' 23 .~ •' SWEL:.. !:lG :AFF . SDE 54 54 54 
:USAFF,S!!lE •. , 53 54 .J ·J 
SHI~ ! 
~LlSCLE '. ::.~! :"·., HT ' ?'\ .... w il J ;.; 
~ ·.,
1£FJJ: r0 1.£ER {W} 222 220 ~46 236 241 238 
1 •c; 
• ! " ~ ~1 l40 154 ' ,.., .i..j ... 130 
·:,E~f :~; ,~, ; -.; ; 41 .65 42 .2s 4! .93 37 .9e 35 .43 36 .82 
:·t .36 21.59 2~ .55 20.74 1 q 7\ . , . ' . 20 .10 
~~SCL£ :::~T D ilFD1 UNA D1 AFD3 UN AD3 AFD7 !JNAD7 c.c "" ~owER : ~~ TM ) H '11' 7 r; c~ 267 274 286 281 ... .,, .:.Jw 
159 171 149 !t9 ! ~,9 174 
END'JR ANCE {JCULES } 3454 3405 3491 3501 3681 4098 
2325 27~,9 2213 2763 2163 2771 
Q/H RATI O AFF SIDE 67 Sb 55 
PA IN (VAS) :24H 3 4 
:PALPATION ·1 6 6 ... 
:MO VEMENT ') "( 5 .. .., 
:111ALKIN6 I 1 6 • 
: J066IN6 ., 8 ') i C 6 27 .. .. .;.J 
SWELL I !lG : AFF. SIDE 57 56 58 
: lJNAFF. SIDE 58 55 56 
GAIT 1 1 2 
MUSCLE TEST CONT'D 
AVER AGE POWER (W) 327 312 335 345 366 419 
236 206 215 223 183 231 
PEAK T .A .E. ,,, 75.85 55.00 81.36 71.91 91.42 91.55 ~ \,J ' 
45.65 26.54 47.87 43.27 52.53 60.52 
IIUSCLE TEST D AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 56 POIIER (NWTII) H 236 256 235 254 247 242 
125 175 116 161 139 165 
ENDURANCE (JOULES) 2937 3835 2912 3783 3332 3951 
1904 2604 2112 3227 3062 3584 
Q/H RATIO AFF SIDE 53 49 56 
PAIN {VAS):24H 8 4 0 
:PALPATION 8 7 2 
:IIOVEIIENT 8 7 0 
:IIAUINS 5 4 0 
:J0661N6 8 37 6 28 1 3 SIIELLIN6:AFF. SIDE 42' 42 42 
:UNAFF.SIDE 42 43 43 
GAIT ') 2 1 .. 
MUSCLE TEST CONT'D 
AVERAGE POWER (II) 249 318 241 299 286 310 
178 238 189 281 274 313 PEAK T.A.E. (J) 45.77 56 •. 98 43.54 53.62 55.77 54.87 
31.16 37.84 27.82 31.03 38.79 40.05 ' 
:';!JS~~: T~ST ? AFDl UN/\Dl AFD3 UNAD3 AFD7 UNAD7 ~i ,; 1 f·Ci-jER : r,Wl Nl H 154 295 324 292 282 ~98 
30 it9 173 149 132 :42 
~;.JuRt;~~CE ;JJi..!LES l 2831 3430 ~CIJ. .u .... ;:393 4376 3774 
!301 2:97 ~~-o, 'i ~ c. t 2547 290~i .;. ..;. :..,\,,• .... _ .. i ~;H ;ATIO AFF ~IDE ~., 53 47 ,u. 
: (._: ;~ i ·.,i~S} : i~!-i ; 2 ,., I ·., 
: fALPAT HlN 7 .; ( 1 ., ,, 
::10\/EMENT 6 ·, 0 i. 
:li ALKING ' ,., ') 't ... 
: JOSGING ~ -.·: : ' ,\ (! · ' "- ~ .. ;,,; '.' 
SIE L'.NG :AFF. CT~C ~B ~o 59 ..... . .u~ • .:i,.; 
!~;iAFF .S!DE ~o 60 1: 'j -.-. ... , , ..: i""l l i , , 
'" ~.! SCLE -~ ,-. T :9" '"' UT ' r. ' :::J ; ..,.., ,1 , U 
t!:.,t;:~cc ?Jt~E~: ! Wi :38 :.:.-vi. -; 7' 294 "tQ! ~ '; 'f _, ... _..,. .. ...... 
:44 , -r. 2:4 .-,·1r1 231 255 ;,, 1 -·J =·=A~: 48 .51 : ,:1 .60 ; - -.c c= Ii 78 .t6 51.67 ' , n . : • . . , ~, . i...; ... ... . 1 J 
22 .70 "".'l •. ·1 .,.., i I 30.59 ~"'.! 'i t 35 .24 .... .. . ~.;. ..;. L. _: .L ...... . k. .. 
.¥. il C~ ! ': M AFD1 ~NAD1 AFD3 l!:JAD3 AFD7 LNAD7 61 
a .: ... _.,__ . _ ... ' II 
~·C~ER l :u i M ! H 139 21)9 176 197 175 197 , :, n 111 1 
28 1G4 36 q.., ... 36 98 E!iDURM, CE { .. •i:l cc \ ~705 Z397 2360 2353 2435 2264 I ~ ...loJI..L..., I 
349 1~79 454 1349 L,·"'.tt; ".· ,'-,,} 1269 G/H RAT IO AFF SIDE 20 20 20 
FAIN : 1/AS) :24H 9 ~ 'l .. 
:PALPAT ION B ~ 4 •' 
:i'!OVEl'IENT 9 5 :, 
: ~ALIJN6 a 6 (I 
:JOGGING 10 44 10 " '"'• 9 18 SW ELLiNG :AFF. SIDE 58 58 59 
: U:IAFF. SIDE 57 57 59 
GAIT .., 2 2 .J 
MUSCLE TEST CONT' D 
AVEF.ASE POWER (W) 170 234 195 215 216 198 
35 157 38 128 56 116 PEAK T.A .E. (J) 22.89 35.91 30.18 36.59 33.42 37.52 
7.78 26.48 8.38 23.16 10.68 16.43 
NUSCLE TEST D AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 62 POIIER (NWTl1) H 100 158 121 139 145 150 
20 76 15 67 19 75 ENDURANCE (JOULES) 1403 1858 1548 1660 1597 1725 
190 845 181 167 452 1068 D/H RATIO AFF SIDE 20 12 13 PAIN (VAS) :24H 7 5 3 
:PALPATION 10 8 6 
:l!OVENENT 5 5 6 
:IIAUINS 5 4 2 
:J0661N6 10 37 9 31 8 25 SIIELLIIIS:AFF. SIDE 38 39 38 
:UNAFF.SIDE 38 39 39 
GAIT 3 " 1 i. MUSCLE TEST CONT'D 
AVERAGE POIIER (II) 129 170 134 150 142 153 
18 77 16 77 39 9b PEAK T.A.E. (J) 23.52 31.49 21.28 26.63 23.82 23.88 
5.40 14.16 4.44 12.23 6.61 15.87 
~,ic;r, i: ;"~ST ii AFDl UN ADl AFD3 LlNAD3 AFD7 !JNAD7 64 . ... ...... 1-~ ,, 
~-QWER fNWTMl H 225 256 207 254 233 273 
45 :61 ~8 149 73 id, 
EN~URANCE ~JJULES ) 2981 3279 3320 :493 3500 7;,,,.., -~ .;;44 
924 :949 1C96 2ri2i 1337 ~ '7., 1 .. , ...... 
Q/ ;1 RATE AFF S!DE ,,,, 28 ,t LV -·· :=·Airl (V~Si :24i'i 4 4 
:PALPA TION 10 " ' ~:~OVE~ENT 4 c. 2 
:wALrniE ' ~· '! ... 
:JOS61NG j -,7 3 i.i. 'i 9 .. , ,. 
2WELLI!lG :AFf . ;: ~ r,c t;:") 52 c~ ...,.,...,,._ ..;-.. ,.!4, 
:t:riAFF.Si~E C". ": -: ·1 = "'.• ... -~ _.,;. .-.,.. -~ 
.;:;1 i 
~ ... 
;~USC'.._~ ' :: : r;\,;T 
I r 1 ..,,...,,1 . 
AVE~; :~ ~: ?Q~ER {W) -.7 , ~ij2 ":'"i 1 .::10 "1" •lj :15 L, O ,,:J.1 ..... 
87 :as •. !• .C: i 29 t '1i 161 • \I V oLJ 
:.:Pr. .!-: • .:. ,, :5.34 46 .64 d9,17 49 .45 ~8. 72 4:,.20 _. __ ! 
15.47 ·17 h O L., • ,.nJ 16.83 30 .51 22 .66 n. 12 
~USCL~ i ~: ; "' AFD1 '.;NAD1 AFD3 0NAD3 ,FD7 UNAD7 65 " FOWER {NW H1J li 196 :oo 189 207 2!4 ,, ..,,, ........ 
'19 118 99 106 1"" .. .:.u 12J 
EN!)URANCE (JOULES) 2715 2621 2461 2436 2838 2676 
1602 1552 1236 t,O~ ... ,uv i840 2008 
~/H RATIO AFF cr~c 50 53 60 ..... J~ 
PAIN {V AS) :24H 6 2 1 
:PALPATlCtl ~ ~ 1 ·' ,, 
::'10\JENENT 0 0 0 
:IIIALrnlS (I 0 0 
:J066Hi6 7 18 ~ 12 1 3 •' 
SWELLIN6:AFF. SIDE 62 62 62 
:UNAFF.SiDE 62 62 62 
3AIT 1 1 1 • 
MUSCLE T~ST CONT'D 
AVERAGE POWER (W) 279 239 237 212 278 235 
166 151 118 132 184 198 
PEAK T. A.E. ( J) 43.31 40.90 41.49 30.12 44.06 35.71 
23.75 21.20 19.21 17.94 29.64 23.48 
11USCLE TEST P AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 67 
POWER (NWTl1) H 292 251 185 250 299 265 
95 153 130 lbl 182 18b 
ENDURANCE (JOULES) 3597 3088 3521 3057 3793 3684 
2087 2789 2843 2712 2984 3009 
Q/H RATIO AFF SIDE 33- 46 " 61 
PAIN (VAS) :24H 2 1 1 
:PALPATION 6 1 1 
:IIOVEl1ENT 3 1 0 
:IIALKIN6 3 0 0 
:J066IN6 7 21 2 5 0 2 
S11ELLIN6:AFF. SIDE 57 57 57 
:UNAFF.SIDE 56 56 57 
EAIT 2 1 
MUSCLE TEST CONT'D 
AVERAGE POIIER (II) 302 290 314 306 335 323 
194 282 261 276 282 296 
PEAK T .A.E. (J) 46.84 49.97 47.50 67.89 70.89 73.42 
30.38 34.65 34.93 41.03 41.42 42.69 
r,1JSCLE TC'C:T Ji.ow• p AFD1 UNAD1 AFD3 ~NAD3 AFD7 UNAD7 68 PDWER (~WTM) Q 1,;11 277 ,,,11".! 288 248 , ,;,; •v>I ,_.,., Lvv 
99 153 119 ~ cc 115 128 j,.J.j 
E~mURAN~:E (J OULES) 2136 2971 2653 3011 3018 3456 
1162 1095 2050 1928 1484 'i".!..,f .. .., ... 
J;H RAT IO AFF SIDE 66 59 46 
PAHi !VAS) :24H 7 <. 2 / •' 
: PALPAT; 0!4 9 9 't 
:~OVEMENT 9 : ·i L 
: ~ALKINS 8 L 1 " ., : jQGGING ~o ~ .. 7 7" - ! ~ ·-· .. L . .. S~ELL iNG :AFF . C'll\C" J.i.;JL. 42 42 43 
:UNAFF.S:DE _,..,. 43 4.3 '-t'-' 
~i1IT - -~USCLE :~~T .- .-.:-.i ! ' !', .-,..; : 1 1 .. 
~VEh ~GE ?Qi~ER ; ;.i, -:r,"? 3.::9 243 -:·pi 'iJ 1 11 '7 1_ n ,' L V V L w l LO.i. _ ... , 
1~8 2:0 --(,~ :96 :39 218 ~ -.1...J =-~:, i· ""." .... : . · ·, 38 .61) oo .94 38.79 48 .86 44 ,(14 4S.79 
,_r;;, ' .. ,.~ . ~ .; ,i 
20.37 3i ,61 25 .11 ·,, ,; 1 :8 .61 25 .96 .. ..; . "'· 
.· ·~SCLE ,, AFD! \!:; /iDl AFD3 UlAD3 AFD7 UNAD7 ~1 ·~- 1 u POWER ~ '-;WTM i :1 215 242 210 216 224 218 
87 LS '13 113 !02 114 
ENDURANCE (JOULES; 2932 3225 2848 2879 3057 2611 
1760 1873 1657 1697 1636 1475 
a/H RATIO AFF SIDE 41 44 45 
?AIN l VAS) :24H 4 4 0 
:PALPAT ION 7 z; 'l / 
" L :MOVEME NT ,; ~ I " v .. : ~ALKINS 4 3 0 
:J066ING 7 i 7 6 23 1 4 .. , SWELLING:AFF. SIDE 46 46 46 
: UNAFF. SIDE 46 46 46 
GAIT 2 1 1 
MUSCLE TEST CONT'D 
AVERAGE POIIER (W) 257 299 266 284 306 252 
175 193 174 171 175 146 PEAK T .A.E. (J) 38.59 47.33 41.90 46.72 41.18 36.58 
25.08 31.94 25.79 27.63 23.84 21.54 
NUSCLE TEST D AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 70 POIIER (NIHN) H 267 262 320 319 299 317 
7( 138 123 175 131 162 ENDURANCE (JOULES) 2845 3827 3351 3588 3634 3523 
600 1651 1421 1810 1895 1768 Q/H RATIO AFF SIDE 28 39 71 PAl'N (VAS):24H 6 2 0 
:PALPATION 8 3 2 
:l!OVENENT 6 4 0 
:IIAUINS 5 0 0 
:J066IN6 9 34 6 15 2 4 SIIELLI NS: AFF. SIDE 59 59 59 
:UNAFF.SIDE 60 59 60 GAIT 3 1 1 MUSCLE TEST CONT'D 
AVERAGE POWER (lrl) 269 318 298 341 318 340 
58 147 129 175 178 180 PEAK T.A.E. (J) ,,.- 43.46 39.10 53.25 55.15 43.84 55.51 
12.59 26.10 27.98 26.25 26.06 32.56 
:1l.:SCL~ TEST ? AFD1 UNAD1 AFD3 UNAD3 AFD7 UNAD7 71 
POWER (NWTII) H 215 273 266 250 253 281 
79 143 104 165 139 181 
ENDURANCE (JOULES) 3244 3631 3756 3752 4021 3871 
1365 2187 1 ': ~'l •.6,,i.JL 2350 2263 2561 
J/H RA TIO AFF S!DE 37 39 55 
f'A.!N (VAS) :24H ? 1 (I ,; 
:PALPATION a 4 
:!'!OVEl'lENT "( ,, ': 0 
:WALKINS "( 2 0 ,J 
: JOGS ING 8 -~ ~ a. ~ , .•, J..,J •' J. "T ,; 
SW EL:.. !NS:AFF . .:T n~ ....... c. ~9 ~8 58 
: LlNAFF. SIDE :8 53 ~8 
,:r,. r 7 
.:;. r , _r, 1 I J.. 
iuSCLE !~ST C~NT1 ~ 
~·. cf. ~5~ ?OilER i\.l) 281 244 ~~ , .341 371 363 ;, ~o 
l<'l ~,,, :1 9 2:7 214 264 J.,JL ~ ·.J ,i,. 
·:~J, T .14 .E. . 1 ·1 44.93 48.50 55.41 47.51 :6.97 58.36 ,;.; ; 
24.12 31.69 25.60 32.58 32.61 36.49 
id1: C:' l ~ : ~ ~ ; J AFDl JNAD1 AFD3 34AD3 AFD7 UNAD7 1") ,1.. .,.;.,..,_ • ~ ... 1 I J.. 
F'Q iiiEF: ~ ~-:~TN i H 193 230 188 na 196 218 
90 136 105 l38 108 136 
ENDLif,AtCE ~JOULES } 2518 2694 3189 3313 3325 3314 
1 ' ~" ,NL 1385 1847 2272 2075 2059 
GIH RATI O AFF SIDE 47 ~,6 55 
PAIN (VAS) :24H 6 ') 1 L 
:PALPATION 6 ,, 2 J.. 
:!'!OVEMENT 4 0 
: WALKING 3 'l 1 " :JOSGING 8 27 'l 9 t 5 J.. . 
SWELL!NS:AFF. SIDE 55 55 55 
:UNAFF.SIDE 55 55 55 
GAIT ,, 1 1 L 
NUSCLE TEST CONT'D 
AVERAGE POWER (Ii) 260 291 321 321 342 328 
131 172 191 218 210 206 
PEAY. T.A.E. (J) 36.39 47.46 42.55 45.21 43.62 45.26 
22.22 33.26 27.76 32.39 32.16 36.37 
NUSCLE TEST D AFDl UNAD1 AFD3 UNAD3 AFD7 UNAD7 75" 
POIIER (NIHNj H 232 257 261 271 236 235 
121 117 137 141 169 144 
ENDURANCE (JOULES) 2589 3162 3456 3647 3046 3114 
1898 1862 2014 2454 2135 2099 
G/H RATIO AFF SIDE 52. 52 72, 
PAIN (VAS):24H 9 4 0 
:PALPATIOH 9 9 6 
:NOVENENT 5 1 0 
:liAUINS 6 5 1 
:J066IN6 10 27 7 23 3 4 
SIIELLINS:AFF. SIDE 55 55 55 
:UNAFF.SIDE 55 55 55 
GAIT 1 1 1 
NUSCLE TEST ~ONT'D 
AVERAGE POIIER (Ii) 246 309 299 307 286 291 
191 198 193 234 206 206 
PEAK T.A.E. (J) 43.68 48.71 67.58 73.02 65.12 66.00 
26.46 28.44 29.41 32.50 28.15 22.84 
82 
APPENDIX 4 
SEVERE INJURY DATA 
SEVERE INJURY DATABASE hamstring injuries 
PT NO ( POWER J [ ENDURANCE ][ SWELLING ]( PAIN ][SUBJ][OBJ ][TREAT 
) 
PTDl PTD3 PTD7 TWD1 TWD3 TWD7 APDl APD3 APD7 PTAED1PTAED3PTAED7 SWD1 SWD3 SWD7 PD! PD3 PD7 SEV. SEV. 
I 0.9b 0.94 0.99 0.93 0.90 1.00 0.89 0.89 0.97 0.88 0.98 0.91 1.00 1.00 1.00 
IV O.bO 0.78 0.83 1.08 0.8b 0.9b 1.08 0.89 1.01 1.0b 0.81 0.9b 0.98 1.00 0.98 
VII 1.49 1.b5 1.15 0.89 1.32 0.95 0.83 1.34 2.31 1.10 1.28 0.87 1.02 1.00 0.98 
IX 0.59 0.58 0.85 O.b2 0.53 0.84 O.b3 0.52 0.87 O.b9 O.b5 1.02 1.02 0.96 0.96 
XIII 1.21 1.17 1.16 1.48 1.16 1.11 1.38 1.23 1.07 1.35 1.23 1.04 1.00 1.00 1.00 
1 0.33 0.40 0.73 0.31 0.3b 0.78 0.27 0.33 0.78 0.52 0.47 0.80 1.04 1.04 1.00 
3 0.33 0.67 0.94 0.05 0.51 0.53 0.06 0.51 0.54 0.27 O.b9 0.82 1.02 1.00 1.00 
4 0.96 0.90 1.02 0.70 0.9b 1.15 0.66 1.00 1.08 0.23 0.91 0.41 1.00 1.00 1.00 
5 0.43 0.66 0.72 0.30 0.83 1.33 0.32 0.88 1.42 0.69 0.67 1.20 1.02 1.00 1.00 
6 0.23 0.40 0.73 0.29 0.59 0.95 0.88 0.98 1.04 0.96 1.00 1.03 1.04 1.00 1.00 
8 0.88 0.85 1.05 0.77 0.52 0.60 0.56 0.90 0.95 0.00 0.73 0.72 1.02 1.00 1.00 
9 0.55 0.65 1.09 0.52 0.75 1.15 0.53 0.77 1.22 0.78 0.73 0.85 1.05 1.02 1.00 
10 1.01 1.01 1.02 1.49 1.36 1.21 1.41 1.42 1.43 1.31 1.28 1.18 0.98 1.00 1.00 
14 0.94 0.91 0.94 1.18 0.98 0.72 1.14 0.97 0.75 0.88 0.98 0.47 1.04 1.02 1.00 
15 0.85 1.09 1.02 1.21 1.01 0.79 1.18 0.97 0.99 0.86 0.83 0.83 1.00 1.00 1.00 
16 0.55 0.60 0.65 0.75 0.75 0.86 0.75 0.80 0.87 1.04 1.00 0.86 0.96 0.98 1.00 
17 0.70 0.85 0.87 0.38 0.59 0.74 0.38 0.58 0.75 0.43 0.50 0.63 0.98 1.02 1.00 
18 0.72 1.00 0.86 0.95 1.22 1.17 1.00 1.20 1.17 0.99 1.12 1.05 1.02 1.00 0.98 
19 0.27 0.39 0.37 0.22 0.34 0.49 0.22 0.30 0.48 0.29 0.36 0.65 1.02 1.02 1.00 
20 1.01 1.01 1.00 1.08 1.11 0.96 1.08 1.13 0.98 1.06 0.94 1.06 1.00 1.02 1.00 
22 0.87 1.08 1.08 1.10 0.92 0.95 1.15 0.05 0.99 0.78 1.06 1.04 1.00 1.00 1.00 
27 0.76 0.80 0.80 0.76 0.93 1.07 0.77 0.93 1.01 0.84 0.96 1.03 0.98 0.98 1.00 
28 0.44 0.75 0.93 0. 69 0.63 0.87 0.61 0.62 0.97 0.62 0.86 0.99 1.02 1.00 1.00 
29 0.83 0.94 0.97 0.94 0.90 1.17 0.88 0.85 0.99 0.94 0.96 0.71 1.00 1.00 1.00 
30 0.81 1.01 1.02 1.00 0.98 1.05 0.99 1.09 1.13 1.18 1.45 1.34 1.00 1.00 1.00 
38 0.56 0.63 0.82 0.78 0.80 0.80 0.76 0.82 0.79 1.16 2.92 0.82 0.98 0.98 0.98 
41 0.45 0.55 0.58 0.55 0.64 0.69 0.53 0.68 0.68 0.77 0.68 0.44 1.03 1.03 1.03 
42 0.87 1.03 0.88 0.97 0.84 1.03 0.98 0.87 1.17 1.02 0.86 1.19 1.03 1.03 1.00 
44 0.73 0.77 1.00 0.63 0.74 0.90 0.69 0.68 0.91 0.74 1.05 0.39 1.04 0.98 1.00 
45 0.86 0.79 1.04 0.47 0.68 0.88 0.48 0.74 0.88 0.78 0.78 0.89 0.98 0.98 0.95 
53 0.56 0.98 1.06 0.77 0.92 1.02 0.76 0.91 1.02 0.74 O. Bb 1.09 1.00 1.00 1.00 
55 0.93 0.88 0.91 0.84 0.80 0.78 1.15 0.96 0.79 1.72 1.11 0.87 0.98 1.02 1.04 
56 0.71 0.72 0.84 0.73 0.65 0.85 0.75 0.67 0.88 0.82 0.90 0.97 1.00 0.98 0.98 
57 0.47 1.16 0.93 0.54 1.06 0.91 0.60 1.06 0.91 0.70 1.07 0.91 0.97 0.97 0.98 
61 0.48 0.79 0.90 0.56 0.82 0.96 1.73 1.23 0.93 0.90 1.04 0.98 1.02 1.02 1.00 
62 0.26 0.22 0.25 0.22 1.08 0.42 0.23 0.21 0.41 0.38 0.36 0.42 1.00 1.00 0.97 
64 0.28 0.39 0.44 0.47 0.54 0.81 0.46 0.56 0.79 0.56 0.55 0.76 1.00 1.00 1.00 
65 0.84 0.93 1.04 1.03 0.89 0.92 1.10 0.89 0.93 1.12 1.07 1.26 1.00 1.00 1.00 
67 0.62 0.81 0.98 0.75 1.05 0.99 0.69 0.95 0.95 0.88 0.85 0.97 1.02 1.02 1.00 
69 0.74 0.82 0.89 0.94 0.98 1.11 0.96 1.02 1.20 0.79 0.93 1.11 1.00 1.00 1.00 
70 0.54 0.70 0.81 0.36 0.79 1.07 0.39 0.74 0.99 0.48 1.07 0.80 0.98 1.00 0.98 
71 0.55 0.63 0.77 0.62 0.53 0.88 0.57 0.52 0.81 0.76 0.79 0.89 1.02 1.00 1.00 
72 0.66 0.76 0.79 0.98 0.81 1.01 0. 76 0.88 1.02 0.48 1.07 0.80 1.00 1.00 1.00 
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PH With transformation 0 
******************************** 
ource df MC , J .., 162.6599 .... .., 3809.158 L. 
4 28.69232 
ithin 1'•7" .t::__:, 74.78684 
Bartlet's criteria 19.59775 with df= 
OR F(MAX)= 0 





24.38 ( 8.97) 15. 31 ( 9.03) 7.85 ( 6.6 
25.36 ( 12.23 ) 12 .57 8.310001 3.86 ( 
26.82 ( 9.96 ) 17.82 ( 8.68 8.76 ( 7.7 ) 





~ -=!'Ci ._1 • •-'W 
suggests that horn. of var. can be accepted at p= .9786746 
\cceptance Intervals based on MEANS: 
~cceptance Intervals based on MEANS: 
model 1= 6.363248 
model 2= 6.826683 
model 1= 8.405506 
model 2= 9.017678 
rhe least significant deviation at p= .05 is= 63.31688 
with a Bonferonni t-value of 2 .425 
fhe least significant deviation at p= .01 is= 78.08971 
with a Bonferonni t-value of 2.990791 
~AMS SWELL With transformation 0 
******************************** 
,ource df MS 
2 2. s:;o9B4E-04 
.544873 
J 
~, 1.08406E-03 ..:.. 
"•Q 4 3.45242E-05 
ithin 1~,..,. L, .. .:i 2.917724E-04 
Bartlet ' s criteria 16.55688 with df= 
OR F(MAX)= 0 





1.008 ( .02) 1.002 ( .012 .995 ( 8.99999 9E-03 ) 
1. 002 ( . 024 ) .998 .02 .994 ( .018 ) 
1.007 ( .018 ) 1. 004 ( . 015 . 998 ( . 01 ~~; ) 
Bartlett criteria= 16.55688 with df= 10 
suggests that horn. of var. can be accepted at p= .9503062 
cceptanc e Intervals based on MEANS: 
Acceptance Intervals based on MEANS: 
model 1= 1.256864E-02 
model 2= 7.488395E-03 
model 1 = .01660 25 
model 2= 9.891763E-03 
The least significant deviation at p= .05 is= .1250631 
with a Bonferonni t-value of 2.425 
The least significant deviation at p= .01 is= .1542422 
with a Bonferonni t-value of 2.990791 
~T With transformation 0 
********************** **** ****** 
. 000024 









~;. 57013~;[:: - 02 
::: . 8(:.,8 .7t32E - ·i)2 
i t h in 123 2.942055E-02 
Bartlet's criteria 8 7 .46601 with df= 
TABLE OF MEANS with sd in brackets 
.951 ( .::os) .918 ( 7.900001E-02 
.946 ( .16;:.i ) 1 .007 
.89 4 ( .105 ) • C/81 
-a rtlett c r iteria= 87.46601 with df= 10 
f 
" 0':t 1. 
• ()7!.:i 
. ()t ..... 9 
sugges t s that horn. of var. can be acc e pted at p= 1 
model 1= .1262094 
mo del 2= .2012972 
mo del l= . 1667158 
1 --;·, 4.. 1:::.t.:r( .. , ... ;, .. ·7 
I.: . , : •• \...,' ._. .' ·--~ _,;_ ·' 
he least significant deviation at p= .05 is= 1.255834 



















Bartlet's crite r i2 8.7985 34 with df= 
OR F(MAX)= 0 
TABLE OF MEANS with sd in brackete 
.692 ( .308 ) .841 ( .312) .899 
. 483 ( .2) .823 .208 ) .871 
. 676 ( .251 ) .769 .235 .859 






















he least signi~icant d eviation at p= .0 5 is= 1 .73368 3 
with a Bo nfe r onni t-value of 2.~~5 
Th e l e ast significant deviation at p= .01 is= 2.138179 
with a Bonferonni t-value of 2.990791 









ithin 123 6.470792E-02 
Bartlet 's criteria 16.14236 with df= 
OF F(l"!AX)= 0 
TABLE OF MEANS with sd in brackets 
• T76 ( • :::::68 ) • 91. 7 
.753 ( .391 ) .8!:'.9 . 27~7 .. ) .906 
.728 ( .301 ) u8()2 II 93~~ 
,artlett criteria= ib.14236 with df= 10 
f 
4.650i66 
i i .. c::, 
& ..!.. •..J\ .. .' 
• 201. 
F' 
u (H).1. 916 
. 13~15989 
suggests that horn. of var . can be accepted at p= . 9447582 
model 1= .1871738 
model 2= .1193806 
model 1= .2472464 
model 2= . 1S76953 
-he least significant de~ i ation a. t p:::: ,I (> ~3 _,_ ::}_ 
with a Bonferonni t-value of 2 . 425 
he least significant deviation at p= .01 is= 2.296995 
with a Bonferonni t-value of 2 . 990791 











.J. • .i....•.-' 
rn=~ F(Mr-~X)= 0 
11 ()Cj' i()Ll,Ll-1 
11.01368 with of= 
"ABLE OF MEANS with sd in brackets 
. 856 ( -:!' L "i \ ,:; ·-'\.-.' ..\., ) 
. 733 ( . :.6 5 ) c,7 r: L•/ 
,-;i r::-. -:~ .\ 
II ..1:.. -.,.,•·-' ) 
r·:,cJ l i 
., ~\......1 - r 
1.026 
(.:: ,·1 
A / ..1. 




suggests that horn. of va r . can be accepted at p= .844472 
cceptance Intervals based on MEANS: 
model 2= . 2436492 
,cceptance Intervals based on MEANS: 
model 2= .3218473 
he least significant deviation at p= .05 is= 2.209189 
with a Bonferonni t-value of 2.425 
rhe leas t sign i ficant d eviation at p= .01 is= 2.724628 
with a Bonteronni t -val ue o f 2 . 990791 











J: l 7~,:~~5.1.8 
·7 a: 1+4-_?'·--)1 (){:_;F::·-(}::? 
ithin 123 9.577103E-02 
Bart let's criteri2 30.05709 with df= 
UP F ( 1··!(.1>'.) == o 
TABLE OF MEANS with sd in brackets 
. 791 ( .3J 9 ) ,--, ·-i r-, 
• \ 
.. ... :: . .i:: . .1::. ,1 • f.329 ( 
c;.,,:::, ·I 
.. ·' \. .. : . .I.. 
a rt lett cr iteria= 30.05709 with df= 10 
..< ; 
1. = s:29s~~)4 
r:,-:~c:• 




sug g es ts that hon. of v2r. can be accepted a t p= .9993681 
cceptance I ntervals based on MEANS: 
mode l 1= .2277106 
ffiCJde l 2:::: -:r /1 -·.re); -: t .. 11 • .. . • "I / \.. .. • .L ...l.. \..l 
model 1= .~007935 
model 2= . 4594402 
fhe leas t si gni fic an t deviation at p= .05 i s= 2.265813 




- - - - - - - 0 N E W A Y - - - - - - - - - -
Variable PD? 
By Variable DRUG 
Analysis of Variance 
Sum of Mean F F 
Source D.F. Squares Squares Ratio Prat 
Between Groups 2 237.8824 118.9412 2.5154 . 11 t 
Within Groups 14 662.0000 47.2857 
Total 16 899.8824 
-----------------------------------------------------------~---------------
Page 224 OBJ SEVERE =O 
Variable PD? 
By Variable DRUG 
Multiple Range Test 
LSD Procedure 
Ranges for the .050 level -
3.03 3.03 
The ranges above are table ranges. 
The value actually compared with Mean(J)-Mean(I) is .. 
4.8624 *Range* Sqrt(1/NCI) + 1/N(J)) 
<*> Denotes pairs of groups significantly different at the .050 level 
Page 225 OBJ SEVERE =O 
Variable F'D? 
(Continued) 
.j. (J(J(_)(_) l::irp (_) 
10.0000 Grp 2 
12.0000 Grp 1 * 
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APPENDIX 7 
DICLOFENAC TABLET DISSOLUTION EXPERIMENTATION 
, 
WARNER LAMBERT_CANADA INC. 
To : Dr. P. AlbriQht
From : Mr. J.K.S. Lee 
Date : Feb. 4, �9n7 
MEMORANDUM 
Subj�ct : Voltaren 25 mg Tablet --- Dissolution 
In November, 1986 2 samples of Voltaren 25 mg tablets <L>633900 
and tablets in e�pty capsule were submitted for dissolution 
testing. Dissolution testing showed that capsule shells slowed 
down dissolution rate (see memo Nov. 27 ,1986 to N. Grewal). 
The tablets were re-packed in capsule shells containing Avicel 
PH 101. The objective is to check if Avicel will prevent the 
softened capsule shells from wrapping the tablet and slows down 
dissolution rate. 
Results show that tablets and tablets in capsule shell containing 
Avicel PH 101 dissolve at about the same rate,(see Table I� II). 
cc: Mr. N. Grewal
Mr. S. Ambike
Mrs. G. Cukic 
M. koP�"1"o...k_
Signature Removed
Table I: Dissolution of Voltaren 25 mg tablet 
Voltaren 25 mg tablet <L> 633900 
Method: USPXXI p. 627 for 
Meclofenamate sodium capsule 
same for Meclomen capsule 
Apparatus: Paddle · 
Dissolution medium: pH 8.0 phosphate buffer 
at 37 C, 900 mL. 
Tablet # 10 mins. 20 30 45 60 
-------- ------- ------ ------ ------ ------
1 3.8 'l. 7.1 36.4 90.1 95.3 
2 4.6 4.8 16.9 60.6 93.7 
3 5.5 4.6 29.3 86.0 97.0 
4 5.6 3.8 16.7 52.1 96.6 
5 4.5 5.0 29.7 75.8 95.5 
6 5.8 c:- ~ ..J • • j 23.B 67.1 95.5 
Average 5.0 5. 1 25.5 72.0 96.0 
Book Reference: GC-367-19145 
Date: Feb. 5, 1987 
-
Table~: Dissolution of Voltaren 25 mg tablet in 
capsules filled with Avicel Ph101 











White OP 999 Body and cap. Hard gelatin 
capsule 
Method: USPXXI p. 627 for 
Meclafenamate sodium caps~le 
same far Meclomen capsule 
Apparatus: Paddle 
Dissolution medium: pH 8.0 phosphate buffer 
at 37 C, 900 mL. 
10 mins. 20 30 45 60 
------- ------ ------ ------ ------
"T ~ 
·-·. ·J 'l. 5.2 30.1 86.1 98.5 
2.8 3.5 6.2 37.9 98.2 
3.9 5.5 26.1 98.8 99.3 
4.6 6.2 18.4 86.1 104.8 
8.8 29. 1 33.6 69.9 93.2 
3.6 4. 1 6.3 29.5 100.1 
4.5 8.9 20.1 68.1 99.0 
Book Reference: GC-367-19147 
Date: Feb. 5, 1987 
